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Hip prosthesis loosening and the problems in elderly 
patients
Approximately one million total hip replacement operations are performed worldwide 
annually, and this number is likely to increase considerably in the next decades. A major 
complication in total hip arthroplasties is loosening of the prosthesis leading to pain 
and walking difficulties and a higher risk for dislocations and pathological fractures.54 
Within ten years of primary hip replacement 7-13 percent of patients need revision sur-
gery due to loosening of the implant.78 Revision surgery has a high morbidity and mor-
tality rate, especially in elderly patients with comorbidity. In the United States Medicare 
Population 5.3% of 3,165 patients undergoing revision surgery at age 80 and older 
died within 90 days of surgery. This was 1.9 times higher than a comparable Medicare 
cohort that had not undergone revision total hip replacement.77 Strehle et al.114 regis-
tered complications and social outcome in a cohort of 53 patients undergoing revision 
total hip arthroplasty older than age 80 years. They reported a total mean blood loss of 
4,730mL and a mean duration of the procedure of 200 minutes. Eleven patients (21%) 
were admitted postoperatively to the intensive care unit, and mean hospital stay was 
30 days. Complication rate was higher in patients with comorbidity. Of the 53 patients 
followed, three patients died during hospital stay, ten patients formerly living alone in 
a house or an apartment went to nursing care institutions and five patients became de-
pendent on outside help from family members, neighbours or health care institutions. 
These figures indicate that revision surgery can be a heavy burden for elderly patients 
and the indication needs to be reconsidered thoroughly before these patients can be 
operated. Consequently, there remains a group of elderly patients with comorbidity 
who are not eligible for surgery and experience incapacitating pain and dependency 
in activities of daily living. Currently there are no alternative treatments for revision 
surgery. 
Aseptic loosening
Aseptic loosening by particulate-induced osteolysis is the most common cause of im-
plant failure. Wear particles, such as particles of polyethylene and metal, are phagocy-
tosed by macrophages, leading to secretion of inflammatory cytokines.43 The resulting 
chronic inflammation eventually produces a pseudomembrane of synovium-like inter-
face tissue with activated macrophages, fibroblasts, giant cells and osteoclasts. 
 At present, experimental approaches to the aseptic loosening problem are preven-
tative rather than therapeutic. Preclinical studies have shown that bisphosphonates 
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might be useful to prevent aseptic loosening,108 but up till now clinical evidence is 
missing that bisphosphonates will prevent aseptic loosening at longer term. An alter-
native preventative approach for aseptic loosening involves gene therapy, e.g. using 
an osteoclast inhibitory protein, osteoprotegerin, delivered by a vector that delivers 
the gene inside the cell, such as an adeno-associated vector.120 Osteoprotegerin serves 
as a competitive inhibitor for the differentiation of osteoclasts, thereby preventing 
osteoclast activation. The vector to express the active ingredient was delivered by intra-
muscular injection into the quadriceps muscles of mice. The effect on osteoclasts was 
therefore systemic and this appeared to be successful in inhibiting the osteolysis that 
was seen in untreated controls.120 Although the results of these experimental animal 
data are interesting, it is unclear what the long-term systemic effects of prolonged 
elevations in serum osteoprotegerin might be. Before clinical application a deleterious 
effect on normal osteoclast function needs to be excluded. 
 In summary, experimental studies on alternatives for revision surgery are primary 
preventative and not yet in clinical trials. 
Removal of interface tissue
This thesis describes an approach to stabilise loosened hip prostheses as an alterna-
tive to regular revision surgery. The technique involves, among other things, injection 
of bone cement around the loosened prosthesis percutaneously, while the prosthesis 
remains in place. Before bone cement can be injected to stabilise the prosthesis, in-
terface tissue preferably needs to be removed to leave space for the cement. As the 
periprosthetic space is a more or less closed compartment local application of a toxic 
component could be a good option. Non-surgical removal of interface tissue has not 
been described in the literature. However, from the early 1950s several chemical agents 
have been used for intra-articular chemical synovectomy in patients with rheumatoid 
arthritis. Synovial tissue has the histological and histochemical characteristics of inter-
face tissue,43 and results of studies with synovial tissue could therefore be an indicator 
for outcome of studies with interface tissue. Chemical agents as osmic acid, nitrogen 
mustard, and thiopeta have been shown successful in non-controlled studies, but not 
in controlled studies and are currently not in use because of potential hazards.25 Cyto-
statics that are used in cancer therapy act by inhibition of cell division. As the cells in 
interface tissue are only slowly dividing cells, the use of cytostatics to remove interface 
tissue is not a good option. Another approach to killing pathological cells is to intro-
duce a gene into the target cells that encodes an enzyme capable of converting a pro-
drug of relatively low toxicity into a potent cytotoxic drug. As the prodrug is converted 
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to the toxic derivative locally, occurrence of systemic adverse effects will be low. This 
approach is known as gene-directed enzyme prodrug therapy (GDEPT).23
Gene therapy 
The definition of gene therapy (according to a medical dictionary) is the insertion of 
normal DNA directly into cells to correct a genetic defect. It involves the treatment of 
disease by replacing, altering, or supplementing a gene that is absent or abnormal and 
whose absence or abnormality is responsible for a disease. 
 The first attempt for human gene therapy was reported in 1975 when Rogers and 
Terheggen combined their knowledge on the Shope rabbit papilloma virus that in-
duces arginase,104 and on the disease argininemia, a genetic disease involving a low 
arginase-level, causing spastic diplegia, epileptic seizures, and mental retardation.119 
They inoculated fibroblasts from humans with arginase deficiency with the Shope vi-
rus, resulting in an induction in arginase activity.105 However, in a clinical trial in three 
patients, intravenous injection of the Slope virus was unsuccessful.118 
 In recent years the potential role of gene therapy has been expanded to gene ther-
apy as a tool for delivering individual proteins to specific tissues and cells. This also 
encompasses delivering proteins to kill cells (e.g. in cancer) and introducing therapeu-
tic proteins locally for a longer period of time (e.g. in rheumatoid arthritis). The most 
common method to introduce the gene into the cell is by using a virus as a vector, as 
viruses are known to deliver their DNA into the host cell for replication. The adenovi-
ral (Ad) vectors are popular for gene therapy since they are very efficient at infecting 
dividing as well as non-dividing cells, are easy to produce in large titers,38 and provide 
ample space for transgenes. Adenoviral vectors deliver their gene outside the host cell 
genome, thereby minimising the risk for disturbing normal cellular gene expression. 
The expression of their inserted gene is transient due to cellular and humoral immune 
responses130 which could actually be an advantage when only transient expression is 
required for adequate therapy. The presence of anti-Ad neutralising antibodies tends 
to be ubiquitous in human adults and greatly reduces virus dissemination while peak 
transgen expression in the targeted tissue is only minimally reduced.15 Moreover, the 
virus has a high particle size which, when introduced in a more or less closed compart-
ment, prevents most of it from diffusing into other tissues. Thus, an adenoviral vector 
can ideally be used to deliver a gene to the interface tissue in the periprosthetic space.
When using adenovirus 5 as a vector to express the gene Escherichia coli nitroreductase 
(Ntr), infected cells become extremely sensitive to the prodrug CB1954. This prodrug 
causes death of the infected cells.34 In a study by Goossens et al.,46 it was demon-
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strated that genes can be transferred to synovial tissue in vivo in rhesus monkeys by 
direct injection into the joint, and that the synoviocytes can be killed with injection of 
a specific prodrug. In our laboratory, previous experiments have shown the efficacy of 
the infection and destroying of synoviocytes and fibroblasts from interface tissue by 
HAdV-5-Ntr and CB1954.
Cement injection
One of the major difficulties in revision surgery is the removal of cement from the 
femoral shaft without fracturing the femur which may be eggshell thin. Therefore 
debate exists whether this cement should be removed completely before a new stem 
can be cemented. Chapchal et al.20 advocated in 1973 to remove all old bone cement 
despite it being time-consuming and hazardous. Later, this advise was more differenti-
ated by Charnley et al.22 who stated that the difficulties of complete removal, the risk 
of fracture, of interrupting blood supply and of reduction in the amount of cancellous 
bone may together represent a greater risk than that of bond failure at an old-new 
cement interface. They recommended, in the replacement of a non-infected femoral 
prosthesis, to ream out sufficient cement to permit a loose fit of the new prosthesis. 
Biomechanical studies showed that recementing over old cement is a practical alterna-
tive when all the blood is removed from the old cement, the old cement is rasped and 
the newly inserted cement is as fresh as possible to assure the presence of non-acti-
vated monomer that can be activated by the benzoyl peroxide activator still present in 
the old cement giving a greater interface strength.49 Lieberman et al.73 showed this in 
clinical practice in 19 patients where a new prosthesis was cemented in an old cement 
mantle. The technique involved rasping and drying of the surface before applying fresh 
cement, to increase interface strength between the old and the new cement. 
 Since the mid 1980s percutaneous cement injection is used for vertebroplasty in 
patients with painful vertebral lesions to relieve pain and provide strength.60 For this 
purpose low viscosity PMMA-cement with additional radio-opacity has been developed 
together with cement-guns and needles for injecting the cement. As aseptic loosen-
ing results in a radiolucent line around the prosthesis and the pain from loosening is 
caused by movement of the prosthesis within the bone, it would be worthwhile trying 
to inject cement in the periprosthetic zone percutaneously. Ideally three or more injec-
tion sites should be used to allow stabilisation in a 3D-space. In this way the prosthesis 
could again be stabilised in the bone, leading to decrease in pain and improvement 
in walking. Furthermore, the mechanical stress on the bone by the loose prosthesis is 
reduced, thus allowing for reconstituting of the resorbed bone14. Percutaneous cement 
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injection in the periprosthetic space has not been described in the literature. To our 
knowledge this procedure has not been studied as an alternative to revision surgery. To 
assess if the periprosthetic space is accessible to bone cement an arthrography of the 
hip can be useful. With arthrography, the periprosthetic space can be visualised when 
the contrast medium is easily distributed around the prosthesis. However, arthrogra-
phy of the hip in a loosened prosthesis often shows just a small line (i.e. <1mm) of con-
trast medium between bone and cement. It should be questioned if this area is large 
enough to inject a sufficient amount of cement to stabilise the prosthesis, particularly 
since the cement has a higher viscosity than the contrast medium. Therefore, before 
cement can be injected, the interface tissue preferably has to be removed. 
Aims and outline of this Thesis
The aim of this thesis was to evaluate risks and benefits of revision hip arthroplasty 
in a retrospective cohort of patients 80 years and older and to develop and assess an 
alternative treatment for revision hip arthroplasty for elderly patients with a high risk 
for complications due to serious comorbidity or a low bone stock (i.e. high likelihood 
of femoral fracture) . In Chapter 2 we analysed the risks of revision hip arthroplasty in 
elderly patients. We studied the burden of hospital stay and occurrence of complica-
tions and the benefits of improvement in social outcome. We assessed social outcome 
of 145 patients 80 years and older undergoing 183 hospital admittances for revision 
surgery of their hip prostheses. Primary objective was to investigate whether hip revi-
sion surgery in elderly patients could improve social outcome (housing situation and 
independency in ADL (activities in daily living)). Secondary objectives were occurrence 
of complications during hospital stay, patient survival, and use of walking aids before 
and after revision surgery.
 In Chapter 3 we studied whether cells from the interface tissue between prosthe-
sis and bone could be killed by Gene-directed Enzyme Prodrug Therapy (GDEPT). We 
investigated whether these cells could be transduced by a human adenoviral-5 vector 
carrying the E.coli-derived nitroreductase gene (CTL102) and sensitised to the prodrug 
CB1954. First, we exposed the cells to various concentrations of Ad.CMV.LacZ to de-
termine the infectivity of interface cells. In the next experiment, interface cells were 
exposed to various concentrations of CTL102 and subsequently to various concentra-
tions of CB1954 to study cell-killing potential of the Ntr/CB1954 GDEPT. In this chapter 
we also discuss the influence of iodide-containing contrast medium on adenovirus-
mediated gene transfer.
 Chapter 4 describes two alternative methods to optimise short-term transgene 
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expression. In clinical studies it is essential to have a predictable and adequate expres-
sion. When the gene expression can be made more efficient and predictable, the vector 
dose can be decreased. This has several advantages, including less evocation of an im-
mune response, a smaller demand for the production of clinical grade adenovirus, and 
less adverse events. A Ubiquitous Chromatin Opening Element (UCOE) was inserted in 
an Ad.CMV.Luc vector, and sodium butyrate (NaB) was added to the culture medium 
of interface cells in various concentrations to study the effect on transgene expres-
sion. Both these methods have a theoretical potential to enhance expression without 
increasing the amount of viral particles. The two methods were tested individually and 
in combination to evaluate their effect on transgene expression. 
 For the clinical use of intra-articular treatments a good exposure of the target tissue 
is essential and the injected active ingredient must remain in the joint for a sufficient 
amount of time to ensure adequate therapy. Beside size of the therapeutic particle, the 
integrity of the surrounding joint tissue (containment) is important in retaining active 
particles within the joint space. Efficacy of intra-articular therapy is also dependent on 
the joint volume, because this determines the concentration of the therapeutic ingredi-
ent. Chapter 5 shows a retrospective analysis of 221 hip arthrograms performed for 
diagnosis of prosthesis loosening. All arthrograms were studied for leakage of contrast 
medium and injected volume. This analysis was performed to determine the percent-
age of hip prostheses that would be eligible for therapy using intra-articular delivery of 
genes and proteins.
 After these pre-clinical studies, a phase-1 clinical gene therapy approach was de-
signed to destroy the periprosthetic loosening membrane, and enable refixing of the 
hip prosthesis with percutaneous bone cement injections under radiological guid-
ance. In this phase-1/2 dose escalating gene therapy trial twelve patients were treated. 
Chapter 6 shows the protocol of the phase-1 clinical study on gene therapy in aseptic 
prosthetic replacement loosening, carried out in the Leiden University Medical Center 
between June 2004 and February 2006. 
 The results of the clinical study are described in two chapters. As the study is a 
phase-1 clinical study, safety is the primary objective. Chapter 7 describes all adverse 
events of the clinical study and their possible relations to gene therapy, cement injec-
tion or other features of the study. Chapter 8 describes the secondary objectives of 
the clinical study. Virus shedding was quantitatively measured by analysis of urine, 
stool, blood, and nose and throat swabs. Biopsies from periprosthetic interface tissue, 
taken during the cementing procedure, were investigated for apoptotic and necrotic 
tissue. X-rays of the hip before and after the cementing procedure were analysed for 
increase in cement thickness. Finally, for clinical evaluation, Harris Hip Score and Visual 
Analogue Scales for pain, walking distance, and independency for activities in daily liv-
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ing, were done pretreatment, and three and six weeks, and three and six months after 
therapy.
 In Chapter 9 a small case series is described in which percutaneous peri-prothetic 
cement injection is performed in elderly patients with hip prosthesis loosening, with-
out previous gene therapy to remove the interface tissue. This series was performed to 
study whether cement injection is feasible without previous interface tissue removal. 
 Finally, in Chapter 10, a general discussion is given on percutaneous peri-prosthetic 
cement injection with or without gene therapy as an alternative to revision surgery, 
based on the work presented in this thesis. 
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We retrospectively reviewed social outcome of all octogenarians undergoing revision 
total hip arthroplasty in two hospitals in the Netherlands. A total of 183 hospital ad-
mittances in 145 patients were identified. Overall in 58% of hospital admittances the 
patient returned to the previous social situation, 35% had a worsening in social situ-
ation, and 8% had an improvement. 59% of patients living in a house or apartment 
went to a nursing institution for rehabilitation after discharge. Presence of a spouse 
was the only predictor for returning home immediately after discharge. There was a 
mean rate of 1.3 medical complications per patient with statistical differences between 
ASA-categories. 29% of patients needed less walking aids after revision surgery.
 Revision surgery gives a high rate of complications in octogenarians, with patients 
with a higher ASA-category having more complications. However, this does not affect 
returning to previous housing situations after discharge. 
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Introduction
The number of revision surgeries in elderly patients is likely to increase considerably 
in the next decades, due to the tendency to insert orthopaedic implants at younger 
ages and the longer life expectancy of patients. Revision surgery has a high compli-
cation rate in elderly patients6,92,99,114 and is associated with less improvement in 
social outcome, compared to primary hip arthroplasty in patients of all ages.103 The 
patients themselves often don’t realise the technical limitations of revision surgery 
and expect the same result as in primary total hip arthroplasty.51 Consequently, over-
all satisfaction in patients after revision total hip arthroplasty is 3.7 times lower than 
after primary hip arthroplasty.36 To stress the burden of revision hip arthroplasty for 
elderly patients we studied the social outcome after surgery in all patients 80 years 
and older who had revision THP in two hospitals in the Netherlands between 1994 
and 2007. Primary objective was to investigate whether hip revision surgery in elderly 
patients could improve social outcome (housing situation and independency in ADL 
(activities in daily living)). Secondary objectives were occurrence of complications 
during hospital stay, patient survival, and use of walking aids before and after revi-
sion surgery. 
Patients and methods
To evaluate outcome of revision hip arthroplasty in octogenarians, all patients who 
were 80 years and older when undergoing removal and/ or insertion of an acetabular 
and/ or femoral component of a hip prosthesis in two hospitals in the Netherlands 
between 1994 and 2007 were included. 
 Preoperative data, surgery data and data regarding the hospital admission were 
collected from the patients’ hospital chart. The patients’ general practitioners were 
asked if and when the patient had died. The physical status of the patient was clas-
sified by the anaesthesiologists according to ASA-classification (American Society of 
Anesthesiologists)121 (Table 1). 
 Information regarding complications that occurred was gathered from the hospi-
tal charts as recorded by the doctors as well as by the nurses. Prophylactic antibiotics 
(cephalosporin) were given routinely 30 minutes before the procedure and this was 
repeated when the surgery time was more than 3 h, and when blood loss was more 
than two litres. Post-operative antibiotics were not given routinely. Thrombosis prophy-
laxis was given until six weeks post-operatively, first as low-molecular-weight heparin, 
in some cases followed by coumarins. To study the impact of different kinds of revi-
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sion operations, the procedures were divided in 7 groups (liner revision, cup revision, 
stem revision, total hip revision, hemi-arthroplasty revised to total hip prosthesis, only 
components removed for infection, and other). For these groups, operative time, blood 
loss, number of complications, duration of hospital stay, and return to home were ana-
lysed. Also, a distinction was made in removal of cemented and uncemented stems for 
the same parameters as noted above.
 To get an impression on pre-operative dependency the Katz-ADL-index was mea-
sured.63 This index is a tool for assessing a patient's ability to perform activities of daily 
living in the areas of bathing, dressing, toileting, transferring, continence, and feeding. 
In each category, a score of one indicates complete independence in performing the 
activity and zero indicates that assistance is required, so that the total score ranges 
from zero to six. 
Primary objective
Social situation of the patients was pre-operatively recorded by the nurses. They re-
corded housing situation (house/apartment, home for the elderly or nursing home), 
the presence or absence of a spouse or child living with the patient, and the kind 
of help the patient received in activities of daily living (no help, informal care from 
children living nearby, house keeper, or home care). The postoperative situation was 
defined as the most favourable situation the patient achieved in social situation after 
the revision surgery. These data were gathered from post-operative correspondence 
between general practitioner and hospital and from the nurses’ charts on consecu-
tive hospital admittances. For patients who went to a nursing home for rehabilitation 
the nursing homes were called to ask for how long the patient had stayed there and 
whether they could return to their own homes after rehabilitation.
Table 1. American Society of Anesthesiologists’ Physical Status Classification
ASA-1 A normal healthy patient
ASA-2 A patient with mild systemic disease (mild diabetes mellitus, controlled 
hypertension, anemia, chronic bronchitis, morbid obesity)
ASA-3 A patient with severe systemic disease that limits activity (angina pectoris, 
obstructive pulmonary disease, prior myocardial infarction)
ASA-4 A patient with an incapacitating disease that is a constant threat to life 
(congestive heart failure, renal failure)
ASA-5 A moribund patient not expected to survive >24 h (ruptured aortic 
aneurysm, head trauma with increased intracranial pressure)
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Secondary objectives
Survival after revision surgery was measured for each patient. For patients who had 
multiple revisions only the latest revision was taken into account for the survival analy-
sis. Kaplan Meier-analysis was performed to compare survival in different ASA-groups 
(American Society of Anesthesiologists) (Table 1)121, with date of death as end point, 
and date of end of follow-up as sensored data.
 The hospital charts were studied for occurrence of complications. The charts made 
by the doctors as well as the charts made by the nurses were studied. A distinction 
was made between orthopaedic complications and medical complications. The list of 
medical complications was subdivided in cardiovascular, renal, gastro-intestinal, pul-
monary, neurological, and other complications. Some complications were defined as 
major: death, pulmonary embolism, myocardial infarction, pneumonia, stroke, deep 
infection, shock, peri-prosthetic fractures, and renal failure. The patient group was 
divided by ASA-category to determine the differences in occurrence of complications 
in the comorbidity-groups. Pressure sores were registered as such when there was at 
least disruption of the skin (grade II pressure ulcer, according to the National Pressure 
Ulcer Advisory Panel).1 Delirium was defined as severe confusion (with interference of 
normal function) during at least one day, that could not be corrected, and with inac-
cessibility to normal contact. Anorexia, and nausea and vomiting were only registered 
when parenteral feeding was necessary. 
The use of walking-aids by the patients was registered by the nurse at hospital admit-
tance. For the post-operative use of walking aids the most favourable situation was 
recorded. These data were gathered from the outpatients’ clinic’s chart, regarding 
post-operative controls and follow-ups. The categories for walking aids were: no aids, 
cane, one crutch, two crutches, walker, wheelchair, or bedridden.
Statistical Methods
Kaplan Meier analysis was performed for analysis of patient survival after revision sur-
gery, with date of death as the end point and end of follow-up as sensored data. 
Log-rank test was used to compare between ASA-categories. A oneway ANOVA with 
Bonferroni test was used to compare between different revision operations. A Student 
T-test was used to compare parameters between cemented and uncemented stems. 
Logistic regression was used to find predictive factors for patients living in a house or 
apartment to return to their own homes. 
 A statistical p-value of <0.05 was chosen as the level of significance. SPSS version 
16.0 was used for statistical analyses. 




Patients and hospital admittances
183 hospital admittances for revision hip arthroplasties were reported between 1994 
and 2007 in the two Dutch hospitals. A total number of 145 patients had 183 hospital 
admittances (1.26 admittances per patient).Table 2 shows demographic characteris-
tics for hospital admittances where at least one component of the hip prosthesis was 
removed or placed. In 41 of 183 admittances the patient went to the ICU (Intensive 
Care Unit) postoperatively, mean length of stay was 2.3 days. Figure 1 shows means 
(and standard deviations) for operative time, blood loss, number of complications and 
duration of hospital stay per type of revision. Operative time was longer in patients 
where a cemented stem had to be removed (mean 190 min, sd 75 min), compared to 
an uncemented stem (mean 149 min, sd 86 min) (p = 0.01). No differences were found 
in blood loss, number of complications, and length of hospital stay, between removal 
of cemented and uncemented stems. 
Social outcome
Figure 2 shows social housing situation before and after hospital admittance for hip 
revision surgery. For the post-operative situation the most favourable situation was 
taken. For example, when patients went post-operatively to a nursing home for reha-
bilitation and returned to home after several months, the latter situation was recorded. 
For all patients information on pre-operative situation was available. In 143 of 183 
hospital admittances patients lived pre-operatively in a house or apartment (78%), in 
21 the patient lived in a home for the elderly (10%), and in 19 the patient lived in a 
nursing home (11%). Four patients died during hospital stay. In the remaining of hos-
pital admittances 138 times (75%) the patient could return to their previous housing 
situation, in 22 cases (12%) there was a worsening in the housing situation, and in 7 
cases (4%) there was an improvement. 
In the cases where the patient was living alone in a house or apartment, 39% returned 
to the same social situation regarding outside help, 58% had a worsening in the situa-
tion and 3% had an improvement. In the cases where the patient lived with a spouse in 
a house or apartment, 70% returned to the same social situation regarding outside help, 
in 24% there was a worsening in the situation, and in 5% there was an improvement.
 Overall (housing situations and help in activities of daily living) 58% remained in 
the same social situation, 35% had a worsening in social situation, and 8% had an 
improvement. 
proefschrift.indd   22 27-11-2009   10:59:22
Revision Hip Arthroplasty in patients over 80 years of age
23
Of the 143 hospital admittances where a patient lived in a house or apartment pre-
operatively, in 84 (59%) cases the patient went post-operatively to some sort of reha-
bilitation facility. Of these cases 64 (76%) went to a nursing home (mean period of 
stay was 114 days), 19 (23%) went to a home for the elderly (mean period of stay was 
44 days), and 1 patient went temporarily to her daughter’s house. 11 Patients never 
returned to their homes. 
Predictors for returning to home in patients living in a house or apartment
To predict which patients could return to their home and which patients had to go to 
Table 2. Demographic Characteristics of the Patients and Outcomes
Parameter Total 183 Hips
Age (years)* 83.9 (Range 80.1 – 97.9; sd 2.9)
Men / women 24 / 159 (13.1% / 86.9%)
ASA score
ASA – 1 4 (2.2%)
ASA – 2 105 (57.4%)
ASA – 3 67 (36.1%)
ASA – 4 7 (3.8%)
Indication for revision
Aseptic loosening 121 (66.1%)
Periprosthetic infection 29 (15.8%)
(Periprosthetic) fracture 12 (6.6%)
(Recurrent) dislocations 18 (9.8%)
Fausse route 1 (0.5%)
Persisting pain 1 (0.5%)










Both components 82 (44.8%)
Operative time (hours)* 2.7 (Range 0.6 – 8.0; sd 1.3)
Blood loss (Liter)* 1.6 (Range 0.15 – 6.5; sd 1.2)
Length of hospital stay (days)* 34 (Range 2 – 197; sd 28)
* Data are given as mean with range and standard deviations in brackets
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a nursing home or a home for the elderly for rehabilitation or permanent stay after 
discharge, a logistic regression analysis was performed. First, the factors we expected 
to be a potential predictor of returning home were tested individually with univariate 
logistic regression. The factors tested were: sex (male/female Odds-ratio for return-
ing home was 6.0, p <0.01); ASA-category ( ASA1-2 / ASA 3-4 OR = 0.74, p = 0.40); 
Figure 1.  Bar chart of means and standard deviation for operative time, blood loss 
during surgery, number of complications, and length of hospital stay per 
component revised.
*  Operative time for a total hip revision was significantly longer than for the other revisions (p < 0.01). 
**  Blood loss was significantly higher in the total hip revision group compared to all other groups (p < 0.03) 
except for stem revision only (p > 0.95). There were no differences in number of complications occurring 
between the revision groups. 
***  Duration of hospital stay was significantly longer in the patients who only underwent removal of compo-
nents compared to the other groups.
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Katz-ADL-index (OR = 1.1; p = 0.47); indication for surgery (p = 0.84); surgery time 
(OR = 1.0; p = 0.87); blood loss during surgery (OR = 1.0; p = 0.94); components 
revised (p = 0.63); removal of cemented or uncemented stem (p = 0.59), presence of 
a spouse (with spouse/ alone OR = 24; p < 0.01); outside help (p = 0.047, with sig-
nificant difference between no help/housekeeper OR = 0.34, p = 0.014; no difference 
between no help/home care OR = 0.65, p = 0.33; and no difference between house-
keeper/ home care OR = 1.9, p = 0.13). The parameters entered in the logistic regres-
sion model were: sex, presence of a spouse, and outside help. With these three param-
eters in the model, only the presence of a spouse was a predictive value for return to 
home (OR = 36, p <0.01). As we expected sex to be a confounder of the presence of a 
spouse we verified this by doing a crosstabs in which we found that 87% of male pa-
tients had a spouse at home, while only 17% of female patients had a spouse. We also 
noticed that the coefficient for sex in the equation changed remarkably when correct-
ing for spouse, proving that sex is a confounder of spouse. To determine whether the 
presence of outside help in patients without a spouse would predict returning to home 
Figure 2.  Social housing situation before and after hospital admittance for revision hip 
arthroplasty. 
The central pie shows the pre-operative situation. The pies on the side show the distribution of post-operative 
situations per pre-operative situation. For example the pie on the right shows the post-operative situation of the 
patients who pre-operatively lived in a house or apartment. 
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we excluded the patients with a spouse and did a logistic regression analysis in patients 
living alone in a house or apartment. In these patients the presence of outside help 
was not a predictor for returning home (p = 0.84). In conclusion, the only predictor for 
returning to their home for patients living in a house or apartment was the presence 
of a spouse, with sex being a strong confounder, as the majority of male patients lived 
with a spouse while the majority of female patients lived without a spouse.
Patient survival
54 Patients died during follow-up. Mean survival after revision surgery in these patients 
was 44 months (range 0 – 135, sd 42). 8 Patients (5.5%) died within 90 days of surgery. 
Figure 3 shows the survival curve of all patients after their latest revision surgery per 
ASA-category. Differences in patient survival between the ASA-categories were signifi-
cant for all groups (Log-rank test: p < 0.01). 
Complications
Table 3 shows the incidence of medical complications during hospital stay per ASA-
group. A total number of 239 complications occurred during 183 hospital admittances 
(mean: 1.3 complications per admittance). Patients in ASA 1 and 2 had 1.0 complica-
tion per admittance, patients in ASA 3 had 1.7, and patients in ASA 4 had 2.6 compli-
cations per hospital admittance. This difference in number of complications between 
ASA-groups was statistically significant (p < 0.01). In 22% of hospital admittances for 
revision hips arthroplasty no complications occurred. Table 4 shows the incidence of 
orthopaedic complications in the first six months after surgery. Orthopaedic complica-
tions occurred in 25% of hospital admittances with no statistical difference in total of 
complications between the ASA-groups (p =0.61). The differences in kind of orthopae-
dic complications was not statistically significant (Chi-square) between the ASA-groups 
(dislocations p =0.07; fractures p =0.10)
Walking aids
Table 5 shows pre-operative and post-operative use of walking aids by the patients. For 
post-operative use of walking aids the most favourable situation was registered. For 
example, when the patient used a walker after discharge from the hospital and used 
a cane six months after surgery until the end of follow-up, ‘cane’ was chosen as the 
post-operative use of walking aids. The table shows changes in the use of walking aids 
after revision surgery. In 1 patient the use of walking aids before revision surgery was 
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unknown and in 6 patients the post-operative data were missing. In 86 of 176 cases 
(49%) the use of walking aids remained the same before and after revision surgery, 
in 39 cases (22%) the situation in use of walking aids had worsened, and in 51 cases 
(29%) the situation improved.
Discussion 
This study describes the social outcome of patients 80 years and older after hospital 
admittance for revision hip arthroplasty. In total there were 183 hospital admittances 
in 145 patients. Table 2 shows peri-operative data of the current study. Mean operative 
time was 2.7 h, mean blood loss was 1.6 litres, and mean length of hospital stay was 
34 days. These data resemble the data in previous studies6,99,114, except for the study 
by Parvizi which showed a much shorter hospital stay.92 Patients who had revision of 
both components had a longer operative time and more blood loss, than patients 
who had revision of 1 component or only removal of components. Patients who only 
had removal of components, due to infection of the prosthesis, had a longer hospital 
stay than patients who had a revision. This can be explained by the fact that in these 
Figure 3.  Kaplan Meier analysis of patient survival per ASA-category. ASA-1 and ASA-2 
are taken together as 1 category. Differences in survival between ASA-cate-
gories was statistically significant (p < 0.01).
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Table 3.  Incidence of medical complications during hospital stays, per ASA-category 
and in total. Complications are divided per organ system. The table shows 
the incidence of the complication, with the percentage in the patient group 
in brackets.










No complications (medical or orthopaedic) 29 (27%) 12 (18%) 0 41 (22%)
Cardiovascular 13 (12%) 20 (30%) 1 (14%) 34 (19%)
Myocardial infarction 3 (2.8%) 2 (3.0%) 0 5 (2.7%)
Congestive cardiac failure 3 (2.8%) 8 (12%) 0 11 (6.0%)
Shock 2 (1.8%) 6 (9.0%) 0 8 (4.4%)
Hypovolemic 1 (0.9%) 4 (6.0%) 0 5 (2.7%)
Septic 1 (0.9%) 2 (3.0%) 0 3 (1.6%)
Hypotension 1 (0.9%) 2 (3.0%) 0 3 (1.6%)
Arrhythmia 2 (1.8%) 1 (1.5%) 1 (14%) 4 (2.2%)
Arterial occlusion in both legs 0 1 (1.5%) 0 1 (0.5%)
Collaps 1 (0.9%) 0 0 1 (0.5%)
Pulmonary embolism 1 (0.9%) 0 0 1 (0.5%)
Renal 8 (7.3%) 14 (21%) 2 (29%) 24 (13%)
Urinary retention 4 (3.7%) 5 (7.5%) 2 (29%) 11 (6.0%)
Urinary tract infection 4 (3.7%) 6 (9.0%) 0 10 (5.5%)
Kidney failure 0 2 (3.0%) 0 2 (1.1%)
Decrease in renal function 0 1 (1.5%) 0 1 (0.5%)
Gastrointestinal 3 (2.8%) 8 (12%) 3 (43%) 14 (7.7%)
Bleeding 1 (0.9%) 2 (3.0%) 0 3 (1.6%)
Severe nausea and vomiting 2 (1.8%) 0 1 (14%) 3 (1.6%)
Anorexia 0 2 (3.0%) 0 2 (1.1%)
Pancreatitis 0 2 (3.0%) 0 2 (1.1%)
Diarrhea 0 1 (1.5%) 2 (29%) 3 (1.6%)
Ileus 0 1 (1.5%) 0 1 (0.5%)
Pulmonary 2 (1.8%) 2 (3.0%) 0 4 (2.2%)
Pneumonia 1 (0.9%) 2 (3.0%) 0 3 (1.6%)
Exacerbation of bronchitis 1 (0.9%) 0 0 1 (0.5%)
Neurological 30 (28%) 23 (34%) 5 (71%) 58 (32%)
Delirium 25 (23%) 19 (28%) 4 (57%) 48 (26%)
Foot drop 3 (2.8%) 1 (1.5%) 0 4 (2.2%)
Femoral neuropathy 1 (0.9%) 1 (1.5%) 0 2 (1.1%)
Transient ischemic attack (TIA) 0 1 (1.5%) 1 (14%) 2 (1.1%)
Cerebrovascular accident (CVA) 0 1 (1.5%) 0 1 (0.5%)
Carpal tunnel syndrome (CTS) 1 (0.9%) 0 0 1 (0.5%)
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Other 53 (49%) 45 (67%) 7 (100%) 105 (57%)
Pressure sore 50 (46%) 35 (52%) 5 (71%) 90 (50%)
Death 0 4 (6.0%) 0 4 (2.2%)
Hyponatremia 1 (0.9%) 2 (3.0%) 1 (14%) 4 (2.2%)
Vaginal infection 0 1 (1.5%) 1 (14%) 2 (1.1%)
Hypokalemia 0 1 (1.5%) 0 1 (0.5%)
Osteomyelitis of MT5 1 (0.9%) 0 0 1 (0.5%)
Polyarthritis 1 (0.9%) 0 0 1 (0.5%)
Allergic reaction to antibiotics 0 1 (1.5%) 0 1 (0.5%)
Tung necrosis 0 1 (1.5%) 0 1 (0.5%)
Total 109 (100%) 112 (167%) 18 (257%) 239 (131%)
Table 3. Continued
Table 4.  Incidence of orthopedic complications within the first six months after surgery, 
per ASA-category and in total. The table shows the incidence of the complica-
tion, with the percentage in the patient group in brackets.










No complications (orthopaedic) 82 (75%) 51 (75%) 4 (57%) 137 (75%)
Peri-prosthetic fracture 5 (4.6%) 9 (13%) 1 (14%) 15 (8.2%)
Wrong head-size 0 1 (1.5%) 0 1 (0.5%)
Dislocation 17 (16%) 4 (6.0%) 2 (29%) 23 (13%)
Infection 3 (2.8%) 3 (4.5%) 0 6 (3.3%)
Superficial 2 (1.8%) 0 0 2 (1.1%)
Deep 1 (0.9%) 3 (4.5%) 0 4 (2.2%)
Arterial bleeding (embolisation needed) 1 (0.9%) 0 0 1 (0.5%)
Total 27 (25%) 17 (25%) 3 (43%) 47 (26%)
cases repeated surgery for debridement of the infected area was performed, weight 
bearing was usually not allowed and even impossible due to leg length discrepancy. 
Furthermore, most of these patients had bed-rest with their leg in traction to prevent 
shortening of the leg. In our study neither blood loss, nor operation time correlated 
with social outcome.
In the current study four patients died during hospital stay. In the remaining of hos-
pital admittances 138 times (75%) the patient could return to their previous housing 
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situation, in 22 cases (12%) there was a worsening in the housing situation, and in 
7 cases (4%) there was an improvement. In 12 cases the post-operative situation was 
unknown. Strehle et al. 114 also compared pre-operative and ultimate post-operative 
situations. They reported that 80% of patients could return to their original environ-
ment eventually and 20% (all patients pre-operatively living in a house or apartment) 
had to move to a home for the elderly or nursing home. Ballard et al. 6 reported that of 
27 octogenarians 11 went to a nursing care institution after discharge for revision hip 
arthroplasty, none of them could return home after rehabilitation. 
 The only predictor for returning home in patients living in a house or apartment 
in the current study was the presence of a spouse, with gender being a strong con-
founder as most of the male patients lived with a spouse and only a minority of female 
patients did. Strehle et al. 114 also compared social situation in patients living with and 
without a spouse. They found that 95% of patients living with a spouse could return to 
their homes compared to 70% of patients living without a spouse. No statistical testing 
was reported. 
 Several studies reported where patients went after discharge from the hospital, 
which was not always the ultimate situation. In the current study 59% of patients living 
in a house or apartment pre-operatively went to a nursing home or home for the el-
derly after discharge from the hospital for rehabilitation. The majority of these patients 
could return to their own homes after a mean rehabilitation period of 106 days. 
In the current study, 8 patients (5.5%) died within 90 days of surgery. This corresponds 
with the findings by Mahomed et al. 77 who studied survival of octogenarians after re-
vision hip arthroplasty and found that 168 of 3165 patients (5.3%) died within 90 days 
of surgery and with the findings of Parvizi et al., 92 who had 7 deaths in 159 patients 
(4.4%) within 90 days. 
 Patient survival differed significantly between ASA-groups, with all the patients in 
ASA-4 having died within two and a half years after surgery and the biggest differ-
ences in survival between patients in ASA-2 and ASA-3 occurring in the first six months 
post-operatively. Prause et al. 98 showed in a large study of over 16,000 patients that 
ASA-category is a good predictor for peri-operative mortality. 
In our study there were 239 medical complications in 183 hospital admittances 
(1.3 complications per case), with 1.0 complication per hospital admittance in patients 
in ASA-1 and ASA-2, 1.7 in ASA-3 and 2.6 in ASA-4. There was no difference in the 
number of complications observed between various kinds (i.e. total hip versus partial 
components) of revision surgery. Delirium (26% of cases) and pressure sore grade 2 
or more (50%) were the most common complications, followed by urinary retention, 
urinary tract infection and congestive cardiac failure (all in 6% of cases). In a study 
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on primary THP and TKP in patients 89 years and older all patients had a delirium 
post-operatively.10 Ballard et al. 6 found 1.5 medical complications per patient (41 in 
27 patients), with urinary retention as the most common (56% of patients). Raut et 
al.99 found 42 complications in 56 patients (0.8 complications per patient), with major 
complications only occurring in patients with ASA-3. They observed a correlation be-
tween seriousness of complications and ASA-category. Brander et al. 16 studied primary 
hip and knee arthroplasty in octogenarians compared to patients aged 65-80 years. 
They concluded that the number of comorbidities did not correlate with the occurrence 
of complications. However, patients 80 years and older who had no comorbidities had 
a lower chance to have complications. Parvizi et al. 92 studied 170 hips in 159 patients 
aged 80 or older undergoing revision hip arthroplasty and compared them to a gender-
matched control group of patients aged less than 70 years. They found a mean com-
plication rate of 0.3 complications per patient, with arrhythmia as the most common 
(3.5%). Leung et al. 71 found ASA-classification to be a predictor for complications in a 
multivariate analysis (besides emergency surgery and pre-operative tachycardia. Com-
pared to previous studies our study shows a high percentage of delirium and pressure 
sores. Probably, these complications can be prevented. Pressure sores can sometimes 
be prevented by using a special mattress. In the two hospitals where the study was 
done these special mattresses were only used when pressure sores were already pres-
ent (as a hospital policy), but because of the high occurrence of pressure sores in these 
octogenarians with a relatively long period of bed rest it would be worthwhile to use 
an anti-pressure sore mattress as a preventive measure instead of a treatment. Delirium 
can sometimes be prevented by keeping the patient in an as best as possible condition. 
In a randomised controlled trial by Marcantonio et al., 80 the occurrence of delirium in 
patients after orthopaedic surgery could be reduced significantly by proactive geriat-
rics consultation. A geriatrician made daily visits and made targeted recommendations 
based on a structured protocol. Introducing these measures will probably reduce the 
occurrence and seriousness of delirium. 
In the current study orthopaedic complications occurred in 25% of cases. 13% of hips 
had one or more dislocations post-operatively within 6 months, 8.2% had peri-pros-
thetic fractures (mostly per-operatively), and 2.2% had a deep infection. A large study 
of complications after revision hip arthroplasty within 6 months in almost 13,000 pa-
tients of all ages showed 1.1% infections and 14% dislocations.94 In Ballard’s study 4 
of 27 octogenarians (15%) had dislocations post-operatively and there were no infec-
tions.6 Raut et al.99 found dislocations in 4 (7%) patients and infections in 2 (4%). There 
were no periprosthetic fractures. In the study by Parvizi et al. 92 1.8% periprosthetic in-
fections occurred in the octogenarians group, which was the same amount for the con-
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trol group of patients aged 70 years and younger. Fractures occurred in 7.6% of elderly 
patients compared to 1.8% in the younger group (p = 0.006), and this difference was 
attributed to a lower bone stock in elderly patients, predisposing to fractures. On the 
other hand dislocations occurred more in the younger patient group (9.4%, compared 
to 2.4% in the elderly patients) (p = 0.01), and this was explained by the fact that for 
the elderly patients more constrained liners were used. In our study there seemed to 
be a difference in occurrence of the kind of complications between the ASA-groups, 
but this was not statistically significant. There were 16 hips (16%) with dislocations 
in the ASA-2 group and 4 (6%) in the ASA-3 group (p = 0.07). In contradistinction to 
Parvizi’s study the same liners were used in all ASA-categories. We explain the higher 
percentage of dislocations in the ASA-2 group by the supposition that these people 
are usually more active in physical activities. In our study there were 5 hips (4.6%) with 
periprosthetic fractures in the ASA-2 group and 9 (13%) in the ASA-3 group (p = 0.10). 
We agree with Parvizi that peri-prosthetic fractures are more likely to occur in patients 
with a poor bone-quality and these patients are probably more represented in the 
higher ASA-groups. Probably, a larger group of patients would have given significant 
differences in the kind of complications in our study.
In the current study the use of walking aids was reported pre- and postoperatively. 
In 49% of cases the use of walking aids remained the same before and after revision 
surgery, in 22% the situation in use of walking aids had worsened, and in 29% the situ-
ation improved. This implicates that there may be a slight improvement in use of walk-
ing aids after revision surgery. No other study reported on difference in use of walking 
aids before and after revision hip arthroplasty in octogenarians. 
Conclusion
Revision hip arthroplasty can be a heavy burden in octogenarians. This study reports 
the social outcome of 183 hospital admittances for revision hip arthroplasty in 145 pa-
tients over 80 years. Some of the very common complications occurring in this study 
(pressure sores and delirium) can probably be minimised by preventive measures such 
as special mattresses and early consultation of a geriatrician.
 Patients with higher ASA-categories had a higher number of complications. How-
ever, this had no influence on whether the patient could be discharged to his or her 
own home or that the patient had to be discharged to a home for the elderly or nursing 
home for rehabilitation or definitive stay. The only predictor for returning home was 
the presence of a spouse at home with gender being a strong confounder. 
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Loosening is a major complication in prosthesis surgery. To stabilise loosened ortho-
paedic implants, the interface tissue surrounding the implant must be removed. As an 
alternative to manual removal, we explored the possibility of removing the tissue by 
gene-directed enzyme prodrug therapy. In the current study we investigated whether 
interface cells can be transduced by an HAdV-5 vector carrying the E.coli-derived nitro-
reductase gene and sensitised to the prodrug CB1954. 
Methods
The gene transfer efficiency into cultures of diploid human interface cells was tested 
by exposing these cells to various concentrations of Ad.CMV.LacZ. Subsequently, we 
studied the susceptibility of cells to the Ntr/CB1954 combination. 
Results
X-gal staining of the Ad.CMV.LacZ-transduced cell cultures revealed that at 200 plaque 
forming units (pfu)/cell, 74% of the cells expressed the LacZ gene. Infection with an 
Ntr construct in interface cell lines resulted in a 60-fold sensitisation to the prodrug 
CB1954. In addition we observed that iotrolan (Isovist) contrast medium had no effect 
on viability of the cells. However, the presence of the contrast medium completely in-
hibited adenovirus-mediated gene transfer. 
Conclusions
From these data we conclude that HAdV-5-based vectors carrying nitroreductase can 
be used to sensitise interface tissue. Instead of contrast medium the clinical protocol 
will use an alternative visualisation procedure.
proefschrift.indd   36 27-11-2009   10:59:23
Killing of interface cells by GDEPT with CTL102 and CB1954
37
Introduction
Approximately 1 million total hip replacement operations are carried out worldwide 
annually for degenerative joint disease, mostly osteoarthritis and rheumatoid arthritis. 
Of these prostheses 7-13% will have loosening within 10 years, causing pain and dif-
ficulty in walking.54,78,112 The current treatment for prosthesis loosening is revision sur-
gery, which has a high mortality and morbidity rate, especially in elderly patients with 
comorbidity.114 For these patients revision surgery is not an option and there remains a 
need for effective treatment of implant loosening in this patient population.
 Loosening of orthopaedic implants is for the greater part caused by an inflam-
matory reaction to wear particles (mostly polyethylene).5 The inflammatory reaction 
causes a periprosthetic tissue to be formed, consisting of fibroblasts and macrophages, 
which is called interface tissue.61,62 Before a loosened prosthesis can be refixed, the 
interface tissue and the prosthesis need to be removed; thereafter a new prosthesis 
is implanted. This revision surgery can often be extensive (3-8 h surgery), due to the 
necessity of removing all interface tissue and the prosthesis, leading to high morbidity 
rates. Alternatively, the interface tissue could be removed by introduction of a toxic 
component. 
 In the current study we tested whether interface cells can be sensitised by nitrore-
ductase (Ntr) to the prodrug CB1954. The prodrug CB1954 (5-(aziridin-1-yl)-2,4-dini-
trobenzamide) is a weak monofunctional alkylating agent, which is converted by the 
Escherichia coli enzyme Ntr to a cytotoxic derivative.68 Cells containing Ntr convert 
CB1954 into a bifunctional alkylating agent which is capable of forming DNA inter-
strand cross links, resulting in apoptosis or cell death.18,34 
 Since there is no human homologue to Ntr23, only cells expressing the nitroreduc-
tase gene are killed when exposed to CB1954. In the present study the therapeutic 
window for interface cells is determined to find out which CB1954 concentrations are 
safe to use in interface tissue, preventing killing of non-transduced cells. 
 To refix a loosened joint prosthesis, the interface cells in the periprosthetic space 
need to be eradicated. The interface cells are located in the joint space, which is a 
closed compartment. This has the advantage that with a high local concentration of 
vector the systemic exposure may be minimal (Figure 1a). 
 Contrast medium may be used to visualise the cavity by radiological images. To as-
sure that the vector is administered in the joint space, the position of the needle in the 
joint space can be monitored by injecting a small amount of contrast medium into the 
cavity, while making fluoroscopic images (Figure 1b). Before the contrast medium can 
be used in a clinical study together with CTL102 and CB1954, its effect on the efficiency 
of transduction and killing should be tested. 
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The effect of contrast medium on fibroblastic cells has been studied previously.69,131 
In various studies it was shown that exposure of cells to low-osmolarity contrast 
media has no significant influence on cell proliferation and apoptosis. These studies 
show that exposure of the interface cells to contrast media with low osmolarity will 
probably have no effect on the cells themselves. However, the influence of contrast 
medium on viral transduction of cells by a HAdV-5-vector has not been reported. In 
this study the influence of low-osmolarity contrast medium on adenoviral transduc-
tion is tested. 
Materials and Methods
Adenoviral vector
The adenoviral vector CTL102 was constructed by homologous recombination in PER.
C6 helper cells,38,114 as described in previous studies.34 CTL102 carries the E. coli Ntr 
gene under control of the cytomegalovirus (CMV) promoter/enhancer. The complete 
Ntr expression cassette is cloned into an E1-deleted HAdV-5 adenovirus transfer vector. 
The Ad.CMV.LacZ122 vector is identical to CTL102, but the E.coli lacZ gene replaces the 
Figure 1.  Schematic representation of a hip joint with a loosened prosthesis (a). Arthro-
gram of a hip joint with a loosened prosthesis (b). 
(a) The gray area indicates the joint space, which is continuous with the periprosthetic space. When injecting a 
fluid into the joint space, this will spread through the area that is marked gray in the image. 
(b) The contrast medium is injected into the joint space under fluoroscopic guidance. The picture shows that a 
part of the area around the prosthesis (periprosthetic space) is filled with contrast medium. This proves that the 
prosthesis is loose in that area.
1a 1b
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Ntr gene. In the rAd5F35.CMV.LacZ vector the shaft and knob of the HAdV-5 fiber were 
replaced by the homologous regions of the HAdV-35 fiber.100
Interface tissue samples
For all experiments described, interface cells were used. Interface tissue was removed 
from the periprosthetic space during revision surgery by an orthopaedic surgeon and 
collected in sterile phosphate-buffered saline (PBS). Connective tissue and fat were re-
moved thoroughly and the interface tissue was digested for at least 2 h at 37°C using 
collagenase 1A (1 mg/ml; Sigma, St Louis, MO, USA). Cells were then harvested by fil-
tering the tissue/collagenase substance through a 200 μm filter (NPBI, Emmer-Compas-
cuum, The Netherlands). The cells were cultured in 75 cm2 flasks (Cellstar, Greiner, Al-
phen aan de Rijn, The Netherlands) with Iscove's modified Dulbecco's medium (IMDM; 
Biowitthaker, Verviers, Belgium), supplemented with glutamax (GibcoBRL, Paisley, UK), 
penicillin and streptomycin (Boehringer Mannheim, Germany), and 10% fetal calf se-
rum (FCS; GibcoBRL) at 37°C and 5% CO2. 
 Before each experiment interface cells were detached from the flasks using 0.25% 
trypsin (GibcoBRL). The cells were counted in a Bürker counter and death cells were ex-
cluded by trypan blue. Cells were seeded in a 96-well plate (flat bottomed) at a density 
of 5000 cells/ well. Cells were incubated overnight to allow attachment to the bottom. 
Before each experiment the wells were washed twice with IMDM. For the experiments 
passage 2 to 4 interface cells were used. Light microscopy indicated that more than 
95% of the cells were interface cells.
 The human hepatoma cell line HepG267 was used as a control for experiments with 
contrast medium and sodium iodide (NaI).
Potential of cell-killing by Ntr/CB1954 GDEPT (Gene-Directed Enzyme Prodrug Therapy)
To investigate cell-killing potential, interface cells were infected by CTL102 (Cobra Bio-
manufacturing plc, Keele, UK) in different concentrations (0, 25, 100, and 200 plaque 
forming units (pfu)/cell) in IMDM/10% FCS for 24 h, washed twice with IMDM, and 
then incubated with the prodrug CB1954 (Oxford Asymmetry Ltd, Abingdon, UK) in 
different concentrations (0, 25, 50, and 100 μM) in IMDM/10% FCS for 24 h. The cells 
were washed again and then cultured in IMDM/10% FCS for 1 day, after which the cell 
viability was measured using cell proliferation reagent WST-1 (Roche, Mannheim, Ger-
many) according to manufacturer's instructions with a 2 h incubation period . 
 To study the infectivity of interface cells by HAdV-5, interface cells were infected 
with Ad.CMV.LacZ vector (in concentrations of 0, 25, 50, 100, 200, 400 pfu/cell). Twen-
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ty-four hours post-infection the cells were washed twice with IMDM, and cultured 
for 2 days. Medium was refreshed each day. On day 3, the monolayer cultures were 
washed twice with PBS and fixed with 0.2% glutaraldehyde and 2% formaldehyde in 
PBS for 10 minutes at 4°C. Subsequently, cells were washed once with PBS and stained 
for β-galactosidase activity in 50 μl of reaction mix (1 mg/ml X-gal (Eurogentec, Se-
raing, Belgium), 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM 
MgCl2 in PBS) for 2 h at 37 °C. The percentage of transduced cells was assessed by 
counting at least 100 interface cells, using light microscopy. All conditions were tested 
in duplicate.
CB1954 toxicity
To assess CB1954 toxicity in interface cells that do not express nitroreductase, interface 
cells were exposed to CB1954 in various concentrations (0-4000 μM) in IMDM/10% FCS 
for 24 h, in duplicate. Cells were then washed twice with 100 μl IMDM, and cultured in 
IMDM/10% FCS for a further 2 days. On the third day, cell viability was measured using 
cell proliferation reagent WST-1 (Roche) according to manufacturer's instructions with 
a 2 h incubation period.
Effect of contrast medium on interface cells
Interface cells and HepG2 cells were seeded in 96-well plates. Into each well 50 μl of 
IMDM/ 20% FCS and 50 μl of a solution containing contrast medium and 0.9% NaCl in 
various concentrations (0, 12.5, 25, and 50% contrast medium) were added. The con-
trast media used were the low-osmolarity, non-ionic dimer iotrolan (Isovist; Schering, 
Berlin, Germany) with an iodide concentration of 300 mg/mL and the low-osmolarity, 
ionic dimer ioxaglate meglumine – ioxaglate sodium (Hexabrix, Guerbet, Aulnay-sous-
Bois, France) with an iodide concentration of 320 mg/mL. As a control, sodium-iodide 
(NaI) was used in concentrations of 0 to 150 mM. After 4 h exposure to the contrast 
medium, the cells were washed twice and incubated in IMDM/10% FCS. The cells were 
cultured for a further 2 days, changing the culture medium every day. On day 4, cell 
viability was determined with the WST-1 cell viability assay kit (Roche) according to the 
manufacturer's protocol.
Effect of contrast medium on HAdV-5 transduction of interface cells
Interface cells and HepG2 cells were seeded in 96-well plates. After overnight incuba-
tion cells were infected with Ad.CMV.LacZ (concentrations of 0, 25, 100, and 200 pfu/
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cell) in IMDM/ 20% FCS, 25 μl per well. Then 25 μl of iotrolan (Isovist) or ioxaglate 
meglumine – ioxaglate sodium (Hexabrix) in 0.9% NaCl were added in concentrations 
of 0, 25, 50, and 100%. (When diluted in the culture medium these concentrations 
decreased to 0, 12.5, 25, and 50%.). As a control for iodide activity, NaI was added in 
concentrations of 0 to 150 mM (0, 1, 2.5, 5, 10, 25, 50, 100 and 150 mM). Four hours 
after infection, the cells were washed twice with IMDM and incubated for the rest of 
the day in IMDM/10% FCS at 37°C and 5% CO2. The Ad.CMV.LacZ transduced cells were 
cultured for 2 days after removal of the vector and contrast medium. Subsequently, 
the cells were fixed and stained for β-gal activity. The transduction rate was assessed 
as described above.
 To investigate the transient effect of contrast medium on transduction of interface 
cells, cells were first exposed to iotrolan for different periods of time. Subsequently, the 
contrast medium was removed, the cells were washed twice, and the vector CTL102 
was added. The interval between removal of the contrast medium and addition of 
the vector was varied. Twenty-four hours post-infection cells were washed twice and 
CB1954 was added. The medium with CB1954 was removed after 24 h, and replaced 
with fresh medium without CB1954. Cell viability was determined after addition of the 
fresh medium.
Statistical analysis
A univariate analysis of variance and Spearman's correlation was used to study the in-
teraction between vector and prodrug and between vector and contrast medium and 
to study the effect of CB1954 on viability of the cells. A Mann-Whitney test for inde-
pendent groups was performed to determine the difference in cell killing between the 
cells that were exposed to contrast medium and the non-exposed cells. In the experi-
ment to study the effect of transient exposure to contrast medium on transduction of 
HAdV-5-vector Spearman's correlation between contact time and viability and between 
delay time and viability was tested. For all statistical analyses p < 0.05 was the level of 
statistical significance. 
Results
Transduction and killing of interface cells by HAdV-5 vectors
To test the susceptibility of interface cells to HAdV-5 vectors, primary cultures of 
interface cells were exposed to the HAdV-5 vector Ad.CMV.LacZ. Twenty-four hours 
post-infection the cells were stained with X-gal solution for β-galactosidase reporter 
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Figure 2.  Transduction of interface cells by Ad.CMV.LacZ in six concentrations (0, 25, 
50, 100, 200 and 400 pfu/ cell). 
After 3 days, cells were fixed and stained with X-gal reaction mix. The percentage of transduced (blue) cells was 
counted. The figure shows the means and standard errors of 12 independent experiments
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To test whether the cells can be sensitised to the prodrug CB1954, interface cells were exposed to increasing 
concentrations of the HAdV-5 vector CTL102, which carries the E.coli-derived Ntr gene. After transduction, the 
cells were exposed to CB1954 and cell viability was assessed with the WST-1 viability assay kit. Cells that were 
transduced with the vector CTL102 without addition of prodrug showed a significant enhancement of cell 
viability with increasing vector concentration (p < 0.001; Figure 3).  
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Figure 3.  Toxicity of adenoviral vector CTL102 in interface cells. 
Cells were infected with CTL102 in concentrations of 0, 50, 100, and 200 pfu/ cell, without subsequent addi-
tion of prodrug. After 3 days cell viability was measured. The figure shows the means and standard deviations 
of 12 independent experiments.
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gene expression. The transduction efficiency increased with increasing vector con-
centration. At 400 pfu/cell the percentage of cells expressing the reporter gene was 
88% (standard deviation (sd) 4.0) (Figure 2). Thus HAdV-5 vectors can transduce 
interface cells. 
 To test whether the cells can be sensitised to the prodrug CB1954, interface cells 
were exposed to increasing concentrations of the HAdV-5 vector CTL102, which car-
ries the E.coli-derived Ntr gene. After transduction, the cells were exposed to CB1954 
and cell viability was assessed with the WST-1 viability assay kit. Cells that were 
transduced with the vector CTL102 without addition of prodrug showed a signifi-
cant enhancement of cell viability with increasing vector concentration (p < 0.001; 
Figure 3). 
In the calculations for the effect of CB1954 we corrected for this effect of CTL102 on 
viability. The level of sensitisation to CB1954 increased with increasing vector titer. At 
200 pfu/cell the mean IC50 value was 25 μM (Figure 4). There is a significant correla-
tion (Spearman) between the viability of the cells and the concentration of CTL102 
(corr. –0.444, p < 0.001) and CB1954 (corr. –0.445, p < 0.001; Figure 4). CTL102 and 
CB1954 showed interaction in their effect on viability (p < 0.001). These experiments 
show that interface cells can be killed using the Ntr/CB1954 approach.
Figure 4.  Viability of interface cells after GDEPT using CTL102 and CB1954. 
Cells were transduced with CTL102 and, after 24 h, CB1954 was added. Viability of interface cells was deter-
mined using WST-1 reagent. Cells were transduced with four concentrations of CTL102: (l) 0 pfu/ cell; (Ñ) 25 
pfu/ cell; (¢) 100 pfu/ cell; (¡) 200 pfu/ cell. (means and standard error of 12 independent experiments)
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Figure 4: Viability of interface cells after GDEPT using CTL102 and CB1954. Cells were transduced with CTL102 and, after 24 
h, CB1954 was added. Viability of interface cells was determined using WST-1 reagent. Cells were transduced with four 
concentrations of CTL102: () 0 pfu/ cell; () 25 pfu/ cell; () 100 pfu/ cell; () 200 pfu/ cell. (means and standard error 
of 12 independent experiments) 
 
CB1954 toxicity  
The toxicity of the prodrug for untransduced cells was tested by a dose ranging study. Interface cells were 
exposed to various concentrations of CB1954 and their viability was evaluated by WST-1 cell viability assay. In 
this assay, the absorbance was converted into viability by setting the absorbance of the wells containing 
interface cells without CB1954 as 100%, and the negative controls, in which no cells were present, as 0% 
viability. In these assays, the absorbance first increased at low concentrations of CB1954 , reaching a 
maximum at 50-100 μM CB1954 (Figure 5). At higher concentrations, absorbance gradually decreased to a 
minimum of 0.211 (sd 0.011), corresponding to a cell viability of around 8.2% (sd 5.4). At a CB1954 
concentration of 1500 μM 50% of the non-transduced cells were killed. The effect of CB1954 on cell viability 




The toxicity of the prodrug for untransduced cells was tested by a dose ranging study. 
Interface cells were exposed to various concentrations of CB1954 and their viability 
was evaluated by WST-1 cell viability assay. In this assay, the absorbance was converted 
into viability by setting the absorbance of the wells containing interface cells without 
CB1954 as 100%, and the negative controls, in which no cells were present, as 0% vi-
ability. In these assays, the absorbance first increased at low concentrations of CB1954, 
reaching a maximum at 50-100 μM CB1954 (Figure 5). At higher concentrations, absor-
bance gradually decreased to a minimum of 0.211 (sd 0.011), corresponding to a cell 
viability of around 8.2% (sd 5.4). At a CB1954 concentration of 1500 μM 50% of the 
non-transduced cells were killed. The effect of CB1954 on cell viability was statistically 
significant (p < 0.001). In CTL102-transduced cells a CB1954 concentration of 25 μM 
revealed killing of 50% of the cells. Transduction of interface cells results in a 60-fold 
sensitisation to the prodrug CB1954.  
Effect of contrast medium on interface cells 
The toxicity of contrast medium (iotrolan) on interface cells was evaluated (Figure 6a). 
Iotrolan does not affect the viability of the cells at any concentration (p = 0.563). Ad-
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was statistically significant (p < 0.001). In CTL102-transduced cells a CB1954 concentration of 25 μM revealed 
killing of 50% of the cells. Transduction of interface cells results in a 60-fold sensitisation to the prodrug 
CB1954.    
























Figure 5: Toxicity of CB1954 on interface cells. Cells were exposed to a range of CB1954 concentrations for 24 h. Cell 
viability was measured using WST-1 reagent. (n=14)  
 
Effect of contrast medium on interface cells  
The toxicity of contrast medium (iotrolan) on interface cells was evaluated (Figure 6a). Iotrolan does not affect 
the viability of the cells at any concentration (p = 0.563). Addition of contrast medium to the interface cells for 
4 h did not lead to killing of the cells. As a control for toxicity of possible iodide release the previous 
experiment was repeated with NaI instead of iotrolan (Figure 6b). There was no effect of NaI on viability of the 
cells (p = 0.903).   
Figure 5.  Toxicity of CB1954 on interface cells. 
Cells were exposed to a range of CB1954 concentrations for 24 h. Cell viability was measured using WST-1 
reagent. (n=14) 
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dition of contrast medium to the interface cells for 4 h did not lead to killing of the 
cells. As a control for toxicity of possible iodide release the previous experiment was 
repeated with NaI instead of iotrolan (Figure 6b). There was no effect of NaI on viability 
of the cells (p = 0.903). 
Effect of contrast medium on HAdV-5 transduction of interface cells 
The effect of contrast medium (iotrolan) on HAdV-5 transduction of interface cells was 
investigated with Ad.CMV.LacZ. Infectivity of the cells increases with the concentra-
tion of HAdV-5 vector. However, the contrast medium has a restraining influence on 
the transduction efficiency. With higher concentrations of iotrolan, the HAdV-5 vector 
concentration has less effect on gene transfer efficiency. At a contrast medium concen-
tration of 50% none of the cells were transduced (Figure 7). Between patients (n=6), 
interindividual differences were observed. The effect of iotrolan on the transduction is 
statistically significant (p < 0.001). Hexabrix was tested simultaneously with Isovist in 
two interface cell lines, and in HepG2 cells for both an Ad.CMV.LacZ and an rAd5F35.
CMV.LacZ vector. Although the rAd5F35.CMV.LacZ vector was much more efficient, the 
results for Hexabrix and Isovist were similar for both viruses.
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Figure 6a: Toxicity of iotrolan (Isovist) contrast medium on interface cells. Interface cells were exposed to contrast medium 
(iotrolan) for 4 h. After 3 days of cell culturing viability of the cells was measured. (n=12) 
 
































Figure 6b: Toxicity of sodium iodide (NaI) on interface cells and HepG2 cells. Cells were exposed to NaI for 4 h. Viability 
was tested after 3 days. (n=6) 
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Figure 6b: Toxicity of sodium iodide (NaI) on interface cells and HepG2 cells. Cells were exposed to NaI for 4 h. Viability 
was tested after 3 days. (n=6) 
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Figure 6.  Toxicity of (a) iotrolan (Isovist) contrast medium and (b) sodium iodide on 
interface cells.
(a) Interface cells were exposed to contrast medium (iotrolan) for 4 h. After 3 days of cell culturing viability of 
the cells was measured. (n=12)
(b) Toxicity of sodium iodide (NaI) on interface cells and HepG2 cells. Cells were exposed to NaI for 4 h. Viability
was tested after 3 days. (n=6)
6a 6b
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To investigate whether the effect of contrast medium on cell transduction by HAdV-5 
vectors was caused by free iodide, NaI was used as a control. Sodium iodide had no 
effect on transduction by HAdV-5 vectors (Figure 8). 
In summary, the results from these experiments suggest that iodide-containing con-
trast medium cannot be used simultaneously with the currently used HAdV-5 vectors.
Therefore, the influence of transient exposure to contrast medium on the transduc-
tion of interface cells was investigated. Interface cells were exposed to contrast me-
dium for 0 to 120 minutes and the period between washing away of the contrast 
medium and performing the Ntr/CB1954 cell killing approach was varied. Cell killing 
was not correlated with contact time (corr –0.033, p = 0.691) or length of the pe-
riod between washing away of the contrast medium and addition of the vector (corr 
–0.004, p = 0.962). After removal of the contrast medium no influence on cell killing 
by Ntr/CB1954 was observed.
Figure 7.  Effect of iotrolan on HAdV-5 transduction of interface cells. 
Cells were exposed to a combination of different concentrations of Ad.CMV.LacZ and contrast medium for 4 
h and then washed and cultured in IMDM/10% FCS. After 3 days the cells were fixed and stained with X-gal. 
Percentage of transduced cells was determined by counting blue cells. Ad.CMV.LacZ used: (¢) 0 pfu/cell; () 25 
pfu/cell; (l) 100 pfu/cell; (£) 200 pfu/cell. (n=12)
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observed. The effect of iotrolan on the transduction is statistically significant (p < 0.001). Hexabrix was tested 
simultaneously with Isovist in two interface cell lines, and in HepG2 cells for both an Ad.CMV.LacZ and an 
rAd5F35.CMV.LacZ vector. Although the rAd5F35.CMV.LacZ vector was much more efficient, the results for 
Hexabrix and Isovist were similar for both viruses. 






























Figure 7: Eff ct of iotrolan on HAdV-5 transduction of interface cells. Cells were exposed to a combination of different 
concentrations of Ad.CMV.LacZ and contrast medium for 4 h and then washed and cultured in IMDM/10% FCS. After 3 
days the cells were fixed and stained with X-gal. Percentage of transduced cells was determined by counting blue cells. 
Ad.CMV.LacZ used: () 0 pfu/cell; () 25 pfu/cell; () 100 pfu/cell; () 200 pfu/cell. (n=12) 
 
To investigate whether the effect of contrast me on cell tr nsduction by HAdV-5 vectors was caused by 
free iodide, NaI was used as a control. Sodium iodide had no effect on transduction by HAdV-5 vectors (Figure 
8).  
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Discussion
This study demonstrates that interface cells can be transduced by an HAdV-5 vector 
and killed by the Ntr/CB1954 approach. 
 Human adenovirus 5 is capable of infecting a broad range of dividing and non-
dividing human cells including fibroblasts and macrophages.34 To our knowledge peri-
prosthetic interface cells have not been used previously as target cells for gene therapy. 
As interface tissue has the histological and histochemical characteristics of synovial 
tissue,43 results of studies with synovial tissue could be an indicator of outcome in 
similar studies with interface tissue. The results of the current study are consistent with 
previous studies that have shown that synovial cells can be successfully transduced by 
HAdV-5 vectors.45,87
 Infection of interface cells with the vector CTL102 without subsequent addition 
of prodrug leads to an increase in cell viability. This anti-apoptotic effect has been 
described previously in lung epithelial cells.39 As the cell viability increases with vector 
concentrations we conclude that the concentrations used in this experiment are not 
toxic for the interface cells.
Figure 8.  Effect of sodium-iodide (NaI) on transduction of two interface cell lines and 
HepG2 cells. 
Cells were exposed to adenoviral vector and various concentrations of NaI in NaCl for 4 h. Cells were cultured for 
3 days and fixed and stained with X-gal. Transduction rates are relative to percentage of transduced cells with 
NaI concentration of 0 mM. Ad.CMV.LacZ as well as rAd5F35.CMV.LacZ were used to infect the cells
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Figure 8: Effect of sodium-iodide (NaI) on transduction of two interface cell lines and HepG2 cells. Cells were exposed to 
adenoviral vector and various concentrations of NaI in NaCl for 4 h. Cells were cultured for 3 days and fixed and stained 
with X-gal. Transduction rates are relative to percentage of transduced cells with NaI concentration of 0 mM. Ad.CMV.LacZ 
as well as rAd5F35.CMV.LacZ were used to infect the cells  
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Discussion 
This study demonstrates that interface cells can be transduced by an HAdV-5 vector and killed by the 
Ntr/CB1954 approach.  
Human adenovirus 5 is capable of infecting a broad range of dividing and non-dividing human cells including 
fibroblasts and macrophages.34  To our knowledge periprosthetic interface cells have not been used previously 
as target cells for gene therapy. As interface tissue has the histological and histochemical characteristics of 
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 Killing of cells by Gene-directed Enzyme Prodrug Therapy (GDEPT) has been stud-
ied before in various cell lines, using various approaches. The Ntr/CB1954 approach 
is attractive for clinical evaluation for several reasons: (1) it generates a toxic agent 
that can kill both dividing and non-dividing cells; (2) induction of cell death occurs 
by a p53-independent mechanism; and (3) CB1954 is well tolerated in humans.34 
Cell killing by the Ntr/CB1954 approach has been proved effective in a variety of hu-
man cancer cells,13,23,48,83,109,125,127 but has not been studied in synovial or interface 
cells. The current study shows that interface cells can be effectively killed by the Ntr/
CB1954 approach. The doses used are assumed to represent concentrations that can 
be achieved in a clinical study. 
 For the current study passage 2 to 4 interface cells were used. These passages 
were used to maximally reduce culture artifacts. On the one hand, in very low pas-
sages (0 and 1) there is a risk of presence of contaminating cells (especially macro-
phages), which decreases with higher passages. On the other hand, at higher pas-
sages, the risk of substantial in vitro alteration/ growth selection exists (especially at 
passages higher than 4).132 In the current study, cultured interface cells of different 
patients were used. For the interpretation of the results the data of all patients were 
pooled. However, it must be noted that interindividual differences in infectivity were 
observed. 
 In this study the influence of contrast medium on transduction by an adenoviral 
vector was investigated in view of future clinical studies. Results show that the con-
trast medium does not seem to have any influence on viability of the interface cells. 
However, transduction of the cells by an adenoviral vector, in the presence of contrast 
medium, is almost negligible. The vector is assumed to be inactivated by the contrast 
medium. This effect was seen in an ionic (Hexabrix) and a non-ionic (Isovist) low-
osmolarity contrast medium . The mechanism of transduction inactivation by iotrolan 
(Isovist) and ioxaglate meglumine – ioxaglate sodium (Hexabrix) remains unclear. The 
effect is not caused by a change of the cells themselves as transient exposure to con-
trast medium does not lead to inactivation of Ad.CMV.LacZ. The effect is independent 
of receptor since rAd5F35, an adenovirus that binds CD46 as receptor, is inhibited by 
Isovist and Hexabrix as well. The inactivation is not caused by iodide itself as exposure 
of the cells and vector to NaI did not lead to decrease in transduction efficacy. In a 
putative clinical study the viral vector will be injected in the joint space. Normally, 
contrast medium is used to verify the position of the needle in the joint. The results 
of this study however show that the use of contrast medium in combination with a 
viral vector is dissuaded. Thus, for a clinical study, we propose that alternative meth-
ods for the visualisation of the needle should be employed such as injection of air to 
create an "air-arthrogram".
proefschrift.indd   48 27-11-2009   10:59:24
Killing of interface cells by GDEPT with CTL102 and CB1954
49
In conclusion, the results of this study show that interface cells can be killed by the 
Ntr/CB1954 enzyme prodrug approach. These data are essential as preclinical work 
for the starting of a clinical study to kill interface tissue in vivo. In such a study, the 
currently employed contrast media cannot be used in one solution with an HAdV-5 
vector given the effect on the transduction of cells.
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Predictable and adequate transgene expression is essential for clinical gene therapy. 
Several studies have focused on optimisation of transgene expression. In this study the 
effect of sodium butyrate (NaB) and a ubiquitous chromatin opening element (UCOE) 
on short-term gene expression after adenovirus-mediated gene transfer in fibroblastic 
interface cells from periprosthetic tissue in loosened orthopaedic implants is investi-
gated.
Methods
Cultures of diploid human interface cells from four patients were infected with an 
adenovirus type-5 vector that carries the luciferase gene driven by the cytomegalovirus 
(CMV) promoter as a reporter. In addition, viruses with a UCOE were evaluated. Twen-
ty-four hours after infection NaB was added in concentrations of 0 to 9 mM. Luciferase 
activity was tested after a further 24 h.
Results
NaB in a concentration of 6 mM caused a 7- to 16-fold increase in reporter gene expres-
sion compared to control condition. There was no difference in reporter gene expres-
sion when cells were infected with Ad.1.5UCOE-CMV.Luc compared to Ad.CMV.Luc. A 
combination of NaB and a UCOE had no advantage over NaB alone. 
Conclusions
Addition of NaB results in a marked increase in transgene expression in cultured cells. 
This would allow the enhancement of the expression of the transgene, without requir-
ing a higher vector dose. Butyrate administration could not be substituted by inclusion 
of UCOEs in the vector. It remains to be established whether the effective concentra-
tions of butyrate can be obtained in vivo. 
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Introduction
Adenoviral vectors have been used in clinical gene therapy trials for various applica-
tions, including disorders of the lungs, cardiovascular diseases, and cancer, and have 
been proven well tolerated in local doses of 2.5 x 1013 particles.55,101 The transgene is 
not inserted into the host chromosome. Therefore, the expression of the transgene is 
usually transient. This makes adenoviral vectors especially suitable for those applica-
tions where short-term expression of the transgene is desirable, such as cancer gene 
therapy. We are currently investigating the possibilities of killing fibroblastic cells 
in the periprosthetic tissue of loosened hip prostheses by a gene-directed enzyme-
prodrug therapy, using a human adenovirus type-5 (HAdV-5) vector, as an alternative 
for revision surgery in patients with a high mortality risk. 
 A common problem in clinical studies is that patients respond differently to treat-
ments. These inter-individual differences can lead to situations in which some pa-
tients show low and others high response to the same treatment. Consequently, the 
occurrence of adverse events can be difficult to predict. Furthermore, several studies 
have shown that some cell types, including bladder cancer cells, vascular cells, mac-
rophages and fibroblasts are more difficult to transduce with adenoviral vectors, 
than other cell types.44,66,89,93 Fibroblastic cells from interface tissue from loosened 
orthopaedic implants can be transduced in vitro, but relatively high HAdV-5 titers are 
needed.30 When the gene expression can be made more efficient and predictable, the 
vector dose can be decreased. This has several advantages, including less evocation 
of a host immune response and a smaller demand for the production of clinical grade 
adenovirus.66 
 In the last decades it has become clear that chromatin structure plays an impor-
tant role in modulation of gene expression.41 The basic subunit of chromatin, the nu-
cleosome, is composed of about 147 base pairs of DNA wrapped around a complex 
of eight histone proteins.41 The organisation of chromatin prevents the transcription 
machinery from interacting with promoter DNA sequences. This can be overcome by 
chromatin-remodeling enzymes that alter the folding, fluidity, and basic structure of 
chromatin.41 Acetylation of histones is one of the mechanisms that alters chroma-
tin structure and increases gene expression. The equilibrium of histone acetylation 
is determined by the net activities of histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). Sodium butyrate (NaB) inhibits the activity of HDACs, while 
the function of HATs is continued, thereby leading to hyperacetylation of the histones 
and an increase in activation of gene expression.27,116,117 The exact mode of action of 
NaB on gene expression is still unknown. Alternatively, gene expression has been aug-
mented by cis-acting DNA sequences inserted in the vector DNA. UCOEs (ubiquitous 
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chromatin opening elements) are methylation-free CpG islands commonly associated 
with dual divergently transcribing promoters, which possess a dominant chromatin-
opening function preventing heterochromatin formation. It has been suggested that 
these elements should be able to provide stable long-term, high-level gene expres-
sion in a gene therapy context.4,126 The advantage of a UCOE would be that the effect 
is generated locally, thereby minimising systemical adverse events. Furthermore, only 
the promoter of the transgene is stimulated, while the other elements in the host cell 
remain unaffected. 
 The goal of this study is to determine the influence of NaB on short-term gene 
expression in fibroblastic interface cells from the periprosthetic tissue in loosened 
orthopaedic implants. Furthermore, the study tries to discover whether the insertion 
of a 1.5 kb UCOE fragment in an HAdV-5 vector gives a more stable expression in 
interface cells compared to the vector without the UCOE fragment. Finally, the influ-
ence of NaB in a vector with a UCOE fragment is investigated. 
Materials and Methods
Cells and cell culture
Cultures of diploid human interface cells were used for all experiments. Interface tissue 
was removed from the periprosthetic space during revision surgery by an orthopaedic 
surgeon and collected in sterile phosphate-buffered saline (PBS). Connective tissue and 
fat were removed thoroughly and the interface tissue was digested for at least 2 h 
at 37°C using collagenase 1A (1 mg/ml; Sigma, St Louis, MO, USA). Cells were then 
harvested by filtering the tissue/collagenase substance through a 200 μm filter (NPBI, 
Emmer-Compascuum, The Netherlands). The cells were cultured in 75 cm2 flasks (Cell-
star, Greiner, Alphen aan de Rijn, The Netherlands) with Iscove's modified Dulbecco's 
medium (IMDM; Biowitthaker, Verviers, Belgium), supplemented with glutamax (Gib-
coBRL, Paisley, UK), penicillin and streptomycin (Boehringer Mannheim, Germany), and 
10% fetal calf serum (FCS; GibcoBRL, Paisley, UK) at 37°C and 5% CO2. 
 Before each experiment interface cells were detached from the flasks using 0.25% 
trypsin (GibcoBRL). The cells were counted in a Bürker counter and dead cells were 
excluded by trypan blue. Cells were seeded in a 96-well plate (flat bottomed) at a 
density of 5000 cells per well. Cells were incubated overnight to allow attachment to 
the bottom. Before each experiment the wells were washed twice with IMDM. Light 
microscopy indicated that more than 95% of the cells were fibroblasts. Cell viability 
was measured using cell proliferation reagent WST-1 (Roche, Mannheim, Germany) 
according to the manufacturer’s instructions with a 2 h incubation period.
proefschrift.indd   54 27-11-2009   10:59:25
Optimisation of short-term transgene expression by sodium butyrate and UCOEs
55
Figure 1.  Schematic representation of the structures of the adenoviral constructs 
Ad.CMV.Luc-SV40p(A) and Ad.1.5kbUCOE-CMV-Luc-SV40p(A). 
Both vectors are derived from adenovirus serotype 5. The luciferase expression cassettes were inserted into the 
E1 region in a left to right orientation. The E1 and E3 regions are deleted from the viruses. CMV (cytomegalo-
virus) is the human CMV immediate early enhancer/promoter. SV40p(A) is the SV40 virus late polyadenylation 
signal from pGL3basic (Promega).
Viral vector construction
PGL3basic was obtained from Promega (Madison, WI, USA) and contains the Luciferase-
SV40p(A) cassette downstream from the multiple cloning site. The human cytomega-
lovirus (CMV) immediate early enhancer/promoter (0.9 kb) was cloned into SmaI di-
gested pGL3basic to generate pGL3/CMV-Luc-SV40p(A). To generate pGL3/1.5kbUCOE-
CMV-SV40p(A), the 1.5 kb UCOE Esp3I fragment was blunted with T4 DNA polymerase 
(NEB, Beverly, MA, USA) and then ligated into NheI digested and T4 blunted pGL3basic/
CMV-Luc-SV40p(A). The UCOE comprises a CpG-rich island containing dual bi-direc-
tional promoters and is derived from the human HNRPA2B1-CBX3 gene locus spanning 
a 1.5kb Esp3I fragment.126 
 To construct pPS1128/CMV-Luc-SV40p(A) and pPS1128/1.5kbUCOE-CMV-Luc-
SV40p(A), the expression cassette was cut out from pGL3/CMV-Luc-SV40p(A) by PvuI/
NheI/BamHI digest and from pGL3/1.5kbUCOE-CMV-Luc-SV40p(A) by KpnI/BamHI di-
gest; both cassettes were then blunted and cloned into SpeI digested and blunted 
pPS1128, which contains the E1-deleted right part of the HAdV-5 genome. The integ-
rity and identity of the plasmids was verified by restriction enzyme analyses.
 The viruses Ad.CMV-Luc-SV40p(A) and Ad.UCOE-CMV-Luc-SV40p(A) were con-
structed by homologous recombination in PER.C638 using pPS1128/CMV-Luc-SV40p(A) 
and pPS1128/1.5kbUCOE-CMV-Luc-SV40p(A), respectively, and the overlapping adeno-
viral backbone vector pPS1160.33 The recombinant adenoviruses were amplified, iso-
lated, CsCl-purified, and titered as described elsewhere75 (Figure 1).
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Transduction efficacy with and without NaB
Interface cells from four patients were infected with Ad.CMV.Luc in different concen-
trations (0, 8, 20 and 80 plaque forming units (pfu)/cell) in IMDM/10%FCS, 40 μl per 
well. After 2 h 60 μl IMDM/10% FCS was added to the wells. After Ad.CMV.Luc-infec-
tion, cells were washed once with IMDM. An interval of 24 h was chosen as this time 
delay was shown to be effective in a previous study.32 The cells were then incubated 
with sodium butyrate (NaB) (Sigma-Aldrich Chemie GmbH, Deisenhofen, Germany) in 
concentrations of 0, 3, 6, and 9 mM in IMDM/10% FCS for 24 h. Then luciferase activity 
was measured. All conditions were tested in triplicate.
Transduction efficacy with and without UCOE
Interface cells from four patients were infected with Ad.CMV.Luc or with Ad.1.5UCOE-
CMV.Luc in concentrations of 0, 8, 20, and 80 pfu/cell in IMDM/10% FCS, 40 μl/well. 
After 2 h 60 μl IMDM/10%FCS was added to the wells. Medium was refreshed after 24 
h. Luciferase activity was measured 48 h after infection. All conditions were tested in 
triplicate.
Combined effect of sodium butyrate and UCOE
To investigate the effect of NaB in the presence of a UCOE, the experiment for transduc-
tion efficacy with and without NaB was repeated with Ad.1.5UCOE-CMV.Luc.
Luciferase assay
Cells were washed twice in PBS, and 100 μl cell culture lysis reagent (Promega) was 
added to the wells. This was left for 10-30 min, and then transferred into another well. 
The luciferase activity present in 10 μl lysate was measured by the addition of 100 μl 
of Luciferase assay reagent (Promega). After 10 s of preincubation the produced light 
was measured for 10 s in a luminometer (Lumat LB 9507, Berthold Technologies, Bad 
Wildbad, Germany).
Statistical analyses
A univariate analysis of variance (ANOVA) was used to determine the effect of NaB and 
UCOE on transduction of interface cells. Also interaction of NaB and UCOE was tested 
with univariate ANOVA. For all statistical analyses a value of p < 0.05 was the level of 
statistical significance. 
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Results
Aseptic loosening by particulate-induced osteolysis is the most common cause of or-
thopaedic implant failure. Wear particles, such as particles of polyethylene and metal, 
are phagocytosed by macrophages, leading to secretion of inflammatory cytokines.43 
The resulting chronic inflammation eventually produces a pseudomembrane of synovi-
um-like interface tissue with activated macrophages, fibroblasts, giant cells and osteo-
clasts. The interface cells (Figures 2a and 2b) are located surrounding the prosthesis 
and in the joint space, which is a closed compartment. As an alternative to manual 
removal, we explored the possibility of removing the tissue by gene-directed enzyme-
prodrug therapy. Here we study how we can increase transgene expression without 
increasing the virus dose.
Effects of NaB on reporter gene expression
Interface cells from four patients were infected with Ad.CMV.Luc at multiplicities of infec-
tions (MOIs) of 0, 8, 20 and 80 and, 24 h later, NaB was added to the tissue culture me-
dium in concentrations of 0, 3, 6, and 9 mM. Figure 3a shows the luciferase activity 48 h 
post-infection. Luciferase activity increases with rising concentrations of NaB. In patients 
2 and 3 maximal effect of NaB is reached at a concentration of 6 mM. The stimulating 
effect of NaB on expression is seen at all MOIs tested. Figures 3b and 3c show the single 
effect of either the vector Ad.CMV.Luc at an MOI of 80 or NaB treatment with a concen-
tration of 6 mM. These figures show that infection with the adenovirus vector or butyrate 
alone does not cause any detectable effect on cell viability.
 Figure 3d shows the induction of reporter-gene expression by NaB per dose group 
per patient. This ratio is obtained by dividing the luciferase activity in the NaB-stimulated 
cells by the activity in the absence of NaB. The mean and standard deviation are then 
calculated for each NaB concentration. Consequently, the induction factor for NaB 0 mM 
is always 1. The differences between the ratios are statistically significant (p < 0.05) in 
all patients except for the differences between the ratios of NaB 6mM and NaB 9 mM in 
patients 2 and 3 (respectively p = 0.717 and p = 0.732). The influence of the amount of 
Ad.CMV.Luc on the ratios did not reach statistical significance (p = 0.086). Fluorescence-
activated cell sorting (FACS) analyses demonstrated that the amounts of coxsackie-ade-
novirus receptor (CAR) on these cells were very low and not affected by butyrate treat-
ment (data not shown). This is consistent with the relatively inefficient transduction of 
these cells by HAdV-5 vectors. The luciferase activity achieved is approximately 2 orders of 
magnitude lower than is achieved in reference tumour cell lines HeLa, HepG2, and Hep2, 
and equals the activity achieved in diploid skin fibroblast cultures (Figure 3e). 
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Figure 2. Photomicrographs of interface cells. 
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Figure 3.  Effect of sodium butyrate (NaB)on transduction of interface cells by Ad.CMV.
luc (a). Effect of the vector Ad5.CMV.Luc on cell viability (b). Effect of the NaB 
on cell viability (c). Influence of different concentrations of NaB on induction 
of reporter-gene expression in interface cells transduced by Ad.CMV.luc rela-
tive to a control condition without NaB (d).Comparison of luciferase activity 
after infection of three types of cells with Ad.CMV.luc (e). 
Interface cells of four patients were infected with Ad.CMV.Luc in four concentrations (0, 8, 20, and 80 pfu/ cell). 
Twenty-four hours after infection four concentrations of NaB (0, 3, 6, and 9mM) were added. All conditions 
were tested in triplicate. The figure shows luciferase activity (mean and standard deviation) for different con-
centrations of vector and NaB. Each graph represents the results from one patient. 
Ad5.CMV.Luc was added to the cells at an MOI of 80 and, 24 h post-infection, cell viability was determined with 
the WST cell-viability assay.
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HAdV-5 vectors. The luciferase activity achieved is approximately 2 orders of magnitude lower than is 
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Figure 3a: Effect of sodium butyrate (NaB)on transduction of interface cells by Ad.CMV.luc. Interface cells of four patients 
were infected with Ad.CMV.Luc in four concentrations (0, 8, 20, and 80 pfu/ cell). Twenty-four hours after infection four 
concentrations of NaB (0, 3, 6, and 9mM) were added. All conditions were tested in triplicate. The figure shows luciferase 
activity (mean and standard deviation) for different concentrations of vector and NaB. Each graph represents the results 
from one patient.  
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NaB was added to cultures of near-confluent cells at a concentration of 6 mM. Twenty-four hours post-infection 
cell viability was assayed with the WST cell-viability assay.
Figure 3d: The figure shows the induction ratio (mean and standard deviation) of luciferase activity between 
different concentrations of NaB (0, 3, 6, and 9 mM) compared to a control of NaB 0 mM. Cells were infected 




Figure 3d: Influence of different concentrations of NaB on induction of reporter-gene expression in interface cells 
transduced by Ad.CMV.luc relative to a control condition without NaB. The figure shows the induction ratio (mean and 
standard deviation) of luciferase activity between different concentrations of NaB (0, 3, 6, and 9 mM) compared to a 
control of NaB 0 mM. Cells were infected with Ad.CMV.Luc in concentrations of 8, 20, and 80 pfu/ cell. Each graph 
represents the results of one patient. 
 
Figure 3e: Comparison of luciferase activity after infection of three types of cells with Ad.CMV.luc. Interface cells derived 
from three patients, human skin fibroblasts, and three tumour cell lines (HeLa, HepG2, and Hep2 cells) were infected with 
Ad.CMV.Luc at an MOI of 20. The figure shows luciferase activity in these cells 36 h post-infection. 
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Influence of UCOE on reporter gene expression 
Enhancing reporter gene expression by NaB may be a method to increase the efficacy 
of gene therapy without increasing the vector dose. However, it may not be trivial to 
achieve locally sufficient concentrations of butyrate. Therefore, we analysed whether 
UCOEs could be used as cis-acting enhancers of gene expression. To study their effect 
interface cells from four patients were infected at MOI 0, 8, 20, and 80 with either 
Ad.CMV.Luc or Ad.1.5UCOE-CMV.Luc and grown in IMDM/10%FCS for 48 h. Figure 4 
shows the luciferase activity for both vectors per patient. There is no effect of UCOE on 
reporter gene expression (p = 0.251). When the influence of vector type on reporter 
gene expression is considered per patient Ad.CMV.Luc gives a significantly higher ex-
pression of luciferase than Ad.1.5UCOE-CMV.Luc in patient 2 (p = 0.049). In the other 
patients there were no significant differences between the two vectors (patient 1: 
p = 0.594; patient 3: p = 0.597; patient 4: p = 0.798).
Combined effect of UCOEs and NaB
Butyrate acts indirectly on transgene expression by inhibiting the histone deacetylases. 
To study whether NaB can also activate the expression of promoters that are linked to 
UCOEs the effects of butyrate in the presence and absence of the UCOEs were com-
pared. In Figure 5a luciferase activity is shown for Ad.CMV.Luc and Ad.1.5UCOE-CMV.
Luc at MOI of 80 with different concentrations of NaB. In the case of a combined effect 
between the two possible gene expression enhancers the regression coefficients would 
be different leading to non-parallel regression-lines. Figure 5b shows that the regres-
Interface cells derived from three patients, human skin fibroblasts, and three tumour cell lines (HeLa, HepG2, 
and Hep2 cells) were infected with Ad.CMV.Luc at an MOI of 20. The figure shows luciferase activity in these 
cells 36 h post-infection.
3e
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sion lines for the two vectors at MOI of 80 are more or less parallel. From these data 
we conclude that there is no difference in effect of NaB in the presence and absence of 
UCOEs (p = 0.424 at all MOIs). 
Discussion
Results of this study show that sodium butyrate (NaB) at a concentration of 6 mM 
increases reporter gene expression by Ad.CMV.Luc with a factor 7 to 16 compared to a 
control condition without NaB. The insertion of a UCOE in the vector did not increase 
reporter gene expression. Also, there was no additive effect when NaB was used in 
combination with a UCOE. 
 Dion et al.32 studied the effect of NaB on transgene expression. They suggested 
that butyrate amplification is both time- and concentration-dependent and found that 
Figure 4.  Transduction of interface cells by vectors Ad.CMV.Luc and Ad.UCOE-CMV.Luc. 
The figure shows luciferase activity (mean and standard deviation) in interface cells from four patients infected 
with four concentrations of vector (0, 8, 20, and 80 pfu/ cell). Two vectors were used, the UCOE-containing 
Ad.1.5UCOE-CMV.Luc and, as a control, Ad. CMV.Luc. Each graph represents the results from one patient.
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optimal NaB concentration was 0.5 to 5 mM and the exposure time to butyrate should 
preferably be 24 h or longer. In our study we used an exposure time of 24 h and found 
6 mM to be the optimal concentration. Sodium butyrate has been used in similar stud-
ies to increase and prolong Ad-LacZ activity in rat fibroblasts.117 In that study by Taura 
et al.117 a strong correlation was found between the amount of hyperacetylation and 
the β-galactosidase activity used as reporter, suggesting that hyperacetylation of his-
tones was responsible for the increase of transcription of the reporter gene LacZ. In 
another study by Lee et al.70 the effect of NaB on transduction of bladder tumour cells 
Figure 5.  Influence of different concentrations of sodium butyrate (NaB) on transduc-
tion of interface cells by Ad.CMV.Luc and Ad.1.5UCOE-CMV.Luc (a). Com-
bined effect of NaB and the different vectors (with and without UCOE). In 
these scatter plots the luciferase activity for different concentrations of NaB 
are shown for Ad.CMV.Luc and for Ad.1.5UCOE-CMV.Luc at MOI 80 and their 
regression lines (b).
The figure shows the luciferase activity at different concentrations (mean and standard deviation) of NaB (0, 
3, 6, and 9 mM) for both vectors at an MOI of 80. For reasons of clarity only MOI 80 is shown in this graph. In 
the statistical analyses all MOIs were taken into account. Each graph represents the results from one patient.
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Figure 5a: Influence of different concentrations of sodium butyrate (NaB) on transduction of interface cells by Ad.CMV.Luc 
and Ad.1.5UCOE-CMV.Luc. The figure shows the luciferase activity at different concentrations (mean and standard 
deviation) of NaB (0, 3, 6, and 9 mM) for both vectors at an MOI of 80. For reasons of clarity only MOI 80 is shown in this 
graph. In the statistical analyses all MOIs were taken into account. Each graph represents the results from one patient. 
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was attributed to a higher CAR expression, but this could not be reproduced by Taura 
et al.117 Since in our study the infection precedes the NaB treatment by 24 h, and since 
there is no induction of CAR expression, enhanced transduction is unlikely to play a sig-
nificant role in the enhancement of luciferase expression. However, formal demonstra-
tion of a direct effect on transcription in the interface cells is thwarted by the inability 
to transfer DNA into the cultured interface cells by any of the commercially available 
transfection reagents. Furthermore, a mechanism in which NaB operates by enhancing 
transcription via inhibition of histone deacetylase is fully consistent with the data of 
Dion et al.32
 Sodium butyrate is a short-chain fatty acid and was found to be rapidly metabo-
lised in vivo, making it difficult to increase or maintain at an effective therapeutic level. 
In a study by Miller et al.84 NaB was administered intravenously at a dosage of 500 mg/
kg/day as continuous infusion over 10 days. No toxicity was encountered. Due to a half-
life of 6.1 min only plasma concentrations of 39-59 μM could be reached. Therefore, 
esterified butyrate derivatives with longer half-lives have been developed that might 
be more effective in vivo as agents for amplification of adenoviral transgenes.88,96,97 As 
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Figure 5b: Combined effect of NaB and the different vectors (with and without UCOE). In these scatter plots the luciferase 
activity for different concentrations of NaB are shown for Ad.CMV.Luc and for Ad.1.5UCOE-CMV.Luc at MOI 80 and their 
regression lines. The figure shows that the lines for the two vectors are more or less parallel suggesting no combined effect 
of NaB and UCOE. For reasons of clarity only MOI 80 is shown in this graph. In the statistical analyses all MOIs were taken 




Results of this study show that sodium butyrate (NaB) at a concentration of 6 mM increases reporter gene 
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a UCOE in the vector did not increase reporter gene expression. Also, there was no additive effect when NaB 
was used  combination with a UCOE.  
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taken into account. Each graph represents the results from one patient.
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an enema, NaB has been shown to be effective and safe in a double-blind clinical study 
in a combinational therapy with 5-aminosalicylates (5-ASA) in patients with refractory 
distal ulcerative colitis.124 Although effective in vitro, the use of NaB for optimisation 
of transgene expression in vivo remains a challenge. However, when a high concentra-
tion of NaB can be achieved locally (e.g. in intra-articular injection), NaB can probably 
be advantageous to increase transgene expression in vivo. With injection in an artificial 
joint in patients with a prosthetic implant, the cells that will most likely be affected will 
be synovium-like interface cells and osseous cells. Schroeder et al.106 studied the effect 
of histone deacetylase inhibitors (HDIs) on osseous cells. They showed that HDIs, like 
TSA and NaB, promote osteoblast maturation and mineralisation in vitro and in vivo in 
calvarial tissues. However, they added that additional studies are needed to examine 
the long-term effects of HDIs on bone formation. 
 In an attempt to increase local effect on transgene expression while keeping sys-
temical effects at a minimum, a vector was developed with a ubiquitous chromatin 
opening element (UCOE) inserted in the vector DNA. The mode of action of the UCOE 
is that the promoter (CMV) is packed in a DNA sequence containing methylation-free 
CpG islands, making the promoter resistant to heterochromatin-mediated silencing of 
these genes. This will cause substantial improvements in the level of expression and 
proportion of transduced cells that express at detectable levels.74,126 Abdullah et al.2 
tested the influence of a UCOE in a plasmid vector on transgene expression in mouse 
airways. Their results showed that in cells with UCOEs the reporter gene expression in 
the first 2 days did not differ from the control group. After 28 days there was a four 
times higher expression in the cells with UCOEs. The effectiveness of this UCOE in en-
hancing expression of CMV-driven cDNA cassette has been demonstrated by Benton 
and collaborators in CHO cell lines after stable transfection, although it should be 
noted that in this study a larger UCOE fragment was used.9 In the current study we 
also found no difference in expression between the vector with and without UCOE. 
The non-integrated CMV promoter is probably not silenced in our target cells within 
the first days after infection, rendering no effect of an anti-silencer insert. Possibly, the 
UCOE could have increased reporter-gene expression in the current study in the longer 
term, but this would be irrelevant in this study, as expression of the transgene is only 
needed for 2 to 3 days. As NaB does activate the reporter gene expression in contrast 
to the UCOE, this suggests that NaB increases reporter gene expression not only by ac-
tivating the activity of the CMV promoter in the transgene, but that other mechanisms 
are also involved. The upregulation of transcription factors by NaB has been discussed 
by other authors.11,17,27,42 This upregulation could be an explanation for the increase in 
reporter gene expression by NaB.
 An alternative method to increase expression is to facilitate binding and infection of 
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the cell by making changes in the adenoviral vector. This method has previously been 
described by our research group.44 Fibroblastic cells have low levels of CAR expression 
and are therefore hard to infect with a HAdV-5 vector. To increase gene expression the 
adenoviral vector was changed by replacing the fibers by those of other serotypes. 
Especially the fibers of the subgroup B (i.e. serotypes 11, 16 and 35) increased the 
reporter gene expression significantly.44
 This study shows that the insertion of a UCOE does not increase short-term reporter 
gene expression in fibroblastic interface cells. Sodium butyrate increases expression by 
a factor of 7-16, but the feasibility for use in vivo remains to be established.
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Assessment of possibilities for intra-articular therapy
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Loosening is a major complication in prosthesis surgery. Less invasive alternatives to 
revision surgery are required to prevent and treat prosthesis loosening. Some experi-
mental therapies investigating alternative treatments exploit the intra-articular space 
as a route of administration. For efficient, local delivery of therapeutic agents a con-
tained joint space is required. Furthermore, the volume of the joint space determines 
the concentration of the therapeutic ingredient in the joint. 
Methods
A retrospective analysis of 221 hip arthrograms performed between 1994 and 2004 
for diagnosis of prosthesis loosening was performed. All arthrograms were studied for 
leakage of contrast medium and the volume of injected contrast medium. 
Results
There was a contained joint in 164 arthrograms (74%). The volume in these hips 
was 31 ± 12.7 mL. Male patients had a larger joint volume than female patients 
(p = 0.019). There was no difference in containment and joint volume between hips 
with a primary and with a revised prosthesis. 
Conclusions
For successful intra-articular therapy it is necessary that the injected agent remains in 
the joint space. As leakage of contrast medium was shown in about a quarter of hips, 
this study shows that an arthrogram may be useful in the inclusion procedure for intra-
articular studies to determine containment of the joint and also the volume that can 
be injected.
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Introduction
For patients undergoing replacement of joints with orthopaedic implants, subse-
quent loosening of the prosthesis is common at long-term follow-up. In addition, 
joint prostheses are increasingly scheduled at a younger age and with increases in 
the average age of developed populations replacement joints experience increased 
activity over longer life spans. Overall loosening of hip prostheses occurs in 7-13% 
of cases within 10 years,54,78,112 this rate is higher in male patients, patients younger 
than 55 years of age and in cemented prostheses (when adjusted for age).78 Revision 
surgery has a 5.7% post-operative mortality (during hospital stay) in elderly patients, 
and in patients with cardiac insufficiency (ASA3 - American Society of Anesthesiolo-
gists) there is an increased risk of major complications such as myocardial failure or 
coronary artery disease. These individuals are therefore ineligible for revision sur-
gery114 and currently have no other treatment options. For these patients there is a 
clear need for alternative therapies that are less invasive. 
 Studies of alternative treatments for prosthesis loosening are currently ongoing, 
in particular intra-articular delivery of therapeutic proteins or genes.37,128 These pro-
tocols involve the inhibition of inflammatory processes within the joint to prevent or 
retard periprosthetic osteolysis19,115,129 or, killing and removal of interface tissue with 
gene-directed enzyme prodrug therapy (GDEPT), with subsequent injection of bone 
cement to refix loosened prostheses. 
 In both such studies good exposure of the target tissue is essential and the inject-
ed active ingredient must remain in the joint for a sufficiently long period. Beside size 
of the therapeutic particle,46,90 the integrity of the surrounding joint tissue (contain-
ment) is important in retaining active particles within the joint space. Leakage of in-
jected fluid can be visualised by arthrography with contrast medium. The presence of 
bursae corresponding with the joint space is a common feature, especially in patients 
with hip prostheses.12,81 Leakage can also occur in the absence of bursae e.g. along 
the psoas muscle. In hips with leakage from the joint, exposure of the target tissue 
to the therapeutic agent will be sub-optimal and there will be an increased risk of 
exposure to surrounding tissues. Thus, before a patient can undergo an experimen-
tal intra-articular treatment it is important to confirm containment of fluid within 
the joint and demonstrate that the tissue surrounding the joint forms a continuous, 
closed compartment . 
 Efficacy of intra-articular therapy is also dependent on the joint volume. In large 
joint spaces the active ingredient will be more diluted than in smaller joint spaces or a 
higher dose will be required with the potential for increased toxicity. Joint spaces can 
also be too small for intra-articular therapy where delivery of the required amount of 
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active ingredient is limited or the local concentrations too high increasing the poten-
tial for normal tissue toxicity. 
 Therefore, for the clinical use of intra-articular treatments it is relevant to dem-
onstrate containment of injected solutions within the joint space and determine the 
volume of that space to optimise the delivery of therapeutic agents to joint tissue. The 
aim of this study was therefore to determine the number of hip prostheses with clinical 
loosening that would be eligible for therapy using intra-articular delivery of proteins or 
genes. 
Methods
Using the hospital database all hip arthrographies performed between January 31st 
1994 and September 30th 2004 were identified. The radiological reports were studied 
for the indication for which the arthrography was made. All arthrographies made in 
hips with a prosthesis in situ were included. Exclusion criteria were a suspected infec-
tion of the prosthesis, dislocation of the prosthesis, procedures in which no contrast 
medium was injected, and arthrographies that could not be found in the archives 
of the radiological department. All arthrograms were performed or supervised by a 
radiologist with arthrography experience. The patient was positioned supine on the 
examination table. The hip region was covered with sterile drapes and the skin was in-
filtrated with a local anaesthetic. Under fluoroscopic guidance a needle directed at the 
femoral neck was inserted into the joint and an attempt was made to aspirate some 
of the synovial fluid for culturing of microorganisms. Ioxaglate sodium meglumine 
(Hexabrix® 320; Guerbet, Aulnay-sous-Bois, France) contrast medium was injected 
through the needle under fluoroscopic guidance. Injection of contrast medium was 
stopped when one of the following events occurred: Rapid increase of pressure while 
injecting the contrast medium; the patient complained of pain in the hip; or presence 
of contrast medium in the lymphatic system on the fluoroscopic images. 
 For retrospective analysis of indication for arthrography and the results of the exami-
nation, the radiological reports and the patient's medical records were used. From these 
records the following data were gathered: age, sex, injected volume during arthrogra-
phy, time span between the total hip arthroplasty and the arthrography, whether the 
prosthesis was a primary hip prosthesis or a revision procedure, and, when applicable, 
findings during subsequent surgery. The results of the arthrography were qualified as 
loose or well-fixed for both the femoral and the acetabular components, respectively. 
The criterion for loosening of the acetabular component was leakage of contrast me-
dium in all acetabular zones or in zone I and II or II and III. The criterion for loosening 
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of the femoral part was extension of contrast medium past the intertrochanteric line of 
the standard stem and halfway down the stem of the long-stemmed component.3
Primary surgery and revisions
Some patients had multiple arthrograms. To compare containment of contrast medium 
and volume of the hip joint after primary and (multiple) revision surgery two subgroups 
of arthrographies were made. In the primary hip group the latest arthrogram before 
surgery was considered. In the revision surgery group the latest arthrogram after the 
most recent revision procedure was considered. In patients with multiple arthrograms 
each hip (right and left) could only be in each group once. 
Containment of contrast Medium
All arthrographies made for diagnosis of aseptic loosening of the hip prosthesis were 
reviewed to qualify containment of the joint. Containment of the joint was defined 
as contained or non-contained, depending on leakage of contrast medium from the 
joint into the surrounding tissues. Presence and localisation of a bursa were noted. To 
investigate containment of the joint space, the spreading of the contrast medium was 
evaluated on the arthrogram prints. When the contrast medium was located in the 
joint space in all prints the joint was considered contained. When the prints showed 
leakage of contrast medium to surrounding tissues the joint was non-contained. There 
was never a contained joint in the presence of a bursa. In some cases a small amount 
of contrast medium leaked out of the joint when the needle was removed, which did 
not count as non-contained.
Sensitivity of arthrogram for loosening
Patients who underwent revision surgery within 2 years after arthrography were in-
cluded in a sensitivity analysis. To study the occurrence of false-negative results loosen-
ing diagnosed with arthrography was compared to findings of loosening during sur-
gery. The prosthesis was considered loose during surgery when there was macroscopic 
movement of the prosthetic component evaluated by means of traction and rotation.
Volume
The volume of the joint was assessed from the radiological report. In hips with a non-
contained joint, injection of the contrast medium was terminated as contrast medium 
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was leaking out of the joint space. The amount of contrast medium injected in these 
cases is probably not the maximal volume. The volumes in non-contained hips were 
therefore not taken into account for determination of mean volumes in patients with 
a clinically loosened prosthesis. 
Statistical Methods
Distribution of contained and non-contained joints was calculated for all arthrograms 
together and for different subgroups. Chi-Square tests and Student's t-tests were used 
to study the differences in containment. 
 For all arthrograms together and for subgroups, mean volume of the joint capacity 
and standard deviations were calculated. Univariate analysis of variance was used to 




Between January 31st 1994 and September 30th 2004 484 hip arthrograms were 
performed at the radiology department of one hospital. In 320 arthrographies a 
hip prosthesis was in situ when the arthrogram was made. 62 arthrographies were 
excluded from the study. In 36 of these an infection was suspected. In 11 patients 
fluoroscopic images were made without injection of contrast medium to analyse 
mechanical problems associated with the hip prosthesis (e.g. dislocation tendency). 
Dislocation of the prosthesis was found in two patients. In one patient only a low 
volume of contrast medium was injected to demonstrate polyethylene wear. Intra-
articular injection was unsuccessful in two patients. Ten arthrograms could not be 
found in the hospital archives. Thus 258 arthrograms were included in the study. 
 125 Patients had an arthrogram made after primary hip replacement in one of 
their hips. The hospital archives from 1994 showed arthrogram of one hip after re-
vision surgery in 53 patients. In these patients there were no data on arthrograms 
before the revision surgery. Ten patients had an arthrogram both before and after 
revision surgery. In six patients there was an arthrogram after primary hip prosthesis 
in the right and the left hip and four had an arthrogram in both hips after revision 
surgery. One patient had an arthrogram of both hips after primary hip replace-
ment and of one of the hips after revision surgery. 26 Patients had more than one 
arthrogram performed without intervening surgery. In these cases the most recent 
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arthrogram was taken into account and the other images were marked as dupli-
cates. There were 31 duplicate arthrograms, which were excluded. In six cases it was 
not possible to determine if the arthrogram was of a prosthesis following primary 
or revision surgery. In total 149 arthrograms were included for analysis of primary 
prostheses and 72 for analysis of revision prostheses. Data regarding sex and age of 
the patient, and side, loosening and survival time of the components are displayed 
in table 1. 
Containment of contrast medium
Of the 149 arthrograms in primary hip arthroplasties 113 (76%) joints were con-
tained. 36 (24%) arthrograms showed a joint that was not contained, 20 (56%) of 
which had a bursa (Figure 1, 2A). In the other arthrograms with a non-contained 
joint the leakage was mainly into the muscles (Figure 3). In the revision hip arthro-
plasties there was a contained joint in 51 of 72 hips (71%). Twenty-one hips were 
not contained and 16 (76%) of them had a bursa.
A number of parameters for differences between the containment groups were 
analysed for primary and revised prostheses. These data are shown in table 2a and 
2b. There was no significant difference in sex distribution and in age between the 
groups. The percentage of hips with a loosened component was higher in the con-
tained group (Table 2). 







Sex male (%) 35/149 (24%) 24/72 (33%) 0.121
Age in years 
(mean ± SD)
68 ± 13 68 ± 11 0.670
Side left (%) 71/149 (48%) 34/72 (47%) 0.952
Loose stem (%) 36/149 (24%) 22/72 (31%) 0.311
Loose cup (%) 64/137 (47%) 38/72 (53%) 0.405
Mean survival time stem (± SD) 103 ± 78 months 105 ± 72 months 0.853
Mean survival time cup (± SD) 108 ± 78 months 87 ± 67 months 0.047
Mean (and standard deviation) of age and survival of prosthesis components are reported for both groups and 
p-values for the differences between the groups are calculated. Distribution of sex and percentage of loose 
components in both groups and their p-values are showed. 
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Figure 1.  Fluoroscopic image of an arthrography of a hip with clinical loosening of the 
prosthesis. 
Example of a hip with a subtrochanteric bursa. Left hip of a 58-year old male patient with an uncemented Mal-
lory head prosthesis implanted five months before the arthrography was done. 70 mL contrast medium could 
be injected, no loosening could be shown.
Table 2a.  Comparison of various parameters between contained and non-contained 






Sex male (%) 29/113 (26%) 6/36 (17%) 0.267
Age in years (mean ± SD) 68 ± 13 66 ± 14 0.387
Loosening of at least one of 
the components
65/113 (58%) 14/36 (39%) 0.051
Loose stem (%) 30/113 (27%) 6/36 (17%) 0.228
Loose cup (%) 53/103 (52%) 11/34 (32%) 0.053
Mean survival time stem (± SD) 106 ± 77 92 ± 81 0.356
Mean survival time cup (± SD) 114 ± 76 89 ± 82 0.129
Mean (and standard deviation) of age and survival of prosthesis components are reported for both groups and 
p-values for the differences between the groups are calculated. Distribution of sex and percentage of loose 
components in both groups and their p-values are shown.
proefschrift.indd   74 27-11-2009   10:59:28
Arthrography in loosened hip prostheses.
75
Figure 2.  Schematic representation of procedure to find percentage of patients with 
contained and non-contained joints (2A). Schematic representation of pro-
cedure to give an idea of the number of patients that can be included in a 
clinical trial based on arthrography data (2B).
 67
 
 all hip arthrograms 
484 
prosthesis in situ 
320 
no prosthesis in situ 
164 
Included in study 
221 (=100%) 
Not for diagnosis of 
loosening  
52 





no bursa: 21 
Good containment 
164 (74%) 












Volume <18 or >44 ml 
78 (46%) 
Suitable for therapy 
90 (54%) 





Figure 2: Schematic representation of procedure to find percentage of patients with contained and non-contained joints (2A). Schematic representation of procedure to give an idea of the 
number of patients that can be included in a clinical trial based on arthrography data (2B). 
 
Table 2b.  Comparison of various parameters between contained and non-contained 






Sex male (%) 14/51 (28%) 10/21 (48%) 0.099
Age in years (mean ± SD) 67 ± 11 72 ±9 0.068
Loosening of at least one of the 
components
35/51 (69%) 13/21 (62%) 0.582
Loose stem (%) 20/51 (39%) 2/21 (10%) 0.013*
Loose cup (%) 25/51 (49%) 13/21 (62%) 0.320
Mean survival time stem (± SD) 110 ± 70 93 ± 79 0.388
Mean survival time cup (± SD) 91 ± 62 77 ± 77 0.470
Mean (and standard deviation) of age and survival of prosthesis components are reported for both groups and 
p-values for the differences between the groups are calculated. Distribution of sex and percentage of loose 
components in both groups and their p-values are shown. 
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Sensitivity of arthrogram for loosening
To investigate whether arthrograms with poor containment exhibited a higher per-
centage of false-negative results, sensitivity of the arthrogram for loosening was cal-
culated. One hundred and two patients underwent surgery of the hip within 2 years 
after arthrography. The mean delay between arthrography and surgery was 6.8 ± 
5.4 months. Of these 102 patients 21 (21%) were not contained and 81 (79%) were 
contained. In the non-contained group 11 hips had loosening of the stem as observed 
during surgery, six of which showed loosening on the arthrogram (sensitivity 55%). In 
the contained group 41 hips had loosening of the stem as observed during surgery, 
28 of which had loosening on the arthrogram (sensitivity 68%). For the cups sensitiv-
Figure 3.  Fluoroscopic image during arthrography in a hip with clinically loose pros-
thesis. 
Example of a hip with a poor containment and leakage of contrast medium along the psoas muscle. Left hip of a 
50-year-old female patient with a cemented Stanmore prosthesis implanted six months before the arthrography 
was done. 40 mL of contrast medium was injected. Loosening could not be shown on the arthrogram. Arrows 
show leakage of contrast medium along the psoas muscle.
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ity was 77% in the group with non-contained joints and 81% in the contained hips. 
Overall sensitivity and specificity for loosening of the stems was 65% and 96%, respec-
tively. For the cups overall sensitivity was 80% and specificity was 93%. There were no 
differences in sensitivity and specificity between primary and revised hips.
Volume
Of the primary hip prostheses 113 had a contained joint, in 88 of which a joint 
volume was noted in the radiological reports. Of the revised hip prostheses 51 had 
a contained joint of which 35 had a known volume. In total 123 arthrograms were 
contained and had a known joint volume. The mean injected volume in the con-
tained hips was 29 ± 12.4 mL (range, 2-60 mL) for the primary prostheses and 34 
± 13.2 mL (range 13-60 mL) for the revised prostheses (p = 0.085). Male patients 
had a larger volume than females when corrected for primary or revision surgery 
(34 ± 13.5 mL and 29 ± 12.3 mL respectively) (p = 0.019). There was no associa-
tion between age and the injected volume (p = 0.192). Mean volumes and the 95% 
confidence intervals for hips with loosening of one or two components are shown 
in Figure 4. 
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Figure 4: Graphic representation of joint capacity in different grades of prosthesis loosening. Error bars represent 
means and their 95% Confidence intervals for four categories of loosening. The mean volume of hips with well-
fixed prostheses is significantly lower than the volumes in all other groups (p = 0.003). There is no difference in 
volumes between the three groups that show loosening (p = 0.171).  
 
In hips with at least ne loose compon nt (di gnosed by arthrography and surgery) the injected 
volume was larger than in hips with no loosened components (33 ± 12.0 mL; and 26 ± 12.6 mL 
respectively) (p = 0.003) (Figure 5). There were no significant differences between hips with only 
loosening of the stem or cup, or loosening of both components with respect to volume of the 
arthrogram (p = 0.171). These results w re similar for loosening diagnosed by arthrography alone.  
 
Figure 5: Fluoroscopic image during arthrography in a hip with clinically loose prosthesis. Example of a contained 
hip with average volume. Right hip of a 76-year-old female patient with a cemented Stanmore prosthesis 
implanted twelve years before the arthrography was done. 20 mL of contrast medium was injected. There is 
loosening of both cup and stem. Arrows show leakage of contrast medium in the periprosthetic space.  
 
Figure 4.  Graphic representation of joint capacity in different grades of prosthesis 
loosening. 
Error bars represent means and their 95% Confidence intervals for four categories of loosening. The mean vol-
ume of hips with well-fixed prostheses is significantly lower than the volumes in all other groups (p = 0.003). 
There is no difference in volumes between the three groups that show loosening (p = 0.171). 
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In hips with at least one loose component (diagnosed by arthrography and surgery) the 
injected volume was larger than in hips with no loosened components (33 ± 12.0 mL; 
and 26 ± 12.6 mL respectively) (p = 0.003) (Figure 5). There were no significant dif-
ferences between hips with only loosening of the stem or cup, or loosening of both 
components with respect to volume of the arthrogram (p = 0.171). These results were 
similar for loosening diagnosed by arthrography alone. 
Figure 5.  Fluoroscopic image during arthrography in a hip with clinically loose pros-
thesis. 
Example of a contained hip with average volume. Right hip of a 76-year-old female patient with a cemented 
Stanmore prosthesis implanted twelve years before the arthrography was done. 20 mL of contrast medium was 
injected. There is loosening of both cup and stem. Arrows show leakage of contrast medium in the peripros-
thetic space. 
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Discussion
In this study joint space containment and volume of hips with a clinically loose prosthe-
sis were evaluated. Of 221 hips, 164 (74%) had a contained joint and 123 of these had 
a known volume. In these hip joints the mean volume was 31 mL. Containment of hip 
joints in patients with a clinically loosened prosthesis has been studied before. Barentsz 
et al.7 studied arthrographies of 24 patients with clinically loosened prostheses. Four of 
24 patients showed leakage of the contrast medium in the surrounding tissues, one of 
them had a bursa. In another study of 178 arthrographies a bursa was found in 35% of 
cases and a non-bursal cavity in seven percent of hips. In total 43% of these hip joints 
had leakage of the contrast medium outside the joint.12,81 
 The volume of the joint cavity is dependent on the method of measurement used. 
In the current study volume was defined as the amount of contrast medium that could 
be injected into the joint until rapid increase of pressure, pain, or lymphatic filling. Hen-
drix et al.58 used the same criteria and found volumes of 7-70 mL in 31 patients. In the 
same way Barentsz et al.7 measured a mean volume of 12 mL (6-30 mL). Seelen et al.107 
performed an arthrography in 30 patients with cementless hip prostheses with clinical 
suspicion for loosening. The mean volume was 18 mL (10-30 mL). Maus et al.81 found a 
small pseudocapsule (0-10 mL) in 32% of arthrographies; a medium size (11-25 mL) in 
47% and a large pseudocapsule (>25 mL) in 21% of 178 arthrograms. Volumes found 
in the current study cannot be compared with studies in which volume of the joint is 
measured by a different method. 
 The results of our study show that there is a higher percentage of loosening in 
hips with a contained joint than in non-contained hips. The association between non-
contained joints (bursae and non-bursal communicating cavities) and loosening has 
not been consistent in the literature. Some authors find a higher amount of loosening 
in hips with a bursa.95 Others conclude that the presence of bursal opacification does 
not have predictive value in identifying loosening or infection.81 However, it must be 
noted that in the case of a bursa or leakage in the soft tissues, the pressure required 
for leakage of contrast medium from the periprosthetic space, cannot be built up. This 
can lead to false-negative results.7 In this study the intra-articular pressure required to 
demonstrate loosening could not be achieved in joints with poor containment. Find-
ings of loosening during revision surgery revealed that in non-contained joints sen-
sitivity of the arthrography for loosening of the stem and cup was lower than in the 
contained group. 
 A drawback of the current study is that the injected volume was not always men-
tioned in the report of the arthrography by the radiologist. 
 Arthrography can be used to calculate the concentration and dose of the active 
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ingredient in patients that are considered for intra-articular therapy for hip prosthesis 
loosening and to exclude patients with leakage from the joint. The volumes that would 
be suitable for intra-articular injections in clinical studies will differ from study to study. 
The range of volumes to be included in a clinical study depend on several parameters, 
including toxicity and the predicted therapeutic window of the injected agent. 
 The data in this study can be used to predict how many patients will be excluded 
from intra-articular therapy protocols based on arthrography results. When hips from 
this study with a known volume are considered 27% (45 of 168) of cases will be ex-
cluded due to leakage of contrast medium. If there is also a limitation to the volume of 
active ingredient to be injected, the number of excluded patients will be larger. When 
a volume of mean ± 1 S.D. is considered to provide a drug concentration within the 
therapeutic range, without a risk for toxic side effects, the volumes to be included in 
the patients in this study would be 18-44 mL, corresponding to a percentage of in-
cluded patients of 54% (Figure 2B). 
 Given the above-mentioned limitation, this study shows that 27% of hips with a 
clinically loosened prosthesis have a non-contained joint. 
Conclusion
In this study containment of injected solutions within the joint space and the volume 
of that space is evaluated to optimise the delivery of therapeutic agents to joint tissue. 
The results of the study show that about one quarter of the hips with a clinically loos-
ened prosthesis has a non-contained joint. When a clinical study with an intra-articular 
therapy is considered, an arthrogram is useful in the inclusion procedure to determine 
containment of the joint and the volume that can be injected.
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Gene Therapy in aseptic prosthetic replacement loosening. 
A phase 1 study
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Elderly patients with debilitating pain from aseptic loosening of the hip prosthesis, as 
proven with arthrography, who are ineligible for surgery due to significant comorbidity
Registration
History, physical examination, radiological studies, laboratory data.
Treatment plan
Hospital admittance for 11 days. Intra-articular HAdV-5 vector injection on day 1, fol-
lowed by intra-articular prodrug injection on day 3. Periprosthetic bone cement injec-
tion 4-7 days after prodrug injection under local anaesthesia (spinal). Mobilisation and 
discharge one day after cement injection.
Dose escalation
The first three patients will be injected with 3 x 109 HAdV-5 vector particles. Dose esca-
lation will proceed to 1 x 1010, 3 x 1010, and 1 x 1011 HAdV-5 vector particles for three 
patients per dose group or until dose limiting toxicity occurs.
Evaluation
Laboratory toxicity evaluation during first six weeks follow up. Clinical evaluation (Har-
ris Hip Score and VAS) at 3 and 6 weeks follow up, 3 and 6 months and every year. X-
rays one day after cement injection, at 6 weeks and 6 months follow up and every year.
Collection of excreta for analysis of shedding from 24 h after vector-injection until 
negative results.
Duration
One period of hospital admittance of 11 days with one single injection of vector and 
prodrug. Follow-up period of 5 years.
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Introduction 
In the Netherlands about 20,000 total hip prostheses operations are performed an-
nually. In the minority of total hip replacements, loosening of the femoral stem and 
acetabulum occurs within 10 years due to aseptic loosening.24,56 Wear particles, 
which are released from the polyethylene acetabular component, travel to all sites 
accessible for joint fluid (including periprosthetic spaces) and are phagocytosed by 
macrophages. This causes an aseptic inflammatory reaction with stimulation of os-
teoclast activity. Activation of osteoclasts in turn causes periprosthetic osteolysis and 
loosening of the implant. Apart from this direct effect mediators released by mac-
rophages stimulate fibroblast-like cells to invade and destroy the bone covering the 
joint prosthesis. The inflammatory process takes place in interface tissue, which is 
located periprosthetically. Interface tissue from patients with loosened prostheses 
exhibits similar behavior as synovial tissue from rheumatoid arthritic joints. When 
prosthesis loosening occurs, patients will experience more pain and walking difficulty 
and have a higher risk for dislocations and pathological fractures.54 
 After 10 years of follow-up 7-13% of patients need revision of their prosthesis 
due to loosening of the implant.79,112 Revision surgery has a high morbidity rate 
especially in elderly patients with co-morbidity. In a study by Strehle et al.114 post-
operative mortality (during hospital stay) in elderly patients was 5.7%. Especially pa-
tients in ASA 3 (grading of mortality risk according to American Society of Anesthe-
siologists)121 with cardiac insufficiency had major complications such as myocardial 
failure or coronary artery disease. In some patients revision-surgery is not an option 
at all, because benefits don’t balance the tremendously high mortality risk. 
 In order to minimise morbidity due to revision surgery we searched for alterna-
tive treatments. In knees (and in a few hips) radiotherapy has been investigated as 
a means to kill synovial tissue in rheumatoid arthritis. In these studies yttrium 90 is 
injected into the joint to destroy the synovial tissue. Yttrium 90 was chosen as the 
best agent for this therapy, because it is a β-emitting radionucleotide (good tissue 
penetration, but not too extensive) with a relatively large particle size (prevents leak-
ing out of the joint) and a short half-life (reduces radiation exposure to non-target 
tissues).25 The results of the studies with yttrium, and other radionucleotides, are di-
verse. However, in a meta-analysis of randomised controlled trials, no clear evidence 
of the efficacy of yttrium synovectomy is shown.59 
 Gene therapy is a tool for delivering individual proteins to specific tissues and 
cells. With gene therapy, target cells can be identified, and then a gene can be de-
livered to these target cells to produce a corrective or killing protein.52 Human Ad-
enovirus 5 is a virus that infects cells from interface tissue with a high efficiency. 
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Moreover, the virus has a high particle size which, in combination with the relatively 
closed joint space, prevents most of it from diffusing into other tissues. When using 
human adenovirus 5 as a vector to express the gene Escherichia coli nitroreductase 
(Ntr), infected cells become extremely sensitive to the prodrug CB1954. The activated 
prodrug causes death of the infected cells.34 In a study by Goossens et al.46 it was 
demonstrated that genes can be transferred to synovial tissue in vivo in rhesus mon-
keys, by direct injection into the joint, and that the synoviocytes can be killed with 
injection of a specific prodrug. In our laboratory previous experiments have shown 
the efficacy of the infection and destroying of synoviocytes and fibroblasts from in-
terface tissue by HAdV-5-Ntr (CTL102) and CB1954.30 This study aims to destroy the 
interface tissue (which causes the loosening), by sensitising the cells to the prodrug 
CB1954, by means of HAdV-5-Ntr (CTL102). Successful destruction and removal of 
the interface tissue is expected to create a periprosthetic space accessible to the injec-
tion of bone cement. To stabilise the prosthesis and re-anchor it to the bone, bone 
cement is injected in the periprosthetic space. This method for stabilising loosened 
femoral stems and acetabula could be especially valuable in patients with high risk 
for complications due to surgical intervention, who are thus defined inoperable. Pa-
tients are admitted to the hospital for 11 days and there is no need for rehabilitation 
afterwards. This is intended to increase the mobility of the patient and decrease pain, 
without the risk of surgical complications.
Objectives
Primary endpoint
To assess the safety of intra-articular injection of the HAdV-5 vector CTL102 and the 
prodrug CB1954 and the percutaneous peri-prosthetic injection of bone cement. 
Secondary endpoints 
•  To histologically investigate a biopsy of interface tissue after the procedure to make 
an assessment of the alterations induced by the intervention. 
•  To establish that this procedure does not cause shedding of the recombinant virus 
into the environment. 
•  To investigate the possibility to stabilise the loosened prosthesis by means of bone 
cement. 
• To investigate clinical results, i.e. pain relief and improvement in ADL
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• aseptic loosened femoral stem implant, as proved by arthrography
• debilitating pain causing ADL dependency 
•  arthrography volume ≤ 45 ml, but injection of a volume of ≤ 30 ml will give suf-
ficient exposure of the interface tissue to the contrast medium
•  significant co-morbidity (ASA 2 and more) causing high mortality risks (>2.5%) 
during or after surgery
•  ability to give informed consent and express a willingness to meet all the expected 
requirements of the protocol
•  patients must meet the following baseline laboratory value guidelines at the screen-
ing and on day 0
 a Haemoglobin > 6 mmol/l
 b Leukocytes 4.0 – 20.0 x 109/l
 c Platelets > 100 x 109/l
 d AST < 50 U/l
 e ALT < 56 U/l
 f AF < 150 U/l
 g Bilirubin < 21 μmol/l
 h Creatinin < 166 mmol/l
 I PT < 14 sec
Exclusion criteria
•  patients who fail to meet the inclusion criteria
•  infection of endoprosthesis
•  patients with obvious adenoviral infection (eye, nose/throat)
•  patients with a history of hepatitis A, B or C or HIV infection
•  patients with a history of alcohol or drug abuse
•  previous gene therapy of any kind
•  patients who underwent chemotherapy, radiotherapy or immune therapy in the 
previous 28 days
•  patients with known immunodeficiency
•  patients with known allergy to E coli proteins
•  patients with life expectancy of <6 months
•  non-cooperating patients
•  patients not able to read and understand Dutch language





The study will be conducted according to the principles of the “Declaration of Helsinki” 
(as amended in Tokyo, Venice and Hong Kong, Somerset West and Edinburgh), and in 
accordance with the Guidelines for Good Clinical Practice (CPMP/ICH/135/95-17th July 
1996). The trial will be conducted in compliance with the protocol. 
Recruitment and consent
The protocol of this study and any subsequent amendments will be submitted to the 
Medical Ethics Committee (CME) of Leiden University Medical Centre and the CCMO 
(Central Committee on Research Involving Human Subjects). The study will not com-
mence before formal approval has been granted. 
 Patients will be recruited from the outpatients’ clinic of the department of Ortho-
pedic Surgery in Leiden. Patients who meet inclusion and exclusion criteria will be 
informed that they are a potential study candidate, by their own orthopaedic surgeon. 
They will be referred to the researcher, who will inform the patient about the study. 
Information will be given both orally and written. The researcher will answer any ques-
tions the patient may have about the study at that time or later, and offer the patient 
the opportunity to participate in the study. She will also be responsible for obtaining 
informed consent from the patient. Patients will be given as much time as they wish to 
decide on participation in the study. At least 1 week should pass between the supply-
ing of information and a positive decision to participate in the study. After approval by 
the subjects, their general practitioners will be notified. Although the subjects will be 
told they are free to leave the study at any time, it will be attempted to recruit subjects 
who are likely to continue the study to completion. 
Justification for the burden of the patients
A loosened prosthesis needs to be stabilised to regain function and decrease pain. The 
current treatment to stabilise the prosthesis is a revision arthroplasty in which the loos-
ened prosthesis is removed and a new one is placed. Patients who undergo revision sur-
gery will have spinal anaesthesia (or general anaesthesia). The mean surgery time for re-
vision THA (total hip arthroplasty) is two to four hours. During surgery 1-2 litres of blood 
may be lost, after surgery drainage systems will collect an additional 500-1000 ml. Com-
plications like cardiopulmonary problems may occur during or after surgery. One major 
risk after revision surgery is the likelihood for deep prosthetic infection (3-5%), which will 
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indicate removal of the prosthesis. Rehabilitation will take about 2-3 months. Patients 
accept this burden as a price they pay for better function of the hip and less pain. 
 In this study, patients with a loosened prosthesis, who cannot be operated upon, 
are included in the study. Currently, no treatment is available for these patients. There-
fore patients included are not restrained from adequate therapy. 
 To adequately refix the prosthesis the interface tissue (which is responsible for the 
loosening) should be removed. In revision surgery this is performed manually. In vitro 
studies in our laboratory have shown that interface tissue can be killed by CTL102/
CB1954 administration. To optimise local dose concentration and minimise systemic ef-
fects, CTL102 and CB1954 need to be administered as locally as possible. Intra-articular 
injection is an adequate method for local administration of fluids and is well tolerated. 
To assure free access of fluids to the periprosthetic space only patients are included 
with an arthrogram that shows contrast medium around the prosthesis. Therefore pa-
tients need to undergo three arthrographies (one to assure access of contrast medium, 
one to inject the viral vector, and one to inject the CB1954 prodrug). 
 When the interface tissue is successfully diminished the prosthesis needs to be refix-
ated. To re-anchor the prosthesis to the bone, cement is injected in the periprosthetic 
space. 
 Although the primary objective of the study is to assess toxicity of local administra-
tion of CTL102/CB1954, it would be unethical to deny a patient a potentially effective 
therapy. For the injection of the cement, holes have to be made through the bone into 
the periprosthetic space. As the bone biopsies are rather painful and the bone could 
not be anaesthetised locally, the patients undergo spinal anaesthesia, with small risk of 
side effects. 
 To assure safety for the environment, patients will be isolated until viral shedding by 
the patient is excluded. Therefore patient’s excreta (nose and throat swabs, urine, and 
faeces) are collected and analysed until negative results are obtained. Then isolation is 
discontinued. 
 To investigate safety for the patient, history, physical examination and laboratory 
parameter measurements are done. These examinations are necessary to detect and 
treat side effects as soon as possible.
Compensation for injury
The chance of injury as a result of the study is small. However the LUMC has insured 
this risk by taking liability insurance that is in accordance with the legal requirements 
in the Netherlands (Article 7 WMO and the Temporary Measure regarding Compulsory 
Insurance for Clinical Research in Humans of 5th July 1999).
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 This insurance provides cover for damage to research subjects through injury or 
death caused by the study. Conditions for benefit of insurance amounts are noted in 
the WMO-declaration.
Trial medication and investigational products
Name and description of investigational products
•  The proposed treatment involves intra-articular injection of a replication deficient 
adenoviral delivery vector (CTL102), engineered to deliver the gene for the enzyme 
E. coli nitroreductase (Ntr). Cells infected with the vector will synthesise the en-
zyme under control of the CMV promoter. The drug product CTL102 is supplied 
by ML Laboratories plc as a sterile, clear, colourless, isotonic aqueous solution at a 
nominal mean potency of between 5 x 108 and 1 x 1012 particles per ml, buffered 
to pH 7.4, in single use polypropylene vials. CTL102 is manufactured by Cobra Bio-
manufacturing plc, Keele, UK, ST5 5SP and formulated into the finished dosage 
form by Q-One Biotech Ltd., Glasgow, G20 0XA.
•  The drug product CB1954 is supplied by ML Laboratories plc as a sterile solution of 
CB1954 17.8 mg/ml in solvent (N-methyl-pyrrolidone 22.2% v/v, polyethylene glycol 
300 77.8% v/v). Just prior to use this prodrug in solvent is diluted using sterile saline 
to a maximum final concentration of 2 mg/ml.
•  To stabilise the prosthesis low viscosity PMMA bone cement is used.
•  For arthrography iodide contrast medium is used. 
•  Ethylene diamine tetra-acetate (EDTA; Sigma Chemical, St Louis, MO, USA) is used 
in a concentration of 2mM in a saline solution to rinse the joint before injection 
with the vector and prodrug.
Summary of findings from non-clinical studies
Pharmacological characteristics
Genetic material delivered by adenovirus is not integrated in the genome of the tar-
get cells, because neither wild type nor recombinant adenoviruses are capable of in-
tegrating their genomes into infected host cells. The CTL102 virus genome remains 
extra chromosomal and does not replicate in the transduced cells. In all cell-lines and 
animals tested, CTL102 has the same tropism and infectivity as the wild type HAdV-5 
from which it is derived. The primary effect of CTL102 infection of a cell will be the 
delivery of the Ntr gene expression cassette. After cell entry and unpackaging from the 
viral capsid, the CTL102 genome will exist as an extra chromosomal DNA element from 
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which the machinery of the infected cell will transcribe Ntr mRNA. This in turn will be 
translated into active nitroreductase, which will accumulate in the cytosol. Expression 
of the Ntr and its persistence is transient both in animal models and cell lines in vitro. 
This is presumed to be due to a combination of protein turnover within the cell, the 
spontaneous loss of CTL102 DNA in infected cells and cell turnover within the popula-
tion. 
 Intracellular Ntr activity is responsible for the activation of prodrug CB1954 to a 
toxic bifunctional alkylating agent inside the cell. Cells able to bioactivate CB1954 are 
cytotoxically affected by crosslink formation at very high frequency. As a consequence, 
cells activating CB1954 are destroyed by death.
 The intended outcome of this study is that infected cells expressing Ntr, which take 
up CB1954, will be killed by the activated prodrug. 
 The potential utility of the GDEPT (Gene-directed enzyme prodrug therapy) ap-
proach is augmented by the so-called “bystander-effect” in which neighbouring un-
transduced interface cells are killed during the prodrug therapy.127 The Ntr/CB1954 sys-
tem offers high selectivity because no natural human enzyme can activate the prodrug 
sufficiently to cause significant biological activity to kill cells in vivo.  
Summary of animal experiments
In mice the peak expression level of Ntr is achieved 48 h after injection of CTL102. Con-
tinued expression ensures adequate levels of the enzyme for prodrug activation over 
several days. In intravenous administration of CTL102 in mice adenovirus DNA is not 
seen in germ cells. In the clinic CTL102 will be administered intra-articularly with low 
risk of systemic exposure to the vector. The safety of CTL102 has been demonstrated 
in single dose and in repeat dose studies in the mouse and in local tolerance studies 
in the rat. Administered intravenously in single doses up to 8.5 x 1010 particles/ml at 
a dose volume of 200 μL per animal, CTL102 was well tolerated and at higher doses 
resulted in some liver damage, reflected by increased liver weight, enzymes and histo-
logical effects. 
 In monkeys CB1954 was injected intravenously. The elimination half-lives (1.5 h) 
indicate there is rapid clearance of the prodrug from the plasma. Clearance is probably 
both hepatic and renal. In general, doses given to mice intravenously represent a 1-2 x 
103 fold safety margin over the same dose given in humans. 
 To assess local tolerance CB1954 was injected subcutaneously in male CD-1 mice. 
High doses were injected (1.5, 6, and 24 mg/kg). As a controls group either the vehicle 
(5% N-methyl pyrrolidone, 17.5% PEG300 and 77.5% physiological saline) or physi-
ological saline alone was injected. No local responses considered to be related to treat-
ment with CB1954 were evident at macroscopic or microscopic examination of the 
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injection site or local lymph nodes. It was concluded from this study that a single subcu-
taneous administration of CB1954 to male CD-1 mice at dosages up to 24 mg/kg, was 
well tolerated, and was without local effect in the subcutis at the injection site or local 
lymph nodes. 
Pharmacokinetic characteristics
Pharmacokinetic results indicate that CB1954 has a mean volume of distribution 
of 14.2 litres/m2 (range 12.8-18.5 liters/m2), a half-life of about 18 minutes (range 
4-35 minutes) and clearance values (range 0.7-1.5 liters/min), which approximate he-
patic blood flow.
Summary of findings from clinical studies with adenovirus gene transfer vectors 
and CB1954
In 1999 18-year-old Jesse Gelsinger died after a direct infusion of an Ad-vector in the 
right hepatic artery. He received 3.8 x 1013 Ad-vector particles, the highest dose ever 
injected in humans. After reviewing clinical and post-mortem findings as well as other 
related studies, members of the Working Group concluded that the research partici-
pant’s death most likely resulted from a systemic, Ad vector-induced shock syndrome. 
A cytokine cascade led to disseminated intravascular coagulation, acute respiratory 
distress, and multi-organ failure. Post-mortem bone marrow biopsy revealed red cell 
aplasia. The data suggested that the high dose of Ad-vector delivered by infusion di-
rectly to the liver, quickly saturated available receptors for the vector within that organ 
and then spilled into the circulatory and other organ systems, including the bone mar-
row, thus inducing a systemic response.8 
 After the tragical death of Jesse Gelsinger doses given to patients by intravenous 
route were limited to 1011 Ad-vector particles. Besides, safety criteria for clinical grade 
adenovirus vector preparations were established, including the criteria of being free of 
endotoxin and infectious agents and containing ≤1 replication-competent adenovirus 
(RCA) for the total dose to be delivered.
 In 2002 Harvey and Crystal brought out two lengthy reports concerning the safe-
ty and toxicity of local delivery of low (<109 particles)- and intermediate (109-1011 
particles)-dose adenovirus gene transfer vectors in humans. The studies analyse the 
adverse events (AE), abnormal laboratory parameters, and deaths observed in 8 trials 
involving a total of 140 local administrations of low and intermediate doses of adeno-
virus gene transfer vectors to 6 sites in 90 individuals. The total experiences from the 
8 trials were grouped to determine whether 10 putative risk factors could be predic-
tive of the safety of trials. The risk factors were structured in 3 groups, associated 
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with the individual (age, sex, comorbid index21, and pretherapy anti-Ad antibody titer), 
adenovirus vector (dose, route of administration, transgene in the expression cassette, 
and number of vector administrations), and the gene transfer trial (trial design and 
involvement of major surgery in the trial). It was found that only the comorbid index 
was a predictor of death. For major adverse events other than death, age and whether 
surgery was part of the trial were determined to be predictors. As no significant asso-
ciation of vector-related factors with major adverse events is seen, it is suggested that 
local administration of these doses of HAdV-5 vectors appear to be well tolerated. For 
all studies combined, the most common abnormal laboratory parameters were a low 
haemoglobin (13.7%) and elevated WBC (12.8%), both occurring mostly in association 
with surgery and returning to normal values within 30 days. Abnormal laboratory val-
ues were mostly seen in participants over 50 years of age and the number of adverse 
events increased with age. Anti-HAdV-5 neutralising antibody did not appear to be 
associated with any aspect of AE or abnormal laboratory parameter. The frequency of 
AEs and abnormal laboratory results slightly increased with HAdV-5 vector dose.26,55  
 There are several differences from the experimental animal studies discussed ear-
lier and the human Ad5 vector trials by Crystal et al.26 in which no association could 
be found between vector dose and major adverse events. First, most studies demon-
strating major ‘toxicity’ of HAdV-5 vectors in experimental animals use doses 102-to 
103-fold greater per kilogram body weight than the doses used in the human studies. 
Second, all the routes used in the human study were local, whereas most experimental 
animal studies use systemic administration. Third, in all human studies HAdV-5 vector 
preparations were thoroughly controlled before injection. Finally, HAdV-5 vectors may 
interact differently with blood elements of humans from that of animals.
25 patients with operable liver, head/neck or prostate tumours have been injected 
intra-tumourally with CTL102 at doses ranging from 108 to 5x1011 particles. No treat-
ment-related serious adverse events have been observed. ELISAs to detect viral proteins 
have been conducted on urine, stools and plasma samples 24 h after injection, and the 
results showed no detectable shed virus at any dose. Following surgical resection of 
tumours in these patients Ntr expression has been monitored by immunohistochem-
istry on tumour sections. Dose-dependent Ntr expression has been observed, and at 
the higher doses Ntr expression observed in >30% of all sections through the tumours 
from several patients.
 Toxicity of CB1954 prodrug was tested23 in humans receiving intraperitoneal doses 
of 3, 6, 12, 18, and 24 mg/m2 and intravenous doses of 3, 6, 12, 18, 24, 30, and 
37.5 mg/m2. There was mild transient treatment-related toxicity due to CB1954 ob-
served in local (i.p.) and systemic (i.v.) administration of doses up to 24 mg/m2. In 
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intravenous administration dose limiting toxicity occurred at a dose of 37.5 mg/m2. 
24 mg/m2 is the CB1954 dose selected for the CTL102/CB1954 clinical studies as giving 
adequate plasma levels without toxicity. 
 In this clinical study CB1954 will be injected intra-articularly ensuring optimal ex-
posure to the target tissue. Due to the small particle size of CB1954, the particles will 
probably leak out of the joint soon. However, when a dose of 24 mg/m2 is injected in 
the relatively small joint the concentration will probably, for a short duration, be so 
high that it is toxic on its own. However, for efficient killing of the interface cells, a 
sufficiently high concentration is needed for a sufficiently long period. Therefore we 
take the advantage of good exposure to the interface cells over the possible toxic-
ity. Patients will be given up to the maximum systemic dose, which is 24 mg/m2. The 
dose will be limited by the volume of the periprosthetic space and the solubility of the 
CB1954 (2 mg/ml). 
 After five patients the dose was lowered to 16 mg/m2 in conformity with protocol 
amendment 2 (03 Feb 2005) due to gastro-intestinal side effects and rise in liver trans-
aminases.
Summary of known and potential risks and benefits
Safety observations found in human studies with other HAdV-5 viral vectors are con-
firmed with animal studies on CTL102:
•  HAdV-5 vector leakage into the systemic circulation from the site of intratumoural 
administration gives rise to transgene delivery to the liver (mainly), as well as the 
spleen, kidney and lung.
•  Leakage from the administration site increases with the speed of injection, as well 
as with the dose of the vector.
•  The presence of anti-HAdV-5 neutralising antibodies tends to be ubiquitous in hu-
man adults and can be induced in animal models by simple exposure to the wild-
type virus (e.g. intranasally). Such neutralising antibodies severely reduce acciden-
tal/incidental liver transduction by up to 1000-fold while peak transgene-expression 
was only reduced by 2.4-fold in the tumours of immune animals in intratumoural 
viral vector injection.15 Varnavski et al.123 performed a study to assess the impact 
of pre-existing immunity to HAdV-5 on the activation of innate immune responses 
to systemically administered HAdV-5 vector. They found that levels of IL-6 in serum 
after vector administration were higher in pre-immunised rhesus monkeys, relative 
to those in naïve animals. They concluded that the pre-existing immunity increased 
the activation of innate immunity. However, the HAdV-5 dosage used in the study 
is a sub-lethal dose; it is not clear whether a lower dose would render the same 
proefschrift.indd   92 27-11-2009   10:59:30
Gene Therapy in aseptic prosthetic replacement loosening
93
results. Furthermore, only two monkeys are used in both groups, and the question 
is whether the same results would be found in larger groups.
•  Possible local toxicity of high concentration of CB1954. Possible local toxicity will 
not be monitored, because invasive interventions are needed to evaluate this. How-
ever, we don’t expect local toxicity as subcutaneous injection of CB1954 into mice 
at a dose of up to 24 mg/kg did not result in toxic effects at the injection site judged 
macroscopically.
Expected adverse events during the study
Intra-articular injection in the hip may cause moderate pain in the joint. 
Rare events during the study
As with any therapy, rare side effects cannot be excluded beforehand. Occasional re-
ports of the following adverse events have been made:
•  When using strict aseptic techniques there is a risk of approximately 0.01% that an 
infection will occur after intra-articular injection. If infection occurs, this complica-
tion will be treated with antibiotics and drainage.
•  Allergic reactions to contrast medium can occur
•  In the case of systemic exposure to significant amounts of CTL102 healthy tissues 
infected by the viral vector will also express Ntr and could sustain damage follow-
ing CB1954 exposure. The liver is in principal at greatest risk of damage as the liver 
takes up the majority of blood borne virus. 
•  From studies it cannot be fully excluded that transgene products can be integrated 
in germ cells, although animal studies show no integration. Therefore, patients 
will be expected to practice contraception for 80 days. This is the period of time in 
which CTL102 can be detected in gonads after administration of the viral vector. 
Potential benefits
If gene therapy is successful and interface tissue is destroyed, patients can experience 
benefits from participation in the study. Bone cement injected into the periprosthetic 
space can then probably stabilise the endoprosthesis, thereby improving ADL-function 
(ADL = activities in daily living) and reducing pain from the loosened prosthesis.
Description and justification of route of administration and dosage
To optimise local delivery of the vector and prodrug to the interface tissue, these prod-
ucts will be injected intra-articularly in the diseased hip. Because of the large differ-
ences in the size of virus and prodrug, these agents will act differently. The virus has a 
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large particle size and when the HAdV-5 vector is administered in the joint space, most 
of the viral vector will probably stay there. As the joint space is a more or less closed 
system, shedding of the virus to other body compartments will be minimised. There-
fore, local administration will give less systemic adverse effects than systemic admin-
istration. Moreover, in local administration the same dosages (compared to systemic 
administration) will give better therapeutic effects. The periprosthetic space is acces-
sible to joint fluid (especially in aseptic loosening) and cells injected intra-articularly can 
thus probably reach target cells (interface cells). During screening period, only patients 
are included with an arthrogram confirming that the contrast medium is easily dis-
tributed in the total periprosthetic space. As in these patients the contrast medium is 
distributed through the entire periprosthetic space we expect that the viral vector and 
prodrug will also be distributed throughout this area. To establish a sufficiently high 
concentration of CTL102 we will only include patients in the study in which a small to 
medium arthrography volume (≤ 30 ml) will give sufficient exposure of the interface 
tissue to the vector. Although arthrography is a rather invasive procedure in the patient 
group to be included, we consider it the only possible way to prove accessibility of the 
entire periprosthetic space. 
 The distribution of CB1954 is a rather different story. CB1954 is a very small mol-
ecule and will thus easily diffuse from the injection site. To assure optimal exposure 
of the prodrug to the transduced interface cells the maximal systemic CB1954 dos-
age without treatment-related toxic side effects is used. This dose (24 mg/m2) will be 
administered in one injection in the hip joint*. During a short period a very high con-
centration of CB1954 will be present in the joint. This high dose is possibly toxic on its 
own (in non-infected cells) and may cause death of some non-infected cells. However 
the highest possible dose is needed to assure a sufficiently high concentration for a 
sufficiently long period. 
As this is a phase I study treatment will start at a low dose of virus. Earlier studies 
showed no serious adverse events when using local administration of <1011 HAdV-5 
vector particles in humans. In this study no dosages of >1011 particles will be adminis-
tered. First three patients will be injected with 3 x 109 particles. When no dose-limiting 
toxicity (DLT) occurs for at least 14 days, the next three patients will be injected with a 
dosage of 1 x 1010 particles. Dose limiting toxicity is defined as any grade 3 or 4 adverse 
event except for nausea and vomiting. In this way dosage increment will continue to 
a dose of 3 x 1010 particles and finally 1 x 1011 particles will be given to the last three 
patients. When DLT occurs in 1 patient of three, three more patients will be included in 
* After five patients the dose was lowered to 16 mg/m2 in conformity with amendment 2 (03 Feb 2005).
proefschrift.indd   94 27-11-2009   10:59:30
Gene Therapy in aseptic prosthetic replacement loosening
95
the same dose. When no other DLT occurs in these patients, the dose will be increased. 
When DLT occurs in 2 or more of the six patients, the given dose will be the maximal 
administered dose and three more patients will be included in the previous dose group. 
When DLT occurs in 2 or more patients of three, no more patients will be included in 
this dose group.
 CB1954 prodrug will be injected intra-articularly 48 h after administration of the 
viral vector. Previous studies have been done in ML Laboratories to observe optimal 
transduction duration of CTL102. It was shown in animal studies that peak expression 
level of nitroreductase (Ntr) was obtained 48 h after intravascular or intratumoural 
injection of CTL102. 
 In earlier studies optimal CB1954 dosage without treatment-related toxic side ef-
fects was found to be 24 mg/m2. In our in vitro studies we pointed out that a CB1954 
concentration of 50 μM for 24 h gives cell viability of <20% in vector concentrations of 
200 pfu/cell. Chung-Faye et al.23 studied toxicity of CB1954 in humans using intravenous 
and intra-peritoneal injections. In intravenous injection, a dose of 24 mg/m2 gave a peak 
serum concentration of 6.3 μM. After 2 h the concentration had decreased to 1 μM. In 
intra-peritoneal injection, the same dose resulted in a peak concentration of 70 μM. Af-
ter 18 h the concentration had dropped to 1 μM. As intra-articular injection has a small 
distribution area, we expect that a dose of 24 mg/m2 will give a sufficiently high con-
centration (50 μM) during a sufficiently long period (24 h) to destroy interface cells. In 
order to maximise the likelihood of achieving adequate exposure of CTL102-infected in-
terface cells to CB1954 the prodrug will be injected intra-articularly at a maximum dose 
of 24 mg/m2. The dose will be limited by the joint capacity and the maximum solubility 
of the prodrug (2 mg/ml), and will have a maximum of 24 mg/m2*. Local toxicity is not 
expected to occur as the prodrug will leak out of the joint space rapidly following injec-
tion. Indeed, because of this rapid efflux it will be essential to inject as much prodrug as 
possible. Consistent with this, subcutaneous injection of CB1954 into mice at a dose of 
up to 24 mg/kg did not result in toxic effects at the injection site judged macroscopically 
and microscopically. Systemic toxicity will not occur as this dose has been shown to be 
well tolerated when administered by intravenous and intraperitoneal routes.
Preparation of treatments
Treatments will be prepared in a clean room within the section IGFL (Interdivisional 
GMP facility LUMC) (GMP (=good manufacturing practice) facility), being part of the 
department of Clinical Pharmacy and Toxicology, by a specially trained and authorised 
* After five patients the dose was lowered to 16 mg/m2 in conformity with amendment 2 (03 feb 2005).
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person. Preparation, transport and other actions done with the vector will be per-
formed according to the safety regulation appended. 
 It is not possible to blind the results. Patients have to be injected in increasing dos-
ages to assess treatment-related toxicity. It is therefore not necessary to label the treat-
ments in a manner in which dosage is blinded from investigators. 
Procedures for monitoring subject compliance
Study medication (HAdV-5 vector and CB1954) will be administered under direct super-
vision. Two investigators will check the medication label for agreement of the contents 
with the study number and the subject’s identity. After intra-articular injection, both 
investigators will sign the drug deposition form.
Methods
Trial design and sample size
The study will be a Phase I, open-labeled, non-randomised trial. Patients who meet 
the inclusion- and exclusion-criteria will be asked to participate in the study. Informed 
consent will then be obtained from the study participants. Power estimations are not 
possible because there are no results from relevant earlier studies. The study scheme is 
outlined in table 1.
 A total of 12 patients will be enrolled in the study. The first three patients will re-
ceive 3 x 109 HAdV-5 vector particles, the second three will receive 1 x 1010 particles, 
the next three 3 x 1010 particles and the last three 1 x 1011 particles. The particles will 
be added to saline in a volume 10% less than the volume used at the inclusion arthro-
gram. This to prevent lymphatic drainage of the vector due to a high pressure, while 
creating a pressure high enough to allow the fluid to reach the periprosthetic space. 
Two days after injection of the viral vector (day 2) patients will receive CB1954 by intra-
articular injection at a concentration of 2mg/ml. The total dose will depend on the 
arthrogram volume of the treated patient and will thus vary from patient to patient. 
The dose will, however, not exceed 24 mg/m2*. To minimise influence of synovial fluid 
on the vector and prodrug the joint will be extensively rinsed with 2 mM EDTA solution 
before administration of vector and prodrug. The EDTA will improve efficiency of gene 
transfer, whereas viability of the cells is not influenced. In a study by de Roos et al.31 
infection of liver cells increased from 21% to 54% after administration of EDTA. The 
* After four patients the dose was lowered to 16 mg/m2 in conformity with amendment 2 (03 Feb 2005)
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exact mechanism of the EDTA on the improvement of gene transfer is unknown, but it 
is assumed that the EDTA causes dissociation of the cells or widening of the fenestrae 
in the cell by binding of Ca2+. After saturation of the EDTA by Ca2+ (from the interface 
cells and from the bone) and other metal ions, the effect on the cells is extinguished 
and EDTA is excreted by the kidneys. On day 9 interface biopsies will be taken to inves-
tigate efficacy of the interface destruction. The patient will undergo spinal anaesthesia 
and a thick needle is introduced in the bone through which the biopsy is taken (at 
three sites around the femoral stem and at one site in the acetabulum). The needle will 
then be used as an introduction site for the injection of bone cement (figure 1). Bone 
cement is injected in the periprosthetic space under fluoroscopic guidance to prevent 
leakage of the cement into the joint space. 
Figure 1. Schematic outline of study
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Adverse events are defined as any undesirable experience occurring to a subject during 
a clinical trial, whether or not considered related to the intervention. Adverse events 
reported by the patient or observed by the researcher or other investigators will be 
subscribed and classified according to intensity, duration and time of occurrence. All 
adverse events will be recorded on the adverse event data collection form.
 For each event the relationship to drug (definite, probable, possible, unknown, 
definitely not) as judged by the investigator, as well as eventual actions taken, will be 
recorded. The occurrence of an adverse event that is fatal, life-threatening, disabling 
or requires or prolongs in-patient hospitalisation, results in persistent or significant 
disability or incapacity, or is a congenital anomaly of birth defect will be described ac-
cording to Clinical Trials Directive 2001/20/EC as ‘serious adverse event (SAE)’.
The responsible investigator will report SAEs as follows:
•  All SAEs will be reported to ML Labs. plc. by telephone and in writing as soon as 
practical, but at least within 24 h of recognition; 
•  All SAEs will be reported by the investigator to the Medical Ethics Review Board and 
the CCMO that approved the study, by telephone and in writing as soon as practi-
cal, but at least within 15 days;
•  SAEs with a suspected (probable or definite) relationship to trial medication (as 
indicated by the responsible investigator) will be reported to the Drug Safety Unit 
of the Healthcare Inspectorate (‘Hoofdinspectie voor de Farmacie en de Medische 
technologie, Inspectie voor de Gezondheidszorg’).
Reports to the Health Authorities are submitted in conjunction with ML Labs. plc. ML 
Labs can prepare additional reports for other authorities.
Safety parameters
Blood pressure, temperature and 22 laboratory parameters (see below) are measured. 
We specifically chose these parameters because they are relevant to laboratory ab-
normalities observed in experimental animals receiving high doses of HAdV-5 vectors. 
Abnormality of laboratory parameters will be classified according to WHO recommen-
dations for grading of acute and sub-acute toxic effects.
•  General safety measurements
  After HAdV-5 vector administration the researcher will visit the patient at least ac-
cording to the following scheme and whenever it is clinically indicated. In each visit 
medical history and physical examination (inspection of injection-area and auscul-
tation of heart and lungs) will be done. Furthermore, vital signs will be recorded. 
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Visits to the patient will be made directly before and after viral vector injection, ½ 
hourly to 4 h, hourly to 8 h and 4-hourly to 24 h. After 24 h, visits will be made at 6 
hourly intervals until CB1954 administration. Vital signs will then be recorded daily 
until discharge from the hospital, and at each assessment point throughout the 
study. 
•  Safety laboratory measurements 
  Hematology: The following assessments will be performed: Haemoglobin, hemato-
crit, ESR, white cell count (WBC), leukocyte differential count and platelet count.  
  Blood biochemistry: The following assessments will be performed: lactate dehydro-
genase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), al-
kaline phosphatase, glucose, amylase, bilirubin, creatinin, Na, K, Ca, Mg, albumin, 
CRP, partial thromboplastin time (PTT) and prothrombin time (PT). CB1954 concentra-
tion in the blood will be measured 5 minutes and 1 and 2 hours after administration. 
  Urine: In the patient’s room a urinestick will be dipped in the urine to assess pro-
teinuria and haematuria.
Secondary study endpoints 
•  Investigation of a biopsy of interface tissue after the procedure
  On day 9 of the study patients will undergo an interface tissue biopsy under spinal 
anaesthesia. Interface tissue biopsies will be done using Jamshidi needles. From bi-
opsy holes interface tissue will be taken. The Pathology laboratory will describe the 
histological appearance of the interface tissue and compare it to interface tissue 
derived during revision surgery. 
•  Endpoints to exclude shedding of the virus and prodrug
  To assess whether any of the vector was shed from the target organ systemically or 
in the environment patients will be monitored on blood, urine, pharyngeal, nasal, 
and rectal samples. Samples will be collected for PCR analysis 24 h after CTL102 
injection, and daily until negative results are obtained. CB1954 concentration is 
measured in the blood 5 minutes and 1 and 2 h after administration. 
•  Endpoints to investigate stabilisation of the prosthesis in the femur
  X-rays will be made to estimate periprosthetic space before and after the proce-
dure. X-rays will be made at screening and one day after cement injection, after 6 
months and then every year.
•  Endpoints to investigate clinical results of the study
 Pain, independency and walking distance
  Pain experienced by the patient will be measured by using a Visual Analogue Scale 
(VAS). In this, patients are asked to score the pain they experience on a gliding 
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scale. The scale is a 10 cm long line, at the left beginning with ‘no pain at all’ and 
at the right ending with ‘unbearable pain’. Patients can score their pain by placing 
a mark on the gliding scale. In the same manner a visual analogue scale will also be 
used to quantify independency and walking distance.
 Ability to walk/ improvements in ADL 
  Improvements of ADL-function will be measured using the Harris Hip Score. In this 
score performance is measured on the following items: pain, limp, support, walk-
ing distance, stair climbing, putting on socks and shoes, sitting, and ability to use 
public transport. 
Withdrawal of individual subjects
Subjects can leave the study at any time and for any reason if they wish to do so with-
out consequences. The responsible investigator can also withdraw a subject if any of 
the following events occur:
•  Significant protocol violation or non-compliance, either on the part of the patient 
or the investigator
•  Refusal of the patient to continue treatment and/or observations
•  Any infection after vector administration, not intended in the study
•  Unacceptable or dose limiting toxicity
•  Decision by the investigator that termination is in the patient’s best medical interest 
•  Unrelated medical illness or complication
•  Loss to follow-up
•  Death of patient (will be reported to the researcher by the general practitioner)
Replacement of individual subjects after withdrawal
Patients who withdraw from the study will not be replaced by other patients. 
Follow up of subjects withdrawn from treatment
Patients withdrawn from treatment will preferably be followed up in the same manner 
as other patients in the study. When patients withdrawn from the study don’t consent 
to further follow up a last analysis is done to investigate whether there are any toxic 
effects at that moment (laboratory parameters and adverse events) and whether there 
is any viral shedding to the environment (urine, faeces, blood, and nose and throat 
swabs). In abnormality of parameters necessary actions will be taken to secure safety 
for the patient and the environment. 
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Discontinuation criteria for the study
The study will be discontinued when an unacceptable adverse event occurs, that is 
definitely or probably related to the procedures in the study. 
Data analysis
Data handling and record keeping
Data will be recorded first on a paper Case Record Form (CRF) and then on a spread-
sheet in which all patient’s data are listed. After validation data will be entered in a 
computer system for subsequent tabulation and statistical analysis. The data will be 
handled confidentially and anonymously. All patients who enter the trial will be anal-
ysed, the patients who complete the trial as well as patients who withdraw from the 
study after injection of the virus and prodrug. 
Statistical analysis
Statistical analysis will be performed at the Department of Orthopaedic Surgery in the 
LUMC.
 Means and standard deviations will be used to describe outcome parameters, sup-
plemented by calculation of confidence intervals wherever this aids interpretation. A 
p - value of <0.05 will be considered significant. Graphical presentations will be made 
in which patterns of adverse events are displayed.
 Laboratory parameters will be subjected to linear regression in which 1.25 x upper 
normal value is taken as upper limit of normal values. Also a linear regression is done in 
which a 25% difference between baseline and follow-up values is taken as upper limit 
for normal variation. 
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Appendix 2. Harris Hip Score
HARRIS HIP SCORE
I PAIN (MAX 44 POINTS)    
None or ignores it 44 pt
Slight, occasional, no compromise in activities 40 pt
Mild pain, no effect on average activities, rarely moderate pain  30 pt
with unusual activity, may take aspirin
Moderate pain, tolerable but makes concessions to pain.  20 pt
Some limitations of ordinary activity or work. May require occasional 
pain medication stronger than aspirin
Marked pain, serious limitation of activities 10 pt
Totally disabled, crippled, pain in bed, bedridden 0 pt
II FUNCTION (MAX 47 POINTS) 














Cane for long walks 7 pt
Cane most of the time 5 pt
One crutch 3 pt
Two canes 2 pt
Two crutches 0 pt




500 – 1000 m 8 pt
100 – 500 m 5 pt
Indoors only 2 pt
Not able to walk 0 pt
Activities (max 14 points) 
 
Stairs 
Normally without using a rail 4 pt
Normally using a rail 2 pt
In any matter 1 pt
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Unable to do stairs 0 pt
Shoes and socks 
With ease 4 pt
With difficulty 2 pt
Unable 0 pt
Sitting 
Comfortably in ordinary chair one hour 5 pt
On a high chair for one-half hour 3 pt
Unable to sit comfortably in any chair 0 pt
Enter public transportation  (if yes) 1 pt
III ABSENCE OF DEFORMITIES (MAX 4 POINTS)
(If all are applicable 4 points, otherwise 0 points)
Less than 30° fixed flexion contracture  
Less than 10° fixed adduction 
Less than 10° fixed internal rotation in extension 
Limb-length discrepancy less than 3.2 cm 
IV RANGE OF MOTION (MAX 5 POINTS)
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Appendix 3. Patient information
Patient information for a scientific study of gene therapy as an experimental 
treatment in a loosened hip prosthesis.
Responsible investigator: Prof. Dr. R.G.H.H. Nelissen
Department:  Orthopaedic surgery
Telephone:  071-5263606
Dear Sir, Madam,
In continuation of the consult with your own orthopaedic surgeon you hereby receive 
information in writing about a scientific study in which we ask your cooperation.
We do not ask you to make a decision immediately. Do take some time for reflection 
before you decide to contribute to the study. We advise you to discuss your co-opera-
tion with your family, general practitioner or others.
Would you feel any need to put your questions to a doctor that is not directly involved 
in the study, you can find the name and telephone number of this independent doctor 
in these information pages.
Introduction
As was discussed with you, the prosthesis in your hip has loosened. Therefore, you 
have complaints of pain in the hip and walking difficulty. Usually the treatment for this 
loosening is an operation. In this operation the old prosthesis is taken out and a new 
one is put in. In some patients (including you) the risk for adverse events during such 
an operation is high. That is why we are searching for alternative treatments to refix a 
loosened prosthesis.
We asked your contribution in a study with a new, not yet registered, gene therapy. To 
gain more information about safety, tolerability and optimal dosing of this experimen-
tal treatment, studies in patients are necessary. 
In animal studies with this form of gene therapy the adverse events were limited up 
till now. There have been limited studies in humans. About the safety and tolerability 
of the treatment, the following can be stated: The doses of the treatments used in pa-
tients in this study have not caused serious adverse events in other studies.
Study objectives
From previous studies we know that certain inflammatory cells, which break down 
the bone around the prosthesis, cause prosthesis loosening. Up till now there are no 
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medications that can stop these inflammatory cells. By means of gene therapy we are 
aiming to remove these inflammatory cells. The effect is as follows:
Gene therapy is a new experimental treatment, which is thoroughly investigated at the 
moment. With gene therapy you can give certain cells specific instructions. An adeno-
virus (which normally causes a cold) is used to deliver this instruction into the cell (like 
a letter). We need the virus, because the letter is not able to go to the cell on its own. 
As a virus normally enters the cells, it can well be used to deliver the message. Before, 
the virus was modified so that it is not able to multiply. All information that the virus 
uses to make people ill, is removed. The virus only knows how to penetrate the cell, and 
that it has to deliver a message. 
In this study a virus is used that penetrates the inflammatory cells (which cause the 
loosening) efficiently. These cells get the instruction to make a certain protein in an 
amount as high as possible. After 2 days a drug is administered to the joint that spe-
cifically destroys the cells that have produced a high quantity of the protein. The body 
then automatically clears these cells away. We investigated in our laboratory that we 
can kill the inflammatory cells in this way. But we don’t know yet whether it also works 
in humans. We will now investigate what happens when the modified virus and the 
drug are injected in a patient with a loosened hip prosthesis. We will study whether 
there are adverse events and whether the virus can leak to the environment. And of 
course we want to know whether the inflammatory cells can be destroyed by the gene 
therapy. We also want to know if we can put bone cement in the space where the in-
flammatory cells were, to refix the prosthesis. 
The study will take place in the Leiden University Medical Center (LUMC) and a total of 
12 patients will participate in the study. 
Design of the study
The participating patients will be divided in 4 groups. Each group will receive a differ-
ent amount of virus to see which dose is the best. First three patients receive the low-
est dose. Then these patients are followed during 2 weeks to see whether they have 
adverse events. Only after this period the second group receives a higher dose, etc. 
When you want to participate in the study history is taken and physical examination 
will be done. Also blood will be drawn and X-rays of your hip are made. These investi-
gations have to be done to see whether you are a good candidate for the study. If you 
appear to be an appropriate candidate and you still want to participate, an examina-
tion will be done in which contrast fluid is injected in the hip joint and X-rays (arthrog-
raphy) will be made to see how loose the prosthesis is. If you are going to participate 
in the study appointments will be made for the days when you are expected in the 
hospital for examinations.
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During the study you will be admitted to the hospital for 11 days, of which the first 
few days in an isolated room. The first day of your admission the virus will be injected 
in your hip joint. On the third day the drug, that will destroy the inflammatory cells, 
will be injected in the same way. To see whether the therapy was successful four holes 
will be drilled through the bone around the prosthesis. Because the bone cannot be 
anaesthetised you will have spinal anaesthesia. Through the drilled holes some of the 
inflammatory tissue will be removed to examine whether the cells were destroyed. 
Furthermore, we will inject bone cement through these holes to refix the prosthesis.
During the 11 days of your admittance to the hospital several examinations will be 
done to investigate whether there are adverse events from the treatment. Just like in 
other medications the body can react to the therapy and you can have adverse effects. 
From the moment that the virus is administered, someone will check on you every 
30 minutes, and measure blood pressure and temperature. When you are doing fine, 
controls will be phased out. To trace down potential adverse effects as soon as possible 
blood will be drawn on day 2 and 5 for laboratory analysis. To check that the virus will 
stay in the hip joint and does not migrate through the body and the environment extra 
examinations will be done. Therefore, you will be asked to cooperate to examination of 
urine, faeces, nose and throat swabs and blood. During the year after your admission 
to the hospital you will visit the out-patient clinic 7 times to check on clinical effects 
of the treatment.
Potential risk of the study
As this form of treatment with gene therapy is new, the experience is still limited. This 
study will be done to track down potential adverse effects. Up till now there are no 
indications that the virus will shed outside the injected joint. Still, to prevent every 
potential shedding of the virus, the virus will be injected in an isolated room. A sample 
of your blood, faeces, urine and sputum will be collected after one day and analysed 
for presence of virus, and every day until negative results. You are asked to stay in your 
room until we know for sure that there is no virus in your urine, faeces, sputum or 
blood.
During the study you will have two injections in your hip joint, once to administer the 
virus, and once to administer the prodrug. Injections in the joint can be painful. After 
injection there is a minimal risk to infection.
On the fifth day of the admission, 4 small holes will be drilled in the bone (under spinal 
anaesthesia). Through these holes through a thick needle, a piece of bone and inflam-
matory tissue will be removed for analysis (biopsy). Through the same needle bone 
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cement will be injected in the open space between prosthesis and bone. The injection 
from the spinal anaesthesia can be painful. There is a small chance that you experience 
a headache after the spinal anaesthesia. The cuts in your skin are so small that you 
don’t need any stitches.
Potential benefits from the study
If the inflammatory cells, which are responsible for the loosening of the prosthesis, 
turn out to be destroyed by the gene therapy, and if the space between bone and 
prosthesis can be filled with bone cement, you could possibly experience a benefit 
from participation in the study. As this study is the first one in which gene therapy is 
used to treat loosening of prostheses, there are no results from previous studies avail-
able. The results, which will proceed from this study are difficult to predict. That is why 
you’d better anticipate that you won’t experience any benefits from participation in 
the study.
Blood transfusion and organ donation
The Minister of VROM (environment) has stated that patients who participate in a gene 
therapy study are not allowed to donate blood for blood transfusion. In case of organ 
donation the physicians need to be informed about the gene therapy study you par-
ticipated in. Although it is unlikely that the virus will still be present in an organ, they 
want to rule out the possibility that the virus will be transferred by blood transfusion 
or organ donation. You therefore have to sign a written declaration.
Voluntary participation
Your participation to the study is voluntarily. If you decide to cooperate in this study, 
you have the opportunity to come back at your decision at any moment. You don’t 
have to give any argumentations, but you are asked to report your decision to your 
physician as soon as possible. He will discuss with you whether discontinuation has any 
consequences for you that make it necessary to start another treatment. Your physi-
cian can also decide to discontinue your participation to the study, when he thinks 
this is better for your well-being. When this is the case your physician will discuss this 
with you. When, during the study, new information becomes available, your physician 
will discuss this with you. The decision to participate or not to participate in the study 
won’t have any influence on the understanding you have with your physician. 
Financial compensation
When you make extra travelling expenses because of participation of the study, these 
will be compensated.




You can be assured that all data that are accumulated under code (i.e. without report 
of your name and address) about you, will be handled confidentially according to the 
medical treatment agree (WGBO (this is a Dutch law in which patient-physician relation 
is made clear)) and that non-competent outsiders don’t have access to your data. The 
results of this study will be used in a scientific publication, but also then the data will 
not be reducible to you as a person. We will inform your general practitioner about 
your participation in the study.
Insurance
The LUMC has effected an insurance to cover potential damage inflicted by the study. 
When you think you have experienced damage from participation in the study you can 
contact the researcher. 
In conclusion
Would you have any questions regarding the information of this study you can ask your 
physician, the researcher and the independent physician.
For general information on participation in scientific studies we refer to the brochure 
“Asked for medical scientifical research” (this is a brochure which patients can ask at 
the information desk), which is available at the patients-service-bureau on the second 
floor of the LUMC. 
When you decide to participate in this study we ask you, at the next visit with reference 
to the study, to sign the informed consent form. By signing this form you are not com-
mitted to anything (your signature is not binding), but you give to understand that you 
have received and understood the information and that you know what is expected 
from you with regard to the study.
Researcher JJ de Poorter  Indep. physician Dr. CF Allaart 
Department Orthop. Surgery  Department Rheumatology
Telephone 071-5263606  Telephone 071-5263598
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Outline of all burdening of the study
During hospital admittance:
  Injections in the joint: To administer the virus and the drug as close as possible to 
the inflammatory cells (which cause the loosening) they are injected into the 
joint. This will take place in the radiology department. First, the skin will be an-
aesthetised and then the fluid will be injected using a thin needle. The injection 
can be painful. Injections will take place on the first and third day of the hospital 
admittance.
 Bone biopsies and injection of cement: On the seventh day of the admittance four 
small holes are drilled through the bone to collect a little inflammatory tissue 
and cement is injected to refix the prosthesis. Because the bone cannot be an-
aesthetised locally you will have spinal anaesthesia. In total this will take about 
one hour. After the procedure you will be taken back to your room.
 Collection of urine, faeces, nose and throat swabs and blood (These are called ex-
creta). These investigations will be done to find out where the virus sheds after 
we have injected it. A sample of the urine and faeces you produce will be col-
lected after 24 h after the injection of the virus and will be analysed for presence 
of virus. Also, with a piece of cotton-wool, a culture will be taken from your 
nose and throat and a blood sample will be taken. All samples will be evaluated 
as soon as possible. The next day samples will be taken again if virus was pres-
ent the previous day. When all samples are free of virus, you are allowed to leave 
the room whenever you want.
 Adverse effects: To track down potential adverse effects of the gene therapy you 
will be observed carefully. We do this by asking you questions about how you 
are feeling and by physical examinations (listening to heart, lungs and abdomen 
and palpation of the abdomen). Also, blood samples will be taken to investigate 
whether you have adverse effects you haven’t mentioned. The physical exami-
nations will take place every day, the blood samples will be taken on the second 
day and the fifth day.
 Hospital visits: In the first part of the study you will be admitted to the hospital dur-
ing 11 days. You will have a separate room. During the first days you are not al-
lowed to come out of the room. Nevertheless you are allowed to receive visitors.
 Until 1 year after the injections you will visit the researcher in the hospital a total of 
7 times for this study. During the visits she will ask you whether there are any 
problems or complaints and she will do physical examinations. The traveling-
expenses you make for visiting the hospital will be compensated. The researcher 
can arrange that a taxi will collect you at home and bring you back after the 
visit, if you like that. 
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 Blood samples: The first three times that you visit the hospital for the study you 
will be asked to have 2 tubes of blood drawn. This will be done to investigate 
whether there are adverse effects that you haven’t mentioned.  Whenever pos-
sible, potential adverse effects will be treated. Three months and 1 year after 
the injections in the hip joint another tube of blood is taken to investigate how 
the immune system has responded to the gene therapy.
 X-rays: To investigate whether the treatment was successful some X-rays will be 
made. At the last day of your admittance an X-ray will be taken from your hip 
and pelvic  region (these pictures are the standard pictures you have had be-
fore). In the control visits after 2 weeks, after 6 months and after 1 year similar 
pictures are taken.
The burdening you may experience from the study is outlined in the scheme on the 
next page.
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Patiënteninformatie ten behoeve van een wetenschappelijk onderzoek naar gen-
therapie als experimentele behandeling bij een losgelaten heupprothese.
Versie 5, 29 september 2003
Verantwoordelijk onderzoeker:   Dr R.G.H.H. Nelissen  
Afdeling:     Orthopaedie   
Tel.:      071-5263606   
Geachte mevrouw, mijnheer,
In aansluiting op het gesprek met Uw behandelend arts ontvangt U hierbij de schrif-
telijke informatie met betrekking tot een wetenschappelijk onderzoek waarvoor Uw 
medewerking is gevraagd.
Wij vragen U niet om onmiddellijk een beslissing te nemen. Neemt U rustig enige be-
denktijd voordat U beslist of U meedoet of niet. Wij raden U aan om Uw deelname te 
bespreken met Uw partner, familie, huisarts of anderen.
Mocht U behoefte hebben Uw vragen voor te leggen aan een arts die niet direct bij dit 
onderzoek betrokken is, dan kunt U de naam en het telefoonnummer van deze onaf-
hankelijk arts vinden op de vijfde pagina van deze informatie.
Inleiding
Zoals met U besproken is, is de prothese in Uw heup los gaan zitten. Daardoor heeft 
U klachten als pijn in de heup en moeite met lopen. Meestal wordt als behandeling 
bij zo’n losse prothese een operatie gedaan. Bij deze operatie wordt de oude prothese 
eruit gehaald en wordt er een nieuwe ingezet. Bij sommige mensen (en ook bij u) is de 
kans op nadelige gevolgen van zo’n operatie echter te groot. Daarom zijn we op zoek 
naar andere methoden om een losse prothese vast te zetten. 
Wij hebben U gevraagd medewerking te verlenen aan een onderzoek met een nieuwe, 
nog niet geregistreerde gentherapie. Voor het verkrijgen van meer informatie over de 
veiligheid, verdraagbaarheid en juiste dosering van deze experimentele behandeling 
zijn onderzoeken bij patiënten noodzakelijk.
Bij dierexperimenteel onderzoek met gentherapie met dit soort virus zijn de bijwerkin-
gen tot op heden beperkt gebleken. Er is in beperkte mate onderzoek bij mensen ge-
daan. Wat betreft de veiligheid en verdraagbaarheid van de therapie uit dit onderzoek 
kan het volgende worden gezegd: De hoeveelheden van het middel dat in dit onder-
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zoek bij patiënten wordt ingespoten hebben bij andere onderzoeken niet gezorgd voor 
ernstige bijwerkingen.
Doel van het onderzoek
Uit eerdere onderzoeken die gedaan zijn weten we dat een prothese loslaat doordat 
bepaalde ontstekingscellen het bot afbreken dat rond de prothese zit. Tot nu toe zijn 
er geen medicijnen die deze ontstekingscellen kunnen tegenhouden. Door middel van 
gentherapie willen we deze ontstekingscellen verwijderen. Dit werkt als volgt:
Gentherapie is een nieuwe experimentele behandeling waar momenteel veel onder-
zoek naar wordt gedaan. Met gentherapie kun je specifieke cellen een opdracht uit 
laten voeren. Er wordt een verkoudheidsvirus gebruikt om deze opdracht (als een soort 
brief) af te leveren in de cel. Het virus is nodig, omdat de boodschap niet vanzelf de 
cel in kan. Aangezien een virus normaal ook cellen binnendringt, kan hij goed gebruikt 
worden om de boodschap in de cel te bezorgen. Het virus is van tevoren wel zo aan-
gepast dat het zich niet meer kan vermenigvuldigen. Daardoor is de kans dat mensen 
ziek worden van het virus veel kleiner. Het virus weet alleen nog hoe het in de cel moet 
komen en dat hij de opdracht moet afgeven. 
In dit onderzoek wordt een virus gebruikt dat onder andere naar de ontstekingscellen 
gaat die de loslating van de prothese veroorzaken. Deze cellen krijgen dan als opdracht 
om zoveel mogelijk van een bepaald eiwit te maken. Na 2 dagen wordt er een medi-
cijn ingespoten dat specifiek de cellen kapot maakt die heel veel van het eiwit hebben 
gemaakt. We verwachten dat we deze cellen daarna uit de ruimte kunnen wegspoelen 
en dat een gedeelte van de cellen vanzelf door het lichaam wordt opgeruimd. We 
hebben in het laboratorium onderzocht dat we op deze manier de ontstekingscellen 
onschadelijk kunnen maken. Maar we weten nog niet of het ook bij mensen werkt. Nu 
zal onderzocht worden wat er gebeurt als we het aangepaste virus en het medicijn bij 
patiënten met een loszittende prothese inspuiten. 
We gaan onderzoeken of mensen er geen bijwerkingen van krijgen en of het virus niet 
in de omgeving terechtkomt. En natuurlijk willen we ook weten of de ontstekingscellen 
kapot gemaakt kunnen worden met de gentherapie. Tevens willen we onderzoeken of 
we in de ruimte waar eerst de ontstekingscellen zaten, botcement kunnen spuiten om 
de prothese weer vast te zetten. 
Het onderzoek vindt plaats in het LUMC te Leiden en in totaal zullen 12 patiënten 
deelnemen. 
De opzet van het onderzoek
De deelnemende patiënten zullen in 4 groepen worden verdeeld. Iedere groep krijgt 
een andere hoeveelheid virus ingespoten om te kijken welke hoeveelheid het beste 
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is. De eerste drie patiënten krijgen de laagste dosis. Dan wordt gedurende minimaal 
2 weken gekeken of zij geen bijwerkingen krijgen. Pas daarna krijgt de tweede groep 
een hogere dosis ingespoten, enz. 
Voordat het onderzoek begint worden, als U mee wilt werken aan het onderzoek, een 
aantal gegevens van U genoteerd, U wordt lichamelijk onderzocht, er worden 2 buisjes 
bloed afgenomen en er worden röntgenfoto’s van Uw heup gemaakt. Als blijkt dat U 
een geschikte kandidaat bent voor de studie en U wilt nog steeds meedoen, wordt een 
onderzoek gedaan waarbij een contrastvloeistof in het heupgewricht gespoten wordt 
en er röntgenfoto’s worden gemaakt om te kijken hoe los de prothese zit (arthrogra-
fie). Als U mee gaat doen in het onderzoek worden er afspraken met U gemaakt over 
dagen dat U in het ziekenhuis verwacht wordt voor het onderzoek. 
Tijdens het onderzoek wordt U 11 dagen opgenomen in het ziekenhuis, waarvan on-
geveer de eerste vier dagen op een eenpersoonskamer. De eerste dag krijgt U het virus 
in het heupgewricht gespoten. Op de derde dag krijgt U het medicijn ingespoten dat 
de cellen kapot moet maken. Om te kijken of de therapie succes heeft gehad worden 
er op de negende dag vier gaatjes geboord door het bot rond de prothese (3 in het 
bovenbeen en 1 in het bekken). Als verdoving krijgt U hierbij een ruggeprik. Via de ge-
boorde gaatjes wordt wat van het ontstekingsweefsel weggehaald om te onderzoeken 
of de cellen kapot zijn gegaan. Bovendien gaan we via deze gaatjes nieuw botcement 
inspuiten om de prothese weer vast te zetten. 
Tijdens de 11 dagen dat U opgenomen bent worden er verschillende onderzoeken 
gedaan om te kijken of er bijwerkingen zijn van de behandeling. Net zoals bij medi-
cijnen kan het lichaam reageren op de therapie en kunt U bijwerkingen krijgen. Vanaf 
het moment dat het virus ingespoten is komt er ieder half uur iemand bij U langs om 
te informeren hoe het met U gaat en om bloeddruk en temperatuur te meten. Als het 
goed met U gaat zullen de controles wat minder vaak gedaan worden. Om eventuele 
bijwerkingen zo snel mogelijk op te sporen wordt ook een aantal keer bloed afgeno-
men voor laboratoriumonderzoek. Dit gebeurt op dag 2 en 5.  Om te controleren dat 
het virus alleen in de heup blijft en dat er niets ‘lekt’ naar de rest van het lichaam en de 
omgeving worden extra onderzoeken gedaan. Daarom wordt U gedurende de studie 
regelmatig gevraagd mee te werken aan lichamelijk onderzoek en aan de controle van 
bloed, urine, ontlasting en een keel- en neusuitstrijk. U zult in het jaar na de opname 
nog zeven keer gecontroleerd worden op eventuele bijwerkingen van de behandeling. 
De eventuele risico’s van het onderzoek
Omdat deze vorm van behandeling met gentherapie nieuw is, is de ervaring nog be-
perkt. Deze studie is bedoeld om eventuele bijwerkingen op te sporen.
Tot nu toe zijn er geen aanwijzingen dat het virus zich buiten het ingespoten gewricht 
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zal verspreiden. Toch zal, om elke mogelijke verspreiding van het virus te voorkomen, 
het virus ingespoten worden op een eenpersoonskamer op de afdeling reumatologie. 
Uw ontlasting, urine en speeksel zullen opgevangen worden en onderzocht worden 
op aanwezigheid van het ingespoten virus. Het is de bedoeling dat U Uw kamer niet 
verlaat totdat wij zeker weten dat er geen virus in Uw urine, ontlasting of speeksel zit. 
Tijdens deze studie zult U 2 maal in Uw heupgewricht geprikt worden, eenmaal om het 
virus in te spuiten en eenmaal om het medicijn in te spuiten. Injecties in het gewricht 
kunnen pijnlijk zijn. Na injectie in een gewricht bestaat een minimaal risico op een 
infectie. 
Op de tiende dag van de opname worden 4 gaatjes in de huid gemaakt (verdoofd met 
een ruggeprik). Via deze gaatjes wordt via een dikke naald een stukje bot en ontste-
kingsweefsel weggehaald (biopsie). Via dezelfde naald wordt daarna botcement in de 
open ruimte tussen prothese en bot gespoten. De ruggeprik kan pijnlijk zijn. Er is een 
kleine kans dat U hoofdpijn krijgt na de ruggeprik. De gaatjes in de huid zijn zo klein 
dat ze niet gehecht hoeven te worden. 
Mogelijke voordelen van het onderzoek
Als zou blijken dat de ontstekingscellen die verantwoordelijk zijn voor het loslaten van 
de prothese kapot gemaakt kunnen worden door de gentherapie en als de ruimte tussen 
de prothese en het bot opgevuld kan worden met botcement, zou U mogelijk een gun-
stig effect kunnen ondervinden van deelname aan het onderzoek. Omdat dit onderzoek 
het eerste is waarbij gentherapie gebruikt wordt om loslating van protheses te behan-
delen zijn er nog geen resultaten uit andere onderzoeken beschikbaar. De resultaten die 
uit deze studie zullen voortkomen zijn moeilijk te voorspellen. Daarom kunt U er beter 
vanuit gaan dat U geen voordelen zult ondervinden van deelname aan de studie. 
Bloedtransfusie en orgaandonatie
De minister van VROM heeft bepaald dat patiënten die aan een gentherapie studie 
deelnemen geen bloed voor bloedtransfusie mogen afstaan. In geval van orgaando-
natie voor transplantatiedoeleinden dienen de artsen geïnformeerd te worden over de 
gentherapie. Alhoewel het onwaarschijnlijk is dat het virus nog in een orgaan aanwezig 
is, wil men uitsluiten dat het virus door bloedtransfusie of orgaantransplantatie wordt 
overgedragen. U dient hiervoor een schriftelijke verklaring te ondertekenen. 
Vrijwilligheid van deelname
Uw medewerking aan dit onderzoek is vrijwillig. Als U toestemming geeft om aan dit 
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onderzoek mee te doen, heeft U te allen tijde de vrijheid om op die beslissing terug 
te komen. U hoeft hiervoor geen reden op te geven, wel wordt U gevraagd dit direct 
aan Uw behandelend arts te melden. Hij zal dan met U bespreken of het stoppen van 
het onderzoek consequenties voor U heeft die het eventueel nodig maken een andere 
behandeling te starten. 
De eerste dagen na injectie in het gewricht zult U verzocht worden op Uw kamer te 
blijven. Uw ontlasting, urine en speeksel worden in deze dagen onderzocht op uit-
scheiding van het virus om te onderzoeken of U mogelijk mensen in Uw omgeving zou 
kunnen besmetten met het virus. Het is belangrijk voor de mensen in Uw omgeving dat 
U zich niet uit de studie terugtrekt gedurende deze periode. Na deze periode staat het 
U vrij op elk moment te stoppen met deelname aan het onderzoek.
Ook Uw behandelend arts kan Uw deelname aan het onderzoek stopzetten als deze 
vindt dat dit ten aanzien van Uw gezondheid beter is. Uw arts bespreekt dit dan met u. 
Wanneer tijdens het onderzoek nieuwe informatie bekend wordt, zal Uw behandelend 
arts dit eveneens met U bespreken.
Het wel of niet meedoen heeft op geen enkele wijze gevolgen voor de verstandhou-
ding met Uw arts.
Vergoeding
Wanneer U in het kader van deelname aan het onderzoek extra reiskosten maakt, wor-
den deze vergoed.
Vertrouwelijkheid van de gegevens
U kunt ervan verzekerd zijn dat alle gegevens die tijdens dit onderzoek onder code 
(d.w.z. zonder vermelding van Uw naam en adres) over U verzameld worden, vertrou-
welijk behandeld worden volgens de wet geneeskundige behandelingsovereenkomst 
(WGBO) en dat niet-bevoegde buitenstaanders geen inzage hebben in Uw gegevens. 
De resultaten van dit onderzoek worden gebruikt in een wetenschappelijke publicatie, 
maar ook dan zijn de gegevens niet tot U als persoon herleidbaar. 
De stukjes ontstekingsweefsel die via de boorgaten worden verwijderd zullen bewaard 
worden. Met dit weefsel kan later eventueel nog onderzoek gedaan worden. De arts-on-
derzoeker zal aan U toestemming vragen om de stukjes ontstekingsweefsel te bewaren.
Ook vragen wij U toestemming om Uw huisarts op de hoogte te stellen van Uw deel-
name aan het onderzoek en andere informatie die wij van belang vinden. Ook vragen 
wij U of wij Uw huisarts informatie mogen vragen over Uw vroegere en huidige ziekten.
Verzekering
Er is door het LUMC een verzekering afgesloten waaruit eventuele schade als gevolg 
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van het onderzoek betaald kan worden. Wanneer U vindt dat U schade heeft onder-
vonden als gevolg van deelname aan het onderzoek kunt U contact opnemen met de 
arts-onderzoeker. Informatie over de afgesloten verzekering treft U aan in de bijlage.
Tot slot
Mocht U naar aanleiding van deze informatie nog vragen hebben met betrekking tot 
dit onderzoek dan kunt U daarmee terecht bij Uw behandelend arts, de arts-onderzoe-
ker of de onafhankelijk arts. 
Voor algemene informatie over deelname aan wetenschappelijk onderzoek verwijzen 
wij U naar de brochure “Gevraagd voor medisch-wetenschappelijk onderzoek”, die 
verkrijgbaar is bij het patiëntenservicebureau op de tweede etage van het LUMC.
Wanneer U besluit aan dit onderzoek deel te nemen vragen we U bij het eerstvolgende 
bezoek aan het ziekenhuis in het kader van dit onderzoek een handtekening te zet-
ten (het informed consent). Met de ondertekening verplicht U zich nergens toe (Uw 
handtekening is niet 'bindend'), maar geeft U te kennen dat U deze informatie ontvan-
gen en begrepen heeft en weet wat er van U verwacht wordt met betrekking tot het 
onderzoek. 
Artsonderzoeker:  JJ de Poorter Onafhankelijk arts:  Dr CF Allaart
Afdeling:  Orthopedie Afdeling:  Reumatologie
Telefoonnummer: 071-5263606  Telefoonnummer: 071-5263598
Verantwoordelijk onderzoeker:   Dr R.G.H.H. Nelissen  
Afdeling:     Orthopaedie   
Tel.:      071-5263606   
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De belasting van het onderzoek op een rijtje 
Tijdens de ziekenhuisopname:
 Injecties in het gewricht: Om het virus en het medicijn zo dicht mogelijk bij de ont-
stekingscellen (die zorgen voor de loslating van de prothese) te brengen worden 
ze in het gewricht ingespoten. Dit gebeurt op de röntgenafdeling. Eerst wordt 
de huid verdoofd en daarna wordt met een dun naaldje de vloeistof ingespoten. 
De injectie kan pijnlijk zijn. De injecties vinden plaats op de eerste en derde dag 
van de ziekenhuisopname.
 Botbioptieën en inspuiten van cement: Op de negende dag van de ziekenhuisopna-
me worden vier gaatjes door het bot geboord om een beetje ontstekingsweef-
sel weg te halen en wordt cement ingespoten om de prothese vast te zetten. 
Omdat het bot niet verdoofd kan worden met een lokale verdoving krijgt U een 
ruggeprik. Om zo hygiënisch mogelijk te werken zal dit alles op de operatieka-
mer gebeuren. In totaal zal dit ongeveer een uur duren. Daarna wordt U terug 
naar Uw kamer gebracht. 
 Verzamelen van urine, ontlasting, keel- en neuskweken en bloedonderzoek (Dit 
worden excreta genoemd). Deze onderzoeken worden gedaan om te onder-
zoeken waar het virus blijft nadat we het hebben ingespoten. De urine en ont-
lasting die U produceert worden gedurende de eerste 24 uur verzameld en er 
wordt onderzocht of er virus in zit. Verder wordt met een wattenstokje een 
kweek genomen uit de keel en uit de neus en wordt een keer bloed afgenomen. 
Al deze onderzoeken worden zo snel mogelijk beoordeeld. De volgende dag 
worden alleen de excreta verzameld waar de vorige dag nog virus zat. (Bij voor-
beeld als in Uw bloed en ontlasting geen virus was aangetoond hoeft U dit niet 
meer in te leveren). Als nergens meer virus in zit mag U de kamer weer verlaten 
wanneer U dat wilt.
 Bijwerkingen: Om eventuele bijwerkingen van de gentherapie op te sporen wordt U 
zorgvuldig geobserveerd. Dit gebeurt door aan U te vragen of U klachten heeft 
en door lichamelijk onderzoek (luisteren naar het hart, de longen en de buik en 
voelen aan de buik). Daarnaast wordt ook bloed geprikt om te onderzoeken of 
er bijwerkingen zijn waar U zelf nog niets van merkt. Het lichamelijk onderzoek 
gebeurt iedere dag, de bloedafnames gebeuren op de tweede dag (2 keer ) en 
op de vijfde dag (1 keer). 
Bezoeken aan het ziekenhuis: In het begin van het onderzoek wordt U gedurende 
11 dagen opgenomen in het ziekenhuis. U ligt dan op een eenpersoonskamer. 
Gedurende de eerste dagen mag U Uw kamer niet verlaten. U mag natuurlijk 
wel bezoek ontvangen. Tot 1 jaar na het onderzoek wordt U in totaal 7 keer op 
de polikliniek orthopedie verwacht bij de arts-onderzoeker. Hierna komt U een 
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keer per jaar op controle bij Uw behandelend orthopaed. Tijdens de poliklini-
sche bezoeken informeert de arts-onderzoeker hoe het met U gaat en of er pro-
blemen zijn. Ook wordt gevraagd of U mee wilt werken aan een kort lichamelijk 
onderzoek. De reiskosten die U maakt om naar het ziekenhuis te komen worden 
vergoed. Als U dat wilt kan de arts-onderzoeker een taxi voor U regelen die U 
thuis ophaalt en na het polibezoek weer naar huis brengt. 
Bloedafnames: De eerste 3 keer dat U op de polikliniek komt wordt U gevraagd om 
na het polibezoek bloed te prikken (2 buisjes). Dit wordt gedaan om te kij-
ken of er bijwerkingen zijn van de behandeling waar U zelf niets van merkt. 
De arts-onderzoeker belt U een paar dagen later thuis op om de uitslag van 
het bloedonderzoek te bespreken. Als het mogelijk is worden eventuele bijwer-
kingen behandeld. 3 Maanden en 1 jaar na de ziekenhuisopname wordt nog 
1 buisje bloed afgenomen om te onderzoeken hoe het immuunsysteem heeft 
gereageerd op de gentherapie.
Röntgenfoto’s: Om te onderzoeken of de behandeling succes heeft gehad worden een 
aantal röntgenfoto’s gemaakt. Op de laatste dag van de ziekenhuisopname 
worden een foto van het bekken en van de heup gemaakt (zoals U die wel eer-
der hebt laten maken bij polikliniekbezoeken). Bij de nacontroles na 2 weken, na 
6 maanden en na 1 jaar worden nogmaals dezelfde foto’s gemaakt.
De belasting die U zult ondervinden van het onderzoek is samengevat in het sche-
ma op de volgende pagina.
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Revision surgery for loosened hip prostheses is a heavy burden for elderly patients 
with comorbidity. As an alternative to surgery we performed a study to stabilise the 
prosthesis by percutaneous cement injection after removing inflammatory tissue with 
an intra-articular virus-directed enzyme prodrug approach. Twelve elderly patients with 
debilitating pain from a loosened hip prosthesis were included in a phase 1 dose-
escalating clinical study. The patients were admitted to the hospital for 10 days for 
an intra-articular vector and prodrug injection, and subsequently for a percutaneous 
bone cement injection. This paper reports the adverse and serious adverse events of 
the study. After prodrug injection 9 of 12 patients had gastrointestinal adverse events 
(nausea, vomiting, and diarrhoea), and 8 patients had hepatic adverse events (rise 
in aspartate aminotransferase and alanine aminotransferase). Five patients developed 
anaemia (World Health Organisation grade 1 or 2) from hematomas after cement injec-
tion. There were four serious adverse events in the first 6 months after vector injection, 
but these were not related to gene therapy as judged by an independent safety com-
mittee. There was no dose-limiting toxicity. However, extensive comorbidity in these 
patients makes it difficult to fully establish the safety of this approach in this small and 
heterogeneous patient population.
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Introduction
A major complication in total hip arthroplasties is loosening of the prosthesis, re-
sulting not only in pain and walking difficulties but also leading to a higher risk for 
dislocations and pathological fractures.54 Revision surgery has a high morbidity and 
mortality rate, especially in elderly patients with comorbidity. At present there are no 
alternative treatments for prosthesis loosening other than extensive surgical revision 
of the prosthesis. 
Aseptic loosening by particulate-induced osteolysis is the most common cause of 
implant failure. Wear particles, produced by any artificial joint, such as particles of 
polyethylene and metal, are phagocytosed by macrophages, leading to secretion of 
inflammatory cytokines.43 The resulting chronic inflammation eventually produces 
interface tissue, a pseudomembrane of synovium-like interface tissue with activated 
macrophages, fibroblasts, giant cells and osteoclasts. 
 The prodrug CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] is a weak mono-
functional alkylating agent, which is converted by the Escherichia coli enzyme nitro-
reductase (Ntr) to a cytotoxic derivative.68 Cells containing Ntr convert CB1954 into 
a bifunctional alkylating agent that is capable of forming DNA interstrand cross-
links, resulting in apoptosis or cell death.18,34,102 Because there is no human homo-
log to Ntr23, only cells expressing the nitroreductase gene are killed when exposed 
to CB1954. This makes the Ntr-CB1954 combination exploitable for a virus-directed 
enzyme prodrug therapy (VDEPT) approach. To this end, CTL102 was constructed, an 
E1, E3-deleted replication-deficient human adenovirus serotype 5 vector, engineered 
to contain the E. coli nfsB gene under the control of the immediate-early (IE) pro-
moter of the human cytomegalovirus.34,125 In our laboratory, previous experiments 
have shown the efficacy of the transduction and destruction of synoviocytes and 
fibroblasts from interface tissue by HAdV-5-Ntr (CTL102) and CB1954.30 On the basis 
of promising preclinical findings we performed a phase 1 clinical trial to test the 
safety and feasibility of an intra-articular VDEPT approach to destroy periprosthetic 
interface tissue and refix loosened prostheses with percutaneous cement injection 
into the periprosthetic space. The clinical results of this phase 1 clinical trial were 
previously published.28
 The study has four potential sources of toxicity: the vector, the prodrug, the vec-
tor-prodrug combination, and the percutaneous cement injection. The safety of the 
prodrug CB1954 in patients was shown by Chung-Faye and coworkers;23 the safety 
of the vector CTL102 was shown by Palmer and coworkers.91 This paper describes the 
safety of the vector-prodrug combination and the cement injection.
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Materials and methods 
Trial design
For a description of the trial design, patient selection, preparation and administration 
of vector and prodrug, and cementing technique (Figure 1), the reader is referred to 
de Poorter et al.,28 where clinical results are shown. 
Safety measurements
Safety for the patient was the primary objective in this study. Adverse events report-
ing is based on the World Health Organisation (WHO, Geneva, Switzerland) recom-
mendations for grading of acute and subacute toxic side effects (World Health Or-
ganisation), using a five-point scale (0, within normal limits; 1, minimal; 2, moderate; 
3, severe; 4, intolerable). Adverse events are defined as pre-existent (before gene 
therapy), early (0-7 days after vector administration), intermediate (8-30 days af-
ter vector administration), and late (> 30 days after vector administration). Adverse 
events were recorded up to 6 weeks after vector administration. Vital signs (blood 
pressure, pulse rate, temperature, and breathing frequency), medical history, and a 
visual analogue scale (VAS) for pain were measured after vector injection every 30 
Figure 1. Schematic overview of study protocol
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minutes for the first 4 h, then hourly to 8 h after vector injection, and then every 
4 h to 24 h. After 24 h these controls were done every 6 h until prodrug injection, 
and subsequently every day. In addition, vital signs were controlled 30 min and 1, 
2, 4, 6, and 12 h after prodrug injection. Blood samples for haematological and 
biochemical analysis and urine samples were taken 1, 3, 6 and 8 days after vector 
injection. After discharge from the hospital adverse events were monitored at time 
points 2, 4, and 6 weeks after vector injection. In some patients who lived far from 
the hospital these controls were done after 3 and 6 weeks. For each adverse events 
the following characteristics were recorded: patient number, description of adverse 
event, WHO grading, date of first occurrence, date of last occurrence, relation with 
study, outcome of the event, relation with gene therapy, and whether the adverse 
event required treatment. 
Results 
Patient characteristics
Twelve patients between 72 and 91 years (mean, 82 years) were treated. Relevant 
medical histories of the patients are outlined in Table 1.





ASA Relevant medical history
1 82 F 4 Myocardial infarction; mamma-carcinoma; congestive cardiac failure; 
hyperthyreoidism
2 72 F 2 CVA; meningitis
3 78 F 4 Rheumatoid arthritis; COPD; myocardial infarction; spondylodiscitis; 
congestive cardiac failure; diverticulosis; osteoporosis; BPPV
4 91 M 3 Prostatectomy; amaurosis fugax; Multiple myeloma stadium II
5 75 F 3 Pneumonia; M Parkinson
6 86 F 3 CABG; aorta valve prosthesis
7 85 F 3 TIA; myocardial infarction; macula degeneration
8 86 F 4 Myocardial infarction; rheumatoid arthritis
9 81 F 2 Recurrent urinary tract infections
10 82 F 2 Uterus extirpation; mamma-carcinoma
11 76 F 4 Rheumatoid arthritis; myocardial infarction
12 89 F 2 Dementia 
Abbreviations: ASA, category according to the American Society of Anesthesiologists; CVA, cerebrovascular acci-
dent; COPD, chronic obstructive pulmonary disease; BPPV, benign paroxysmal position vertigo; CABG, coronary 
artery bypass grafting; TIA, transient ischemic attack. 
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The dose of CTL102 vector ranged from 3 x 109 particles to 1 x 1011 particles. One 
patient in the second dose group (1 x 1010 particles) and one patient in the third dose 
group (3 x 1010 particles) actually received a lower vector dose (8.3 x 109 and 2.6 x 1010 
particles, respectively) than was planned, because the contents of the syringe could not 
be injected entirely.
 All patients were intended to receive a prodrug dose of 24 mg/m2 with a maximal 
concentration of 2mg/ml in the joint space, but after gastrointestinal and hepatic ad-
verse events in the first four patients this dose was lowered to 16 mg/m2. Five of the 
patients received a lower dose than planned because of a small joint capacity. Patient 
characteristics and actual vector and prodrug doses are shown in table 2 and have 
been previously published.28 
Adverse events
Overall there were 100 adverse events observed in the 12 patients (Table 3). Fifteen 
adverse events were hematologic, 12 were metabolic, 17 gastro-intestinal, 19 hepatic, 
15 renal and 22 were in the category ‘other’. There were no adverse events in the co-
agulation, pulmonary, cardiovascular and neurological categories. The number of ad-
verse events per patient ranged from three for patient 6 to 19 for patient 4. Thirty-two 
Table 2. Demographic characteristics, and information on vector and prodrug dose.
































1 82 F 4 OA 2.13 3x109 3x109 24/ 51.1     24/ 51.1 27
2 72 F 2 OA 1.64 3x109 3x109 24/ 39.4 20/ 32.0 16
3 78 F 4 RA 1.58 3x109 3x109 24/ 37.9 24/ 37.9 30
4 91 M 3 OA 2.04 1x1010 8.3x109 24/ 49.0 24/ 49.0 30
5 75 F 3 OA 1.83 1x1010 1x1010 24/ 43.9 8.2/ 15.0 7.5
6 86 F 3 OA 1.48 1x1010 1x1010 16/ 23.7 16/ 23.7 22
7 85 F 3 OA 1.87 3x1010 2.6x1010 16/ 29.9 15/ 27.9 14
8 86 F 4 RA 1.77 3x1010 3x1010 16/ 28.3  11/ 20.0 10
9 81 F 2 OA 1.66 3x1010 3x1010 16/ 26.6 16/ 26.6 27
10 82 F 2 OA 1.73 1x1011 1x1011 16/ 27.7 16/ 27.7 30
11 76 F 4 RA 1.68 1x1011 1x1011 16/ 26.9 11/ 18.0 9
12 89 F 2 OA 1.6 1x1011 1x1011 16/ 25.6 16/ 25.6 18
Abbreviations: F, female; M, male; OA, osteoarthritis; RA, Rheumatoid Arthritis.
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of the findings that had to be marked as adverse event according to the WHO criteria 
were present during the inclusion procedure, but were not a reason to exclude the 
patient from the study. Fifty-one adverse events occurred in the first week after vector 
injection. Seventeen adverse events occurred between the second and sixth weeks. The 
events are discussed per organ system. 
Hematologic adverse events
Four patients had pre-existent anaemia grade 1 (patient 1, Hb 6.7 mmol/litre; pa-
tient 3, Hb 6.5 mmol/litre; patient 4, Hb 6.4 mmol/litre; patient 11, Hb 6.3 mmol/litre). 
One patient had a low haemoglobin level at hospital admittance, but not during the 
inclusion procedure (Patient 8: at inclusion Hb 7.8 mmol/litre, at hospital admittance 
7.3 mmol/litre), and one patient with a grade 1 anaemia at inclusion had grade 2 anae-
mia at hospital admittance (patient 4, Hb 6.0 mmol/litre at hospital admittance). Three 
patients without previous anaemia developed anaemia grade 1 after cement injection 
(patient 2, Hb at inclusion 8.7 mmol/litre, Hb after cement injection 7.2 mmol/litre; 
patient 5, Hb 7.9 and 7.2 mmol/litre at inclusion and after cement injection; Patient 12, 
Hb 8.2 and 7.0 mmol/litre at inclusion and after cement injection), and in two patients 
with pre-existent anaemia, the anaemia worsened to grade 2 (patient 3, Hb 6.1 mmol/
litre; patient 8, Hb 6.1 mmol/litre) after cement injection. One patient in the third vec-
tor dose group had a low (grade 1) leukocyte count (patient 7, 3.4 x 109 leukocytes/
litre) 1 day after vector injection with normal values 3 days after vector injection, and a 
patient in the highest vector dose group had a low leukocyte and thrombocyte count 
(patient 11, 3.5 x 109 leukocytes/litre 1 day after vector injection, recovering to 4.6 x 
109 leukocytes/litre 5 days after vector injection; and thrombocytes 99 x 109/litre 1 day 
after vector injection and still less than 100 x 109/litre at end of follow-up).
Metabolic adverse events
One patient had diabetes mellitus and had grade 1 hyperglycaemia (Patient 8, glucose 
7.3 mmol/litre) at inclusion. Four patients without diabetes had grade 1 or 2 hyper-
glycaemia 1 to 3 days after vector injection once (Patient 10, glucose 8.4 mmol/litre 
1 day after vector injection; patient 11, glucose 7.1 - 7.4 mmol/litre 1 to 3 days after 
vector injection; patient 12, glucose 7.3 mmol/litre 1 day after vector injection; patient 
7, glucose 9.2 mmol/litre 3 days after vector injection), and the patient with diabetes 
had grade 2 hyperglycaemia (Patient 8, glucose 9.2 mmol/litre) on day 3 after vector 
injection. One patient with multiple myeloma, treated with prednisolone, had grade 1 
hypocalcaemia (patient 4, calcium 2.15 mmol/litre) at inclusion, worsening to grade 2 
(calcium 1.80 mmol/litre) during hospital stay. This patient also had a low magnesium 
level (grade 1) (magnesium 0.57 mmol/litre) 3 weeks after vector injection. Patient 5 
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had transient low calcium (grade 1), 1 day after cement injection (2.13 mmol/litre), and 
one patient had a transient increase in amylase level (patient 11, amylase 266 U/litre) 
1 day after prodrug injection. All metabolic adverse events were asymptomatic.
Gastro-intestinal adverse events
One patient had pre-existent nausea and vomiting. Approximately 6 h after prodrug 
injection 9 of 12 patients developed nausea and vomiting (Table 4). Patient 2 had vom-
iting grade 3 (8 episodes in 24 h). Patient 4 had nausea grade 3 (insufficient intake) and 
vomiting grade 3, and needed parenteral fluid administration because of dehydration. 
Three of the first four patients had diarrhoea grade 1 (increase of defecation frequency 
of two to three times per day) up to 2 weeks after prodrug injection. After the fourth 
patient the prodrug dose was lowered to 16 mg/m2. 
Hepatic adverse events
Figure 2 shows aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
levels over time per patient. In patients with adverse events regarding AST and ALT the 
patient number is placed near the corresponding line in the Figure 2. Patient 11 had 
high AST and ALT at hospital admittance, returning to normal in 1 week, whereas she 
had normal levels at inclusion. Eight patients had a rise in AST 4 to 6 days after vector 
Table 4. Gastrointestinal adverse events.








1 24 51.1 1 - 1
2 20 32 1 3 1
3 24 37.9 1 1 -
4 24 49 3 3 1
5 8.2 15 - - -
6 16 23.7 - - -
7 15 27.9 1 1 -
8 11 20 - - -
9 16 26.6 1 - -
10 16 27.7 1 - -
11 11 18.0 1 1 -
12 16 25.6 1 2 -
To stress a possible relationship with the prodrug, prodrug concentration is also shown. Nausea, vomiting and 
diarrhoea are graded according to WHO criteria. Nausea: grade 1, reasonable intake; grade 2, decreased intake; 
grade 3, no meaningful intake. Vomiting: grade 1, 1 episode in 24 h; grade 2, 2-5 episodes in 24 h; grade 3, 
6-10 episodes in 24 h. Diarrhoea: grade 1, increase of defecation two or three times per day
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injection (2 to 4 days after prodrug injection), and four of these patients also had a 
rise in ALT. In patients 2 and 3 these were grade 2. Patient 4 had a second rise in AST 
30 days after vector injection, and a second rise in ALT with a maximum at 7 weeks 
follow-up.
 Patient 2 had a temporary rise in alkaline phosphatase (157 U/litre) 3 weeks after 
vector injection. Patient 12 had a pre-existent high level of alkaline phosphatase (201 
U/litre at inclusion, decreasing to 156 U/litre at the end of follow-up).
Figure 2. AST and ALT levels after gene therapy.
(A) AST levels per patient over time; (B) ALT levels per patient over time. Time point -1 is the inclusion day. Time 
point 0 is the day of vector injection. In patients with adverse events regarding transaminases, the patient 
number is noted near the corresponding line, and is further discussed in the Results and Discussion sections.
2a
2b
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Renal adverse events
Patient 1 had pre-existent grade 1 hematuria (Hb: 2+/ 25 Ery/μl) at inclusion and devel-
oped proteinuria (protein 1+/ 30mg/dl) 5 days after vector injection and continuing until 
after the end of follow-up. Patient 4 had high creatinine levels (creatinine, 156 μmol/litre), 
proteinuria (protein 1+/ 30mg/dL) and grade 1 hematuria (Hb: 2+/ 25 Ery/μl) at inclu-
sion; the proteinuria worsened to grade 2 (protein 2+/ 100mg/dl) on day 6 after vector 
injection. Three patients had a transient hematuria 1 day after vector injection (patient 6: 
Hb: 1+/ 10 Ery/μl; patient 11, Hb 2+/ 25 Ery/μl; Patient 12, Hb 2+/ 25 Ery/μl), and one of 
these patients also had transient proteinuria (patient 11, protein 1+/ 30mg/dl). Two more 
patients had transient hematuria, one after 6 days (patient 8, Hb: 2+/ 25 Ery/μl), and one 
9 days after vector injection (patient 5, Hb: 1+/ 10 Ery/μl). One patient had a transient pe-
riod of proteinuria starting 9 days after vector injection (patient 5, Protein 1+/ 30mg/dl). 
Other adverse events
All patients had pre-existing pain in the hip (WHO-grade 4; needing pain killers), which 
was an inclusion criterion. Ten of 12 patients had at any time point a body temperature 
between 37 and 38°C. One of these patients had a body temperature of 38.1°C 0.5 h 
after prodrug injection, which is an adverse event grade 2.
 
Serious adverse events
Four serious adverse events were registered during 6 months follow-up; none was di-
rectly related to the VDEPT approach. Patient 1 was diagnosed with uterine carcinoma 
8 weeks after vector injection. The patient died of the carcinoma 4 months after vector 
injection. 
 Patient 4 was a 91-year old patient with multiple myeloma who died of progressive 
kidney failure 3 months after vector injection. The exact cause of the kidney failure 
could not be determined, but it was assumed to have its origin in a kidney localisation 
of the multiple myeloma. Consent for autopsy was not obtained. 
 Patient 6 was admitted to the hospital 6 months after vector injection for dehydra-
tion and was discharged after a few days. 
 Patient 8 was admitted to the hospital 3 months after vector injection for hypona-
tremia and hypotension and was discharged after a few days. 
Discussion
In this phase 1 clinical gene therapy study no dose-limiting toxicity occurred. Vector ad-
ministration could be continued until the proposed highest dose of 1 x 1011 particles. 
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However, prodrug dose was lowered because of inconvenient adverse events in the 
first four patients (i.e., nausea and vomiting, and hepatic adverse events). At 6 weeks 
follow-up, 8 of 12 patients had clinical benefit from the gene therapy and cement 
injection treatment.28
 Harvey et al.55 summarise experiences on adverse events in local administration 
of HAdV-5 vectors in 90 individuals. The most common adverse events they reported 
were transient fever and leucocytosis. In our study on hip prosthesis loosening 10 of 
12 patients had grade 1 fever at any time (mostly already at inclusion), and 1 patient 
had a temperature of 38.1°C (grade 2) 30 min after prodrug injection. Occurrence of 
fever was not related to the time of vector injection. As temperature exceeding 37°C 
were already present mostly at inclusion, and it did not increase much further during 
the study, it is not likely that it was caused by any of the study products. In a phase 
1 study for safety of the CTL102 vector alone, the vector was injected directly into 
hepatic tumours up to doses of 5 x 1011 particles (Palmer et al.)91 and asymptomatic 
fever (≤38.5°C) was seen in 4 of 18 patients 4 to 8 h after vector injection; leukocytosis 
was not seen in any of the patients. As a joint is a more or less closed compartment, 
and inclusion of the patients was limited to those who had neutralising antibodies 
against HAdV-5, thereby inactivating the viral vector outside the joints, exposure of the 
vector particles to the immunologic system may be minimal, which explains the lack 
of leukocytosis. Two patients, one in the third and one in the fourth dose group, had 
leukopenia (grade 1) 1 day after vector injection. This has been described previously in 
a suicide gene therapy trial, and was explained by bone marrow depression by the pro-
drug, whereas in our study the leukopenia occurred before the prodrug was injected. 
The cause of leukopenia in our study is unknown.
 One patient in the highest vector dose group, who already had a platelet count of 
112 x 109 at inclusion, showed an asymptomatic decrease in platelet level grade 1. This 
feature of thrombopenia was shown previously in a toxicity-study with baboons,85 and 
was also shown in one study with human subjects,110 and in these studies was attrib-
uted to probable cytokine induction. 
 Besides a rise in creatinine levels no renal adverse events after local vector injection 
are recorded in the literature.55 In our study 8 of 12 patients had hematuria or protein-
uria. Patient 1 had hematuria at inclusion and developed proteinuria during follow-up. 
This patient was diagnosed with uterine carcinoma, which could be an explanation for 
her hematuria and proteinuria. Patient 4 had pre-existent kidney failure with hematu-
ria, proteinuria and high levels of creatinine. Patient 11 had a catheter à demeure at 
hospital admittance, which could explain her hematuria and proteinuria. Two patients 
(patient 5 and 12) developed cystitis during hospital stay, explaining the hematuria and 
proteinuria. Hematuria among the other three patients might be explained by antico-
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agulants, which are given to all surgical patients in the department during hospital stay 
for thrombosis prophylaxis. 
 Nine of 12 patients experienced nausea and vomiting starting 6 h after prodrug in-
jection, with patient 4 needing parenteral fluid administration because of dehydration. 
Nausea and vomiting, and other flulike symptoms, were reported by previous studies 
as side effects from Ad-vectors.65,110,113 However, in the present study the nausea and 
vomiting are more likely to be caused by side effects from the prodrug, as the occur-
rence decreased after lowering the prodrug dose and did not increase with the 30-fold 
increase in HAdV-5 vector. Besides nausea and vomiting eight patients had a rise in 
AST levels, with a maximum 4 days after prodrug injection, and four of these patients 
also had a rise in ALT levels. These were asymptomatic and completely reversible. Two 
patients in the high prodrug dose group (and lowest adenoviral vector group) had 
grade 2 rises in AST and ALT levels, and three had diarrhoea. In the prodrug toxicity 
study of Chung-Faye et al.23 these adverse events were also reported. In their study 
patients received a prodrug dose of 24, 30 or 37.5 mg/m2 intravenously, without previ-
ous vector administration. In the 24 mg/m2 group three of four patients experienced 
nausea and vomiting (up to grade 3), but no biochemical liver abnormalities occurred. 
In the higher dose groups five of eight patients did have a transaminase elevation, 
after which the authors concluded that 24 mg/m2 would be the recommended dose. 
One patient received 24 mg/m2 in a peritoneal injection and experienced grade 1 diar-
rhoea and grade 1 transaminitis. The pathophysiology of the gastrointestinal adverse 
events of the prodrug is unknown; two possible explanations are considered. First, the 
most likely explanation is indirect gastrointestinal epithelial toxicity. Another explana-
tion might be conversion of CB1954 to the activated form by Ntr from E. coli present 
in colonic flora. This pathophysiologic mechanism is impossible to prove because the 
activated form of CB1954 is highly reactive and has a halftime (i.e., 18 min) that is too 
short to be detected. In the study by Chung-Faye et al.23 less than 5% of the drug was 
detected in the urine and the drug clearance was 184 to 958 ml/min, indicating that 
the CB1954 metabolism is predominantly hepatic. The latter underscores that the rise 
in transaminase levels can be explained by liver cell damage by CB1954 metabolites 
during drug clearance. Although liver toxicity by CB1954 would be a feasible explana-
tion for the rise in transaminases, previous studies with intravenous HAdV-5 injections 
have also shown a role for HAdV-5 vectors in transaminitis.110 Morral et al.85 gave a 
very high dose of adenoviral vector (1.2 x 1013 particles/kg) to a baboon and observed 
severe liver damage, with AST levels rising from 37 to 7440 U/litre after 48 h and ALT 
levels rising from 30 to 1520 U/litre. The platelet count decreased from 558,000 to 
18,000/ mm3 with this high vector dose. Liver toxicity caused by local administration of 
adenoviral vector was not reported in the meta-analysis by Harvey et al.55 The CTL102 
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safety study performed by Palmer et al.91 also showed, throughout the study period, 
no changes in biochemical estimates of liver function after local injection, giving an 
additional argument that the transaminitis found in our study is caused by the prodrug 
rather than the (intra-articularly administered) vector. The dose and delivery routes 
used in the Palmer study and ours may minimise potential adenovirus-mediated liver 
toxicity. Patient 4 had a second rise of AST and ALT 1 month after vector injection, most 
probably due to feeding by stomach tube. 
 None of the patients had adverse events from the spinal anaesthesia. Besides lo-
cal pain, the percutaneous cement injection caused hematomas and anaemia in five 
patients. One patient had a large hematoma and developed a transient rise in alkaline 
phosphatase levels. These adverse events due to cement injection were inconvenient, 
but relatively mild compared with local complications in revision surgery. Complica-
tions caused by the cement itself are rare, as described in the literature, and are associ-
ated mostly with hypotension directly after injection of cement or with fat embolisa-
tion.86,111 Furthermore, these complications will probably not occur with percutaneous 
cement injection, in which only small amounts of cement are injected. To our knowl-
edge no hematological or biochemical changes have been reported after cement injec-
tion.
 Four patients not previously diagnosed with diabetes had grade 1 hyperglycaemia 
1 to 3 days after vector-injection and one patient with diabetes had grade 2 hyper-
glycaemia. Hyperglycaemia has been reported as an adverse event in another suicide 
gene therapy approach by Freytag et al..40 A definite explanation for the hyperglycae-
mia could not be found, but the authors concluded that it may be related to the fact 
that many elderly patients are known to be borderline diabetics and/ or experiencing 
treatment-related stress.40 
 All four serious adverse events were reported to the Medical Ethics Review Board 
and the Central Committee on Research Involving Human Subjects by telephone and in 
writing within 24 h after the SAE was known to the investigators.
 In all cases the study’s independent safety committee judged the relationship of 
the SAE with the study. In all four adverse events the safety committee could not find 
a causal relation between the gene therapy and the occurrence of the serious adverse 
event. 
 In conclusion, an intra-articular VDEPT approach with an adenoviral vector and 
CB1954 as prodrug and percutaneous transosseous bone cement injection is a viable 
option in the treatment patients with hip prosthesis loosening. No dose limiting toxic-
ity occurred and all adverse effects could be treated. However, the extensive comorbid-
ity in these patients makes it difficult to fully establish the safety of this approach in 
this small and heterogeneous patient population.
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Loosening of orthopaedic hip prostheses is an increasing health problem. In elderly pa-
tients with comorbidity, revision surgery may lead to high mortality rates. A less inva-
sive surgical technique is therefore required to reduce these patient risks. To this end a 
percutaneous gene therapy approach was designed to destroy the periprosthetic loos-
ening membrane, and enable refixing of the hip prosthesis with percutaneous bone 
cement injections under radiological guidance. In this phase 1/2 dose-escalating gene 
therapy clinical trial, 12 patients were treated. Toxicity and hip function variables were 
monitored up to 6 months posttreatment. All patients completed the study and no 
dose-limiting toxicity was observed. Improvement in walking distance, independence, 
and pain was demonstrated particularly in patients receiving 3 x 1010 and 1 x 1011 viral 
particles. Taken together, these data show that this gene therapy approach targeted at 
the interface membrane around a loosened hip prosthesis is a feasible treatment op-
tion for elderly patients for whom surgical intervention is not appropriate. 
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Introduction
Annually, approximately 1 million total hip replacement operations are performed 
worldwide. This number is likely to increase considerably in the next decade because of 
two effects: (1) the longer life expectancy of populations in Western society and (2) the 
relative success of hip replacements at long-term follow-up, and the tendency to insert 
prostheses at a younger age (i.e., patients younger than 55 years). However, within 
10 years of follow-up after primary hip replacement 7-13% of patients will require revi-
sion surgery because of loosening of their implant.78 
 The major cause of loosening in the longer term is aseptic, mechanical loosening 
due to wear-related particles of the articulating artificial joint. These wear particles, 
such as particles of polyethylene and metal, are phagocytosed by macrophages, ini-
tiating the secretion of inflammatory cytokines.43 This in turn activates a cascade of 
inflammatory processes resulting in periprosthetic bone resorption and the formation 
of a loosening membrane, the interface tissue. This tissue constitutes a pseudo-mem-
brane of synovium-like tissue with activated macrophages, fibroblasts, giant cells and 
osteoclasts. 
 The induced bone resorption process causes mechanical loosening of the prosthe-
sis. Because a loosened prosthesis migrates into the endosteal medullary canal of the 
femur, pain is caused by any movement of the hip. At first pain is brought on by walk-
ing, but ultimately any movement (i.e., turning in bed) may cause incapacitating pain. 
The only treatment for this inevitable prosthesis-loosening process is revision surgery, 
during which the loosened prosthesis and the interface tissue are removed and a new 
prosthesis is implanted. This is an extensive procedure with subsequent blood loss and 
an infection risk that is twice as high as during primary surgery. Increasing age (the pa-
tients are at least 10 years older than during the primary hip prosthesis implantation), 
hypovolemia during surgery, and administration of large amounts of fluid intra- and 
post-operatively are risk factors for multiorgan failure.57 Consequently, revision surgery 
has a high morbidity and mortality rate, especially in elderly patients with comorbidity. 
In the United States Medicare Population 5.3% of 3165 patients who received revision 
surgery at age 80 and older died within 90 days of surgery.77 Strehle et al.114 registered 
complications and social outcome in a cohort of 53 patients older than 80 years of age 
and undergoing revision total hip arthroplasty. Eleven patients (21%) were admitted 
postoperatively to the intensive care unit, and 3 patients died during their hospital stay. 
Despite the invalidating pain, these high morbidity and mortality rates are the major 
determinants for the eligibility for surgery of elderly patients. At present there are no 
alternative treatments for prosthesis loosening. 
 Hip prostheses can either be fixed to the bone with bone cement or designed to 
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have bone ongrowth properties such as a calcium phosphate coating or a rough tita-
nium surface. Bone cement, acting as a filler for the periprosthetic cavities next to the 
metal prosthesis, has also been used to refix loosened hip prostheses during revision 
surgery. In these cases the old cement of the primary hip arthroplasty is left in place 
and a new prosthesis is inserted in this cement canal using new cement. A prerequi-
site for this recementation technique is that a good integration of new and old bone 
cement is possible.49,73 These data led to the idea of a percutaneous technique for re-
moval of the loosening membrane (i.e., interface tissue) and subsequent percutaneous 
cement injection in the periprosthetic cavity. Neither part of this technique has been 
described so far in the literature. As was shown by our group, the interface tissue can 
be transduced and killed in vitro30 and in vivo in animals46 by the viral vector HAdV-5-
Ntr in combination with the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). 
To evaluate this concept of removal of interface tissue by a gene-directed therapy and 
cement refixation of the prosthesis, a phase 1/2 clinical trial was performed in 12 el-
derly patients with considerable comorbidity. Because these patients had an increased 
surgery risk, revision surgery is no longer feasible and these patients are wheelchair 
bound. This paper describes the feasibility and 6-months follow-up of the clinical re-
sults. 
Materials and methods 
Trial design
In this phase I dose escalation study of the replication-deficient adenoviral vector 
CTL102 and the prodrug CB1954, safety is the primary objective. Adverse events were 
defined according to World Health Organisation (WHO, Geneva, Switzerland) recom-
mendations for grading of acute and sub-acute toxic effects. Dose-limiting toxicity was 
defined as any WHO grade 3 or 4 adverse event except for pain, nausea, and vomiting. 
Secondary end points were to assess virus distribution, efficiency of cell killing by the 
gene therapy approach, and clinical outcome. 
 Patients eligible for inclusion were informed orally and in writing about the study 
and were given at least 1 week for reflection before informed consent was obtained. 
For inclusion an arthrogram of the hip with aspiration of joint fluid was performed to 
exclude bacterial infection, to confirm loosening, and to determine containment (i.e., 
leakage of contrast medium) and the volume of the hip joint. Patients who satisfied the 
inclusion and exclusion criteria and who were willing to participate in the study were 
admitted to the hospital for 11 days. The study had a dose-escalating design, with 
four patients in each group. On day 1 the vector was injected directly into the hip joint 
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and 2 days later the prodrug was injected in the same way. Five to 7 days after vector 
injection, cement was injected around the prosthesis under spinal anaesthesia. Patients 
were ambulated the day after cement injection. After discharge from the hospital pa-
tients were assessed after 3 and 6 weeks, 3 and 6 month and every year. 
Patient selection
Patients eligible for inclusion were elderly patients with debilitating pain from a loos-
ened hip prosthesis causing ADL (activities of daily living) dependency, and with signifi-
cant comorbidity making them ineligible for normal revision surgery. Exclusion criteria 
included infection of the prosthesis, absence of neutralising antibodies against human 
adenovirus subtype 5, obvious adenoviral infection at the time of vector injection, his-
tory of hepatitis, human immunodeficiency virus (HIV) infection, alcohol or drug abuse, 
and known immunodeficiency (including chemotherapy, radiotherapy or immunother-
apy within the previous 28 days). The study protocol was approved by the Central Com-
mittee on Research Involving Human Subjects (CCMO, The Hague, The Netherlands); 
the Ministry of Housing, Spatial Planning and the Environment (VROM, The Hague, 
The Netherlands); and the local ethics committee and was conducted according to the 
principles of the Declaration of Helsinki (as amended in Tokyo, Venice and Hong Kong, 
Somerset West and Edinburgh), and in accordance with the Guidelines for Good Clini-
cal Practice (CPMP/ICH/135/95- July 17, 1996).
 
Vector and prodrug preparation 
The adenoviral vector CTL102 was constructed by homologous recombination in PER.
C6 helper cells,38 as described in previous studies.34 CTL102 is an E1, E3-deleted repli-
cation-deficient human adenovirus serotype 5 (HAdV-5) vector, engineered to contain 
the Escherichia coli nfsB gene under the control of the cytomegalusvirus immediate-
early (CMV-IE) promoter.34,125 The complete Escherichia coli nitroreductase (Ntr) ex-
pression cassette was cloned into an E1-deleted HAdV-5 adenovirus transfer vector. 
Virus batches of 4.2 x 1010 and 4 x 1011 particles/ml with a particle : infectivity ratio of 
18 and 20, respectively, were used in the study. The batches were free of replication-
competent adenovirus (RCA) at a detection limit of 1 in 1010 plaque-forming units, and 
free of mycoplasma and other impurities, thereby meeting the specifications agreed 
upon with the Dutch regulatory authorities. The drug product CB1954 was supplied 
by ML Laboratories plc (Liverpool, UK) as a sterile solution of CB1954 17.8 mg/ml in 
solvent (N-methyl-pyrrolidone 22.2% v/v, polyethylene glycol 300 77.8% 
v/v). The pro-
drug CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] is a weak monofunctional alkyl-
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ating agent, which is converted by Ntr to a cytotoxic derivative.68 Cells containing 
Ntr convert CB1954 into a bifunctional alkylating agent that is capable of forming 
DNA interstrand cross-links, resulting in cell death.18,34,102 Because there is no human 
homolog to Ntr,23 cells expressing the nitroreductase gene are killed when exposed 
to CB1954, as are neighbouring cells by means of bystander effect. This makes the 
Ntr-CB1954 combination exploitable for a virus-directed enzyme prodrug therapy (VD-
EPT) approach. Just before use this prodrug in solvent was diluted in sterile saline to a 
maximum final concentration of 2 mg/ml.
Administration of vector and prodrug
The vector CTL102 was diluted in an isotonic buffer (Tris [25 mmol/litre, pH 7.4]; 
0.14 M NaCl; KCl [5 mmol/litre]; Na2HPO4 [0.6 mmol/litre]; CaCl2 [0.9 mmol/litre]; MgCl2 
[0.5 mmol/litre]; 5% sucrose) in a volume representing 90% of the volume injected dur-
ing the inclusion arthrogram. The initial dose was 3 x 109 particles (Table 1). Dose escala-
tion proceeded in 3-fold increments up to 1 x 1011 particles. The vector was administered 
by direct intra-articular injection. Therefore, a spinal needle directed at the femoral neck 
was positioned in the hip joint under fluoroscopic guidance and synovial fluid was aspi-
rated. Before injection of the vector, the joint was rinsed with ethylenediaminetetraacetic 
acid (EDTA; Sigma Chemical, St Louis, MO, USA) at a concentration of 2 mM in a sodium 
salt solution to remove as much neutralising antibody from the joint cavity as possible. 
 The prodrug CB1954 was diluted in sterile saline to the same volume as the vector 
and was also injected intra-articularly. Before injection of the prodrug, synovial fluid 
was aspirated for quantitative ploymerase chain reaction (PCR) analysis of adenoviral 
DNA. All patients were intended to have a prodrug dose of 24 mg/m2 with a maximal 
concentration of 2 mg/ml injected in the joint space, but after gastrointestinal and 
hepatic adverse events in the first four patients this dose was lowered to 16 mg/m2.
Cementing technique
Two techniques for cementation of the prosthesis were used in the study: fluoroscopy-
controlled and computer tomography (CT)-controlled combined with fluoroscopy. For 
both techniques, areas of the periprosthetic space most suitable for cement injection 
were identified on the basis of previously performed X-rays, that is, the region where 
the greatest amount of periprosthetic radiolucency was present was targeted. All pa-
tients underwent spinal anaesthesia. Patients were positioned supine with the hip and 
groin region sterilely covered. In the CT-controlled group a planning scan was per-
formed to exactly define the positions for introduction of the needles. Three to five ver-
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tebroplasty needles of 3.2 x 100 mm (Biomet, Dordrecht, The Netherlands) were intro-
duced into the periprosthetic space using a hammer. The position of the needles was 
controlled by CT guidance. After placement of the needles the C-arm was positioned 
over the patient. The polymethylmethacrylate (PMMA) cement (Osteopal, Biomet; Disc-
O-Tech, Disc-O-Tech Medical technologies , Herzeliya, Israel) was injected into the peri-
prosthetic space under high pressure with a Cementoset (Biome). During injection the 
flow of the PMMA cement was continuously monitored by fluoroscopy. Injection was 
continued until the periprosthetic space was filled and was discontinued when the 
cement threatened to leak into the joint space or when there was leakage of cement 
into the soft tissues (i.e., extraosseous). Before removal, the needles were turned in a 
clockwise or counterclockwise manner several times to ensure easy removal. 
Objectives
Safety measurements
Safety for the patient was the primary objective in this study. Adverse events were 
monitored according to WHO Recommendations for Grading of Acute and Subacute 
Table 1. Patient characteristics
































1 82 F 4 OA 2.13 3x109 3x109 24/ 51.1     24/ 51.1 27
2 72 F 2 OA 1.64 3x109 3x109 24/ 39.4 20/ 32.0 16
3 78 F 4 RA 1.58 3x109 3x109 24/ 37.9 24/ 37.9 30
4 91 M 3 OA 2.04 1x1010 8.3x109 24/ 49.0 24/ 49.0 30
5 75 F 3 OA 1.83 1x1010 1x1010 24/ 43.9 8.2/ 15.0 7.5
6 86 F 3 OA 1.48 1x1010 1x1010 16/ 23.7 16/ 23.7 22
7 85 F 3 OA 1.87 3x1010 2.6x1010 16/ 29.9 15/ 27.9 14
8 86 F 4 RA 1.77 3x1010 3x1010 16/ 28.3  11/ 20.0 10
9 81 F 2 OA 1.66 3x1010 3x1010 16/ 26.6 16/ 26.6 27
10 82 F 2 OA 1.73 1x1011 1x1011 16/ 27.7 16/ 27.7 30
11 76 F 4 RA 1.68 1x1011 1x1011 16/ 26.9 11/ 18.0 9
12 89 F 2 OA 1.6 1x1011 1x1011 16/ 25.6 16/ 25.6 18
Shown are demographic characteristics and information about vector and prodrug dose.
Actual prodrug dose: milligrams per square meter/ total milligrams
Abbreviations: F, female; M, male; ASA-cat, category according to American Society of Anesthesiologists; OA, 
osteo- arthritis; RA, Rheumatoid Arthritis.
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Toxic Effects. Vital signs (blood pressure, pulse rate, temperature, and breathing fre-
quency), medical history, and a Visual Analogue Scale (VAS) for pain were done after 
vector injection every 30 min for the first 4 h, and then hourly to 8 h after vector injec-
tion, and every 4 h to 24 h. After 24 h these measurements were done every 6 h until 
prodrug injection, and subsequently every day. In addition, vital signs were monitored 
30 min and 1, 2, 4, 6, and 12 h after prodrug injection. Blood samples for hematologi-
cal and biochemical analysis and urine samples were taken 1, 3, 6 and 8 days after vec-
tor injection. After discharge from the hospital adverse events were monitored at time 
points 3 and 6 weeks after vector injection. 
Virus shedding
After vector injection, patients were kept in isolation until virus shedding was nega-
tive. Plasma, urine, stool, and nose and throat swabs were analysed for the presence 
of adenoviral DNA as previously described35 by real-time PCR. Samples were taken 24 h 
after vector injection and every 24 h until negative results. The detection limit of this 
assay was determined to be 500 copies/ml.  
Biopsies
Whenever possible, during cement injection procedure, biopsies from the peripros-
thetic interface area were taken. These biopsies were investigated by the Department 
of Pathology (Leiden University Medical Center, Leiden, The Netherlands) for the pres-
ence of apoptotic and necrotic tissue. 
X-ray measurements
Standard anteroposterior (AP) and lateral radiographs of the hip were performed in all 
patients during the inclusion period and at 1 day, 6 weeks, 6 months and every year af-
ter cement injection. On the radiographic images the perisprosthetic space was divided 
in 14 zones (Gruen zones) according to Gruen, McNeice, and Amstutz.50 In the AP im-
age zone 1 to 7 could be identified, with zone 1 being located on the lateral proximal 
side, zone 4 on the distal side, and zone 7 on the medial proximal side. In the lateral 
image zone 8 to 14 could be identified, with zone 8 being the proximal posterior zone, 
zone 11 the distal zone, and zone 14 being the proximal anterior zone. The maximal 
cement layer thickness and the minimal and maximal wideness of radiolucency were 
measured using Ortho-CMS software (Medis, Leiden, The Netherlands). These mea-
surements were performed for X-rays made during the inclusion period and 1 day and 
6 months after cement injection, and the differences between these measurements 
were analysed. 
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Patient satisfaction
For clinical evaluation, the Harris Hip Score53, and Visual Analogue Scales (VASs) for 
pain, walking distance and dependency in activities of daily living were done pretreat-
ment and 3 and 6 weeks, 3 and 6 months and every year after treatment. The HHS 
was used to evaluate outcome of hip prostheses. The score (maximum, 100 points) is 
composed of outcome measurements for pain (maximum, 44 points), activities (maxi-
mum, 14 points), walking (maximum, 33 points), absence of deformities (maximum, 
4 points), and range of motion (maximum, 5 points). Each VAS was administered by 
asking the patient to place a mark on a 10 cm line at an appropriate distance between 
two end points. For purposes of, 0 cm was always a bad result and 10 cm a good re-
sult. To compare the VAS with the HHS , the HHS results were multiplied to obtain a 
maximum score of 100. For comparison with pain by VAS the pain score from HHS was 
used (maximum, 44 points). For walking distances the HHS measurement of walking 
distance (maximum, 11 points) was compared with the VAS.
Statistical analysis
Means and standard deviations for all variables, and correlations between HHS and 
VAS scores, were calculated using SPSS 12.0 for Windows (SPSS, Chicago, IL, USA).
Results 
Patient characteristics
Twelve patients ranging in age from 72 to 91 years (mean, 82 years) were treated; 
1 male, and 11 females. Comorbidity of the patients was graded according to the 
criteria of the American Society of Anesthesiologists (ASA categories).121 Four patients 
were in ASA category 2 (mild systemic disease); four patients were in ASA category 3 
(severe systemic disease), and four patients were in ASA category 4 (severe systemic 
disease that is a constant threat to life). Three patients were diagnosed with rheu-
matoid arthritis; the other patients had osteoarthritis. Neutralisation tests using Ad5 
β-galactosidase showed that all patients had specific activity against Ad5 before treat-
ment. Two patients had a somewhat lower level of neutralising antibodies than the 
other patients. There was no relationship between level of neutralising antibodies and 
the occurrence of adverse events, shedding of the virus, or therapeutic benefits. The 
dose of the CTL102 vector ranged from 3 x 109 particles to 1 x 1011 particles (Table 1). 
All patients were intended to have a prodrug dose of 24 mg/m2 with a maximal con-
centration of 2mg/ml injected in the joint space, but after moderate gastrointestinal 
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and hepatic toxicity in the first four patients this dose was lowered to 16 mg/m2. Two 
patients had a slightly lower vector dose and five patients had a lower prodrug dose 
than was planned, because the contents of the syringe could not be injected entirely 
(Table 1). 
Toxicity
Nine of 12 patients experienced nausea and vomiting starting 6 h after prodrug injec-
tion, with 1 patient needing parenteral fluid administration for dehydration. Besides 
nausea and vomiting, eight patients had a rise in aspartate aminotransferase (AST) 
levels, with a maximum 4 days after prodrug injection, and four of these patients also 
had a rise in alanine aminotransferase (ALT) levels. These were asymptomatic and com-
pletely reversed. Two patients in the high prodrug dose group had grade 2 rises in AST 
and ALT levels, and three had diarrhoea. 
 Four serious adverse events occurred. One patient was diagnosed with a uterine 
carcinoma, and died of the carcinoma at 4 months follow-up. One patient developed 
kidney failure, probably from a previously diagnosed multiple myeloma, and died at 
3 months follow-up. One patient was admitted to the hospital for dehydration at 
6 months follow-up, and one patient was admitted to the hospital for hyponatremia 
and hypotension at 3 months follow-up. A detailed description of all adverse events is 
provided elsewhere. 
Virus Shedding
Plasma, urine, and stool samples, and nose and throat swabs were analysed for the 
presence of adenoviral DNA by real-time PCR as previously described.35 All patients in 
the lowest three vector dose groups (3 x 109, 1 x 1010, 3 x 1010 particles) had negative 
shedding results (guaranteed detection limit of 500 copies/ml) at the first measure-
ment (after 24 h). Two patients in the highest dose group (1 x 1011 particles) tested 
positive. One patient had 250 copies/ml in her blood plasma after 24 h. Urine and stool 
samples, and nose- and throat-swabs were negative. All samples taken at 48 h showed 
no presence of adenoviral DNA. Another patient in the highest dose group showed a 
plasma concentration of vector DNA equivalent to 480 adenoviral particles per millilitre 
at 24 h. All other samples were negative. The next day samples were taken again; these 
all tested negative. 
 To investigate whether the adenoviral DNA was successfully introduced into the inter-
face tissue and joint space, joint fluid was tested for adenoviral DNA by PCR. Before rins-
ing the joint and injecting the prodrug at day 2, joint fluid was aspirated whenever pos-
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sible. In five patients aspiration was unsuccessful or the amount of aspirated fluid was 
too small for analysis. In one patient only qualitative analysis was performed, showing 
adenoviral DNA in the joint fluid. In the other six patients quantitative analysis showed 
the presence of a considerable number of adenoviral particles in the joint (Table 2). 
Plaque assays of the adenoviral DNA from the joint fluid showed no infectious virus. In 
two patients the hip joint was punctured at another time point, giving the opportunity 
for collecting joint fluid. These samples both showed the presence of adenoviral DNA, 
one at 10 days after vector injection and the other at 11 months after vector injection.
Biopsies
Whenever possible during injection of cement, needle biopsies from the interface tis-
sue were taken for histological investigation. Biopsy of interface tissue was unsuccess-
ful in three patients. The specimens were analysed for apoptotic cells or necrosis. In 
two patients the amount of material obtained was insufficient to analyse. In the speci-
mens from the remaining seven patients, necrotic tissue was found in the biopsies of 
four patients. The other materials showed partly vital and partly degenerative fibrous 
tissue, bone marrow, and blood.
Table 2. Adenoviral DNA in the joint fluid.
Patient 
number






1 27 3x109 NS
2 16 3x109 5.24 x 105
3 30 3x109 5.07 x 107 +10 days: 2.60 x 105 particles
4 30 8.3x109 3.21 x 107
5 7.5 1x1010 1.45 x 107
6 22 1x1010 1.23 x 107
7 14 2.6x1010 NS
8 10 3x1010 NS
9 27 3x1010 NS
10 30 1x1011 1.00 x 107
11 9 1x1011 NS +11 months: 1.88 x 104 particles
12 18 1x1011 positive
Whenever possible before prodrug injection, joint fluid was aspirated for quantitative analysis of adenoviral 
DNA by PCR. In five patients aspiration was not successful, or the amount of aspirated fluid was too small for 
analysis (NS, not successful). In one patient only qualitative analysis was done showing positive results. In the 
remaining patients number of particles in the joint fluid is shown in the table as the number of particles per ml 
multiplied by the joint capacity. In two patients an additional measurement was done.
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Outcome measured by imaging: Radiographic analysis
To objectively measure the changes on X-rays, for each patient X-rays taken at inclusion 
period, 1 day after cement injection and at 6 months of follow-up were compared. 
At each of these time points anteroposterior and lateral X-ray views of the hip were 
taken. In each Gruen zone the maximal cement thickness and maximum and minimum 
widths of radiolucency were measured. Figure 1 shows the mean increase in cement 
mantle thickness per Gruen zone and per dose group, after cement injection compared 
with the inclusion period. In Figure 1 the periprosthetic bone is divided in 14 areas 
according to Gruen and co-workers.50 For each zone the maximal thickness of cement 
was measured before and 1 day after cement injection. The increase in cement thick-
ness was calculated and in Figure 1 the mean increase is shown per dose group. The 
exact numbers of these calculations and the standard deviations are shown in Table 3. 
Table 3 shows that the largest amount of cement could be injected in Gruen zone 1 
(3.98 +/- 5.4mm). In the higher dose groups more cement could be injected (mean 
in group 1 was 0.44; in group 2 it was 0.77; in group 3 it was 1.74; in group 4 it 
was 2.05). This difference in increase in cement thickness was significant only in the 
third group (Group 1, p = 0.836; group 2, p = 0.450; group 3, p = 0.024; group 4, 
p = 0.418). 
 Figure 2 shows the filling of the maximum radiolucent zone by cement per dose 
group. In Figure 2 the maximal radiolucency width before cement injection is shown, 
along with the part of the zone that was filled by cement after cement injection. 
 Maximal cement thickness and maximal radiolucency width were also measured 
at 6 months of follow-up. Compared with 1 day after cement injection the maximal 
cement thickness at 6 months follow-up had decreased by 0.02 mm (p = 0.91). The 
correlation between maximal cement thickness at 1 day and at 6 months after cement 
injection was 0.94 (p < 0.01). After 6 months the maximal radiolucency width had 
increased with 0.19 mm (p = 0.11). Correlation between maximal radiolucency width 
at 1 day and at 6 months after cement injection was 0.820 (p < 0.01).
 Figure 3 shows an example of radiographic examination before and after gene 
therapy and cement injection. Figure 3 shows that cement that is injected can easily 
spread through the periprosthetic space to provide more strength and stability.
Clinical outcome: Patient satisfaction
At inclusion and at 3 and 6 weeks and 3 and 6 months after cement injection Visual An-
alogue Scales (VASs) for pain, walking distance and activities in daily living (ADL) and 
the Harris Hip Score53 were performed. Figure 4a and 4b shows means and standard 
deviations for, respectively, decrease in pain and increase in walking distance by VAS 
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Figure 1.  Mean and standard deviations for the increase in cement mantle thickness 
per Gruen zone, per dose group after cement injection compared to the situ-
ation in the inclusion period.
The figure shows division of the periprosthetic space in 14 zones according to Gruen. Per zone the maximum 
cement thickness is measured before and after cement injection. The increase in cement thickness is represented 
graphically per Gruen zone and per dose group. Table 3 shows the exact numbers.
Table 3.  Mean and standard deviations for the increase in cement mantle thickness per 
Gruen zone, per dose group after cement injection compared to the situation 
in the inclusion period.











Total of all 
groups
1 2.75 (sd 5.7) 3.09 (sd 1.9) 2.32 (sd 5.0) 7.75 (sd 8.4) 3.98 (sd 5.4)
2 1.00 (sd 1.2) 0.57 (sd 5.2) 1.41 (sd 0.3) 2.43 (sd 20.) 1.35 (sd 2.5)
3 0.68 (sd 1.0) -0.29 (sd 1.3) 0.06 (sd 1.6) -0.02 (sd 1.1) 0.11 (sd 1.2)
5 -0.83 (sd 0.3) -1.30 (sd 1.3) 5.27 (sd 2.4) 2.42 (sd 2.7) 1.39 (sd 3.2)
6 -0.68 (sd 0.3) 1.90 (sd 2.6) 1.54 (sd 2.3) 1.46 (sd 1.3) 1.06 (sd 1.9)
7 -0.73 (sd 0.6) 1.54 (sd 1.2) 1.39 (sd 1.8) 0.17 (sd 0.6) 0.59 (sd 1.4)
8 2.46 (sd 0.5) 1.08 (sd 0.8) -0.69 (sd 0.9) 2.73 (sd 1.6) 1.30 (sd 1.7)
9 1.04 (sd 0.2) 1.81 (sd 1.8) -0.85 (sd 1.8) 0.37 (sd 5.1) 0.55 (sd 2.8)
10 1.18 (sd 1.8) 0.69 (sd 2.5) 4.49 (sd 2.0) 0.16 (sd 4.2) 1.67 (sd 3.0)
12 -0.43 (sd 1.1) 1.05 (sd 0.9) 1.22 (sd 1.0) 1.64 (sd 2.3) 0.99 (sd 1.5)
13 -0.36 (sd 0.7) -0.42 (sd 0.6) -0.07 (sd 2.4) 2.48 (sd 2.7) 0.48 (sd 2.1)
14 -0.61 (sd 7.4) -0.48 (sd 0.4) 4.79 (sd 2.0) 2.95 (sd 2.2) 1.87 (sd 3.6)
Total 0.43 (sd 2.5) 0.77 (sd 2.1) 1.74 (sd 2.8) 2.05 (sd 3.6) 1.28 (sd 2.8)
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measurement and from the Harris Hip Score at various time points and per dose group. 
Figure 4a shows that when pain is measured with VAS, maximum pain reduction is at 3 
to 6 weeks follow-up and declined further over time, except for the second dose group. 
In the second dose group one patient died after 6 weeks and one patient was lost to 
follow-up after 3 months. Final follow-up results of these patients were extrapolated 
for the remaining of the follow-up period. Correlation between the two types of pain 
measurement was 0.6 (p < 0.01), showing that the two methods indicated the same 
outcome, but an HHS of 100 points did not correspond to a VAS score of 100 points.
Figure 2. Maximal width of the radiolucent area per Gruen zone and per dose group. 
Also shown is the filling of this area with cement after gene therapy and cement injection. Per Gruen zone, the 
filling of cement in the widest radiolucent area is represented. Open portions of the columns show preopera-




Figure 2 shows the filling of the maximum radiolucent zone by cement per dose group. In Figure 2 the maximal 
radiolucency width before cement injection is shown, along with the part of the zone that was filled by 
cement after cement injection.  
 
Figure 2: Maximal width of the radiolucent area per Gruen zone and per dose group. Also shown is the filling of this area 
with cement after gene therapy and cement injection. Per Gruen zone, the filling of cement in the widest radiolucent area 
is represented. Open portions of the columns show preoperative maximal radiolucency zones. Solid portions of the 
columns show filling of these radiolucent zones after cement injection. 
 
Maximal cement thickness and maximal radiol cency width were also measured at 6 months of follow-up. 
Compared with 1 day after cement injection the maximal cement thickness at 6 months follow-up had 
decreased by 0.02 mm (p = 0.91). The c rrelation between maximal cement hickness at 1 day nd at 6 
months after cement injection was 0.94 (p < 0.01). After 6 months the maximal radiolucency width had 
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 Figure 4b shows increase in walking distance as measured by Visual Analogue Scale 
and Harris Hip Score (walking distance). Walking distance increased after cement injec-
tion, especially indose groups 3 and 4. In both measurements (VAS and HHS) the best 
improvement seems to be at 3 to 6 weeks of follow-up, after which walking distance 
declined to a level that was higher than preoperatively. Correlation between HHS and 
VAS for measurement of walking distance was 0.746 (p < 0.01). 
 Figure 5a shows means and standard deviations for improvement in dependency 
for activities in daily living at various time points per dose group. Best improvement is 
achieved in the highest dose group. Figure 5b shows increase in total Harris Hip Score 
at various time points per dose group. Scores increased after cement injection, espe-
cially in the highest dose group. 
Figure 3. Example of radiographic results after cement injection. 
Shown are X-rays from patient 12 before (left) and after (right) gene therapy and cement injection. Note that 
the newly injected cement is radio-opaque and therefore has a whiter appearance than the older cement. The 
radiolucent zone has a dark appearance on the pretreatment X-ray.
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Figure 4.  Mean and standard deviations for pain (a) and for walking distance (b) at 
various time points per dose group (group 1, 3 x 109 particles; group 2, 1 x 
1010 particles; group 3, 3 x 1010 particles; group 4, 1 x 1011 particles) . 
Solid columns represent VAS-measurements and shaded columns represent HHS-measurements for the same 
outcome variable. A score of 0 means unbearable pain; 100 means no pain;
Solid columns represent VAS-measurements and shaded columns represent HHS-measurements for the same 




Figure 4b: Mean and standard deviations for walking distance at various time points per dose group (group 1, 3 x 109 
particles; group 2, 1 x 1010 particles; group 3, 3 x 1010 particles; group 4, 1 x 1011 particles). Solid columns represent VAS-
measurements and shaded columns represent HHS-measurements for the same outcome variable. A score of 0 means not 
able to walk; 100 means unlimited walking distance. 
 
 
Figure 5a shows means and standard deviations for improvement in dependency for activities in daily living at 
various time points per dose group. Best improvement is achieved in the highest dose group. Figure 5b shows 
increase in total Harris Hip Score at various time points per dose group. Scores increased after cement 
injection, especially in the highest dose group.  
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4a shows that when pain is measured with VAS, maximum pain reduction is at 3 to 6 weeks follow-up and 
declined further over time, except for the second dose group. In the second dose group one patient died after 
6 weeks and one patient was lost to follow-up after 3 months. Final follow-up results of these patients were 
extrapolated for the remaining of the follow-up period. Correlation between the two types of pain 
measurement was 0.6 (p < 0.01), showing that the two methods indicated the same outcome, but an HHS of 
100 points did not correspond to a VAS score of 100 points. 
Figure 4b shows increase in walking distance as measured by Visual Analogue Scale and Harris Hip Score 
(walking distance). Walking distance increased after cement injection, especially indose groups 3 and 4. In 
both measurements (VAS and HHS) the best improvement seems to be at 3 to 6 weeks of follow-up, after 
which walking distance declined to a level that was higher than preoperatively. Correlation between HHS and 
VAS for measurement of walking distance was 0.746 (p < 0.01).  
 
Figure 4a: Mean and standard deviations for pain at various time points per dose group (group 1, 3 x 109 particles; group 2, 
1 x 1010 particles; group 3, 3 x 1010 particles; group 4, 1 x 1011 particles). Solid columns represent VAS-measurements and 
shaded columns represent HHS-measurements for the same outcome variable. A score of 0 means unbearable pain; 100 
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Figure 5.  Means and standard deviations for Activities of Daily Living (ADL) dependency 
(a) total Harris Hip Score (b) per dose group (group 1, 3 x 109 particles; group 
2, 1 x 1010 particles; group 3, 3 x 1010 particles; group 4, 1 x 1011 particles). 
A score of 0 means totally dependent on others; a score of 100 means totally independent for ADL. 




Figure 5a: means and standard deviations for Activities of Daily Living (ADL) dependency per dose group (group 1, 3 x 109 
particles; group 2, 1 x 1010 particles; group 3, 3 x 1010 particles; group 4, 1 x 1011 particles). A score of 0 means totally 
dependent on others; a score of 100 means totally independent for ADL.  
 
Figure 5b: means and standard deviations for total Harris Hip Score per dose group (group 1, 3 x 109 particles; group 2, 1 x 
1010 particles; group 3, 3 x 1010 particles; group 4, 1 x 1011 particles). This score represents function after total hip 




Figure 5a: means and standard deviations for Activities of Daily Living (ADL) dependency per dose group (group 1, 3 x 109 
particles; group 2, 1 x 1010 particles; group 3, 3 x 1010 particles; group 4, 1 x 1011 particles). A score of 0 means totally 
dependent on others; a score of 100 means totally independent for ADL.  
 
Figure 5b: means and standard deviations for total Harris Hip Score per dose group (group 1, 3 x 109 particles; group 2, 1 x 
1010 particles; group 3, 3 x 1010 particles; group 4, 1 x 1011 particles). This score represents function after total hip 
prosthesis, with a maximum score of 100 points. 
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This study provides the first description of the use of gene therapy and cement injec-
tion to stabilise loosened hip prostheses. The study was designed as an alternative to 
revision surgery for elderly patients with serious comorbidity and thereby a high mor-
bidity and mortality risk perioperatively. 
 The primary objective of the study was to determine safety and tolerability for the 
vector CTL102, the prodrug CB1954 and the cement injection. Secondary objectives 
included measurement of shedding of the virus, histological analysis of interface biop-
sies, and clinical outcome. Up to the maximal vector dose of 1 x 1011 particles no dose-
limiting toxicity was observed, and no adverse events were reported. A prodrug dose 
of 24 mg/m2 resulted in nausea and vomiting and rises in AST and ALT, despite the fact 
that prodrug concentrations measured in plasma in this study were substantially lower 
than in earlier toxicity studies.23 Therefore the prodrug dose was lowered to 16 mg/m2; 
this did not result in dose-limiting toxicity. Cement injection resulted in pain at the site 
of injection or hematoma in some patients, but these subsided over the following days. 
Four serious adverse events occurred, and these were all reported to and investigated 
by the local medical ethics review board (MEC) and the Central Committee on Research 
Involving Human Subjects (CCMO). In all four patients the safety committee, in agree-
ment with the MEC and CCMO, could not find a connection between the study and the 
occurrence of the serious adverse event. 
 Shedding of the virus in blood plasma, stool, and urine samples, and nose and 
throat swabs, was measured by quantitative PCR. Two patients in the highest dose 
group (1 x 1011 particles) showed virus load in the blood plasma after 24 h. These 
results were both below 500 particles/ ml. Because of the positive results the patients 
were kept in isolation and new samples were taken the next day, showing no virus load 
in either of these two patients. Previous studies with CTL102 as a vector showed no 
shedding of viral particles in blood plasma, urine, or stool samples, or nose and throat 
swabs after 24 h.91 An explanation for the presence of viral particles in the blood plas-
ma after 24 h in this study could be that the joint is a more or less closed compartment 
from which particles will slowly release. Although adenoviral DNA could not be de-
tected outside the joint, puncture of joint fluid after 48 h tested positive for adenovirus 
in all patients. In one of the patients in whom joint fluid was collected 11 months after 
gene therapy the sample showed adenoviral DNA at a concentration of 1.88 x 104 DNA 
particles per millilitre. In seven patients needle biopsies provided a sufficient amount 
of material for histological analysis. The samples were analysed for apoptosis and ne-
crosis. None of the samples showed apoptotic cells; however four samples showed 
necrosis. Lipinski et al.76 studied the mode of action of CTL102-CB1954 suicide gene 
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therapy and concluded that cells appeared to die by pathways that suggest necrosis 
more than that of classical apoptosis. This finding supports the presence of necrosis 
without apoptosis in the interface samples.
 In this study the systemic presence of neutralising antibodies was desirable, al-
though neutralising antibodies in synovial fluid inhibit HAdV-5 gene transfer.47 There-
fore, before local injection of the vector each joint was rinsed to remove as many 
neutralising antibodies as possible. This was done to ensure maximal transduction of 
interface cells in the more or less closed periprosthetic space while protecting the pa-
tient against adverse events, as the HAdV-5 particles that leak from the joint are im-
mediately recognised and attacked by the systemically present neutralising antibodies. 
The presence of anti-HAdV-5 neutralising antibodies tends to be ubiquitous in human 
adults,15 but in this group of vulnerable elderly patients with comorbidity this presence 
was investigated before viral injection to ensure adequate immunologic response to 
possible systemic leakage of HAdV-5 particles. Two patients had a somewhat lower 
level of antibodies compared with the other patients, but there was no relationship 
with shedding, adverse events, or therapeutic benefits.
 This study is the first to describe percutaneous cement injection periprosthetically 
to stabilise loosened hip prostheses. Additional injection of PMMA-cement has been 
used to refix prostheses,73 and is shown to have good biomechanical properties.49 
Results of this study show that part of the radiolucent zone can be filled with cement, 
but not all. However, the stability of each prosthesis in the bone has increased. The 
question that remains unanswered in this short follow-up concerns whether stabilisa-
tion of the prosthesis leads to an increase in bone stock over time, due to reduction of 
stress shielding of the bone, and consequent bone loading after fixation of the pros-
thesis. This principle has been proven by the Wagner SL revision stem, which is used 
to achieve a successful revision total hip replacement in patients with severe bone loss 
in the proximal part of the femur (Gruen zones 1, 7, 8 and 14). Distal fixation of the 
prosthesis in the bone with only minor prosthesis-bone contact, in a study by Böhm et 
al.,14 led to restoration of the proximal bone stock of the femur in 88% of the patients 
after a follow-up of 5 years. Whether the principle of the Wagner revision stem also 
applies for stabilisation of the prosthesis with percutaneous cement injection remains 
to be seen.
 Analysis of clinical outcome by Harris Hip Score and Visual Analogue Scale for pain, 
walking and Activities of Daily Living showed improvement of function and pain after 
gene therapy and cement injection, especially in the two highest dose groups. Whether 
this difference between dose groups is caused by the higher dose of adenoviral vector 
or by an increasing learning curve for percutaneous cement injection cannot be differ-
entiated. However, this is inevitable when implementing a new technique. According 
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to both VAS and HHS results, patients benefited from the treatment. In this study, pa-
tient’s opinion on clinical outcome was considered more valid than physician’s opinion, 
as physicians tend to assign better rankings to walking distance, pain and dependency 
in ADL.72,82 
 In conclusion, gene therapy and cement injection as an alternative for revision 
surgery in elderly patients with comorbidity represent a safe and potentially feasible 
approach. Clinical outcome improves according to patient’s opinion and radiographs 
show filling of radiolucent zones by cement. Whether stabilisation of the prosthesis 
leads to increase of bone stock on the longer term remains to be seen. 
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Elderly patients are sometimes not eligible for revision arthroplasty due to high mor-
tality risks. Previously, a minimal invasive approach was developed to percutaneously 
inject bone cement periprosthetically after removal of interface tissue using a suicide 
gene therapy approach. This case series was performed to investigate the possibility 
of injecting bone cement around the loosened prosthesis without previous removal of 
the interface. 
Methods
Seven patients with high morbidity risks due to high age, serious comorbidity or low 
bone stock were treated with percutaneous, periprosthetic cement injection. Patients 
had spinal anaesthesia and bone cement was injected after CT-guided placement of 
vertebroplasty needles. The amount of cement that could be injected and the distribu-
tion in the periprosthetic space was recorded. Patients were followed up in the out-
patient clinic.
Results
A mean volume of 16 ml of cement could be injected around the stem and 5.5 ml 
around the cup. All seven patients reported improvement in walking distance and pain. 
Interpretation
This small case series shows that bone cement can be injected periprosthetically in 
patients with loosened hip prostheses, as an alternative for revision surgery in high risk 
patients. Due to small patient numbers no conclusions can be drawn on the necessity 
to remove interface tissue before injecting bone cement to stabilise aseptically loos-
ened prostheses.
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Introduction
Revision surgery for hip prosthesis loosening has a high complication rate in elderly 
patients with comorbidity.6,92,99,114 Revision hip arthroplasty is associated with a higher 
number of complications and less improvement in social outcome compared to prima-
ry hip arthroplasty.103 Due to the tendency to insert orthopaedic implants in younger 
patients and their longer life expectancy, the number of revision surgeries in elderly 
patients is likely to increase considerably in the next decades. Kessler et al.64 concluded 
that duration of surgery, which is about 3 times longer in revision than in primary sur-
gery, is the main indicator for the severity of the operation. Elderly patients with ASA-
category 3 and more (American Society of Anaesthesiologists)121 are at higher risk for 
developing major and moderate complications after revision hip arthroplasty.6 
 One of the major difficulties in revision surgery is the removal of cement from the 
femoral shaft, without fracturing the femur. Biomechanical studies showed that rece-
menting can give a good interface strength with the old cement.49 Lieberman et al.73 
showed this in practice in 19 patients where a new prosthesis was cemented in an old 
cement mantle. In a previous study we showed that bone cement can be injected per-
cutaneously in the periprosthetic space of loosened hip prostheses after the interface 
tissue was removed with a suicide gene-directed enzyme-prodrug therapy (GDEPT).28 
Some of these patients had to be recemented after 6 months, with successful relief 
of symptoms. Therefore, and to bypass the more complicated GDEPT-approach, we 
refixated prostheses in patients that were at high risk for perioperative morbidity. In a 
small case series of percutaneous peri-prosthetic cement injections, the results for this 
increase of stabilisation of loosened hip prostheses were evaluated.
Materials and methods
Patients
Goal was the evaluation of CT-guided periprosthetic percutaneous cement injection 
to increase stabilisation of aseptically loosened total hip prostheses. Patients with de-
bilitating pain from a loosened hip prosthesis and a high perioperative morbidity and 
mortality risk if revision total hip arthroplasty was performed, were included. Risks 
were advanced age, serious comorbidity, and low bone stock. Before the procedure, 
laboratory tests (ESR, CRP) were done, and a routinely performed arthrogram was 
made with aspiration of joint fluid to exclude the presence of a (low-grade) infec-
tion and to verify loosening of the prosthesis. Furthermore, marcainisation of the hip 
joint was performed to confirm that the pain experienced by the patient was due to 
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a loosend hip prosthesis. Patients who had undergone previous peri-prosthetic per-
cutaneous cement injections combined with gene therapy28 were excluded from the 
case series. Patients undergoing the cement injection were admitted to the hospital 
for 1 or 2 days. On the first day bone cement was injected peri-prosthetically in a 
predefined space as described below. Depending on post-procedural pain and / or 
travelling distance patients stayed overnight before returning home. Patients were 
then once seen for follow-up in the outpatient’s clinic, or at a later time point when-
ever patients were capable. 
Cementing technique
On previously performed routine radiographs and a CT-scan of the hip and pelvis the 
areas most suitable for cement injection were identified. These were the areas with 
the widest periprosthetic radiolucency. All patients were screened by the anaesthesi-
ologist prior to the procedure and underwent spinal anaesthesia preferably. Patients 
were positioned supine on the CT-table with a marker grid fixed to the patient’s hip 
region and a planning CT-scan was performed. The markers and planning CT were 
used to exactly define the positions for introduction of the needles through the skin 
and the angle by which the needle needed to be introduced to reach the designated 
periprosthetic radiolucent zone. In this way 3 to 5 points were marked on the skin for 
introduction of the needles. All patients received prophylactic antibiotics (cephalo-
sporin) intravenously as is routinely used for any arthroplasty procedure. The hip and 
groin region were then disinfected and sterilely covered, and 3 to 5 vertebroplasty 
needles of 1.8 or 3.2 x 100 mm (Biomet, Dordrecht, The Netherlands) were intro-
duced with soft blows into the periprosthetic space where the cortex was thinnest 
(usually <2mm), using a hammer, advancing 1-2 mm per blow and controlling the 
position with CT-scan (Figure 1). If the cortex was too thick (i.e. >3mm) a needle with 
a drill bit was used first, after which the cement needle was used. The areas where 
the radiolucent zones were widest were preferrably chosen as entrance points. The 
position of the needles and the depth of the insertion were then controlled by CT 
guidance (Figure 2). The needles were turned in such a way that the opening faced 
the prosthesis to minimise leakage of the cement. After placement of the needles 
the fluoroscopy C-arm was positioned over the patient (Figure 3). Polymethylmeth-
acrylate (PMMA) cement (Osteopal [Biomet] or Disc-OTech [Disc-O-Tech Medical Tech-
nologies, Herzeliya, Israel]) was injected into the periprosthetic space under high 
pressure with a Cementoset (Biomet). During injection, the flow of the PMMA ce-
ment was continuously monitored by fluoroscopy, and intermittantly with CT-scan. 
Injection was continued until the periprosthetic space was filled or until the cement 
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Figure 1.  CT-guided placement of vertebroplasty needles in the periprosthetic space 
around stem and cup a) and cement injection under fluoroscopic guidance (b). 
1a
1b
Figure 2.  CT-guided verification of correct needle tip position. Needle tip is facing the 
prosthesis
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Figure 3.  Positioning of the fluoroscopy C-arm over the patient (a) and position of the 
fluoroscopy C-arm over the patient (b).
3a
3b
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threatened to leak into the joint space or when there was leakage of cement into the 
soft tissues (i.e., extraosseous) (Figure 4). Before removal, the needles were turned in 
a clockwise or counterclockwise manner several times to ensure easy removal.
Follow-up
Standard anteroposterior (AP) and lateral radiographs of the hip were performed in all 
patients pre- and post-operatively (before discharge) and whenever patients came to 
visit the outpatient’s clinic. On the radiographic images the periprosthetic space was 
divided into 14 zones according to Gruen, McNeice, and Amstutz.50 The maximal ce-
ment layer thickness was measured with Ortho-CMS software (Medis, Leiden, The Neth-
erlands). These measurements were performed for X-rays made pre-operatively and the 
first post-procedural X-ray. The differences between these measurements were analysed.
 The objective was to measure functional outcome in this small, diverse patient 
group the patients were asked about the differences in pain before and after the proce-
dure, changes in walking distance and changes in walking aids. No statistical analyses 
were performed.
Figure 4. Fluoroscopy-guided injection of bone cement




5 Female and 2 male patients, with a mean age of 85 years (range 76-91 years) were 
treated. One patient had cement injections around both hips. Table 1 shows patient 
characteristics and the volumes of cement that could be injected. One patient could be 
discharged to her home on the same day of treatment; 3 patients could be discharged 
the next day. The patient with injections in both hips was admitted for 3 days, and the 
other 2 patients were admitted for 5 and 11 days. In the patient with bilateral cement 
injections a periprosthetic fissure was initiated in the right femur. This patient had to 
mobilise with partial weight bearing for 3 months. X-rays after this period showed 
good consolidation of the fracture and full weight bearing was allowed. No other 
adverse events occurred.
Figure 5 shows an example of radiographic examination before and after cement injec-
tion in patient 2. The figure shows that the injected cement can easily spread through 
the periprosthetic space to provide more strength and stability. To objectively measure 
the changes on anteroposterior and lateral X-rays taken before and after cement injec-
tion, in each Gruen zone (except for zones IV and XI) the maximal cement thickness 
was digitally measured for each patient. In one patient accidentally no post-procedural 
X-ray was made, and consequently this patient was excluded from X-ray analysis. Fig-
ure 6 shows the mean (with standard deviation and range) increase in cement mantle 
thickness per Gruen zone after cement injection compared to the cement mantle be-
fore the procedure. The largest increase in cement thickness were in Gruen zones I 
(mean 3.8 mm, range -0.5 – 7.9 mm), zone VIII (mean 6.5 mm, range 2.1 – 13.8 mm) 
and zone XIII (mean 4.0, range 1.2 – 8.6 mm). 
Table 1. Patient characteristics




Side Age of prosthesis 
(years)
Volume of cement injected
1 F 88 2 R 14 Stem: 18 mL
2 F 84 3 R 20 Stem: 25 mL; cup: 12 mL
3 M 91 2 R 16 Stem: 23 mL; cup: 2 mL
4 F 83 2 R 7 Not registered
5 M 81 3 R 11 Cup: 4.5 mL
6 F 87 3 R 25 Stem: 10 mL; cup: 7 mL 
7 F 76 2 R + L 17 and 16 L: stem: 10 mL; cup: 3 mL
R: stem: 8 mL; cup: 4.5 mL
Mean 85 2.4 16 Stem: 16 mL; cup: 5.5 mL
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Figure 6.  Increase in cement mantle thickness after percutaneous periprosthetic ce-
ment injection. 
Number show mean increase in millimetres, with standard deviations in brackets and the range in square 
brackets.
Figure 5.  X-rays of right hip in anteroposterior and lateral view before percutaneous 
cement injection (a) and after percutaneous cement injection (b).
5a 5b
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Before the cement injection, patients were asked about the walking aids they needed 
and the maximal distance they could walk. After cement injection patients were asked 
again about the walking aids and distance, and differences in pain and performance. 
 Patient 1 could walk less than 500 meters using a walker and had pain in the hip 
before the cement injection. Acetaminophen had no effect on the pain. 14 Months af-
ter the procedure she could walk for 800 meters with a walker, she reported only mild 
pain in the groin, and better movement of the hip. Putting on her shoes was easier 
than before the cement injection. 
 Patient 2 could walk 50 meters with a cane in-house and used a scoot-mobile for 
mobilisation outside the house before the procedure. She had pain in her right hip. 
10 Months after percutanous cement injection she reported no pain and she did not 
need home care anymore. Walking had improved.
 Patient 3 had complaints of the right hip with nocturnal pain and problems with 
raising the right leg. His left hip was revised three times, even more both his knees 
showed severe osteoarthritis. He walked with 2 canes before the procedure. In order 
to distinguish between right joint pain and pain in the other lower extremity joints 
marcainisation of the right hip was performed. This completely resolved the pain in his 
right leg and improved his walking capability despite the instability complaints of his 
left leg. 12 Months after cement injection the patient reported only mild pain in the 
groin, he still walked with 2 canes (due to complaints of the knees and left leg), but 
could now do his own grocery shopping.
 Patient 4 had pain in her right leg and groin for which she used Indometacin 3 times 
a day, Acetaminophen, and morphine. She could only walk for 40 meters with a walker 
in-house. 2 Years after cement injection she had no pain and did not use any painkill-
ers. She still used a walker, but could now walk for 300 meters, and she could do her 
own grocery shopping.
 Patient 5 had pain in his right hip and could walk 100-200 meters without any 
walking aids. 9 months after cement injection the patient could walk for 1 kilometre 
without any walking aids, and he had no pain. 
 Patient 6 had debilitating pain in the right hip and could only walk in-house with 
a walker. She used Acetaminophen as a painkiller. 7 weeks after cement injection she 
reported no pain and an improvement in walking.
 Patient 7 had pain in both hips with nocturnal pain and pain during walking. Her 
walking distance was 100 meters maximum. She used Acetaminophen and tramadol 
as painkillers. During the procedure a fissure occurred in the right femur. Directly after 
the procedure she was told to minimise weight bearing of the right leg. After 6 weeks 
weight bearing of the right leg could be increased to 50%, and six weeks later full 
weight bearing was allowed. Consecutive X-rays showed increasing consolidation of 
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the fissure. At 10 months follow-up she still used Acetaminophen as a painkiller for 
pain in the left hip. She could walk 1 kilometre using 2 crutches. Pain recurred after 
12 months, due to the severe bone loss and the varus position of the hips.
 
Discussion
This small case series shows that it is possible to inject cement around a loose total hip 
prosthesis percutaneously without previously removing the interface layer. However, 
the effect of this extra cement was different among patients. In the 7 patients a mean 
volume of 16 ml could be injected around the stem and 5.5 ml around the cup. All 
patients reported an increase in walking distance and a decrease in pain. Although 
peri-prosthetic cement injection is possible without removing the interface layer it 
seems logical that a better fixation of the prosthesis is achieved when the interface 
is removed. In a previous study we performed percutaneous periprosthetic cement 
injection in elderly patients with aseptic loosening of the hip after gene directed en-
zyme prodrug therapy to remove interface tissue. In this study patients also reported 
increase in walking distance and decrease in pain.28 However, the gene therapy itself 
required at least one week hospital admittance and some of the patients suffered from 
systemic adverse events by the prodrug.29 Due to the low numbers of patients in both 
studies no conclusions can be drawn on the best method to refix the prosthesis. Fur-
thermore, no predictions can be made for follow-up results.
 Although the percutaneous cement injection is a relatively small procedure with 
probably low risks for the patient, the procedure should only be performed in patients 
with very high risks for peri-operative morbidity and mortality during normal revision 
surgery. This is because normal revision surgery in low risk patients has proven to be 
effective and has better functional results at long time follow-up compared to the per-
cutaneous cement injection technique. On the other hand, after percutaneous cement 
injection, regular revision surgery can always be considered as a last resort option. Fur-
thermore, if a high risk patient of 80+ years has less or no nocturnal pain and can walk 
better for more ADL indepency with a small procedure, quality of life will be improved. 
Percutaneous cement injection can only be performed when fixation in the present 
prosthesis position will relieve the complaints, i.e., not in patients with complaints due 
to polyethylene wear or recurrent dislocations.
 In conclusion, this small series shows that percutaneous cement injection around 
an aseptically loosened prosthesis without previously removing the interface tissue is a 
feasible approach, but based on the current data no conclusions can be made on the 
preference to remove the interface tissue before injecting cement. However, it seems 
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logical that removal of the interface tissue will give an improved stabilisation compared 
to a situation where this soft tissue is left in place. The patient with the best clinical 
results had a radiolucency of <1mm, indicating presence of little soft interface tissue.
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Approximately one million total hip replacement operations are performed worldwide 
annually, mostly for osteoarthritis and rheumatoid arthritis. A major complication in 
total hip arthroplasties is loosening of the prosthesis leading to pain and walking dif-
ficulties and a higher risk for dislocations and pathological fractures.54 Within ten years 
of primary hip replacement 7-13 percent of patients need revision surgery due to loos-
ening of the implant.79 The number of revision surgeries in elderly patients is likely to 
increase considerably in the next decades, due to the tendency to insert orthopaedic 
implants at younger ages and the longer life expectancy of patients. Revision surgery 
has a high complication rate in elderly patients6,92,99,114 and is associated with less 
improvement in social outcome, compared to primary hip arthroplasty in patients of 
all ages.103 Many studies have focused on the relatively good technical outcome of revi-
sion hip arthroplasty in patients of all ages. However, the impact on the patient’s life, 
especially in elderly patients has been underemphasised. 
This thesis was set up to develop and analyse an alternative treatment for hip pros-
thesis loosening. We used a gene-directed enzyme-prodrug therapy to kill and remove 
interface tissue, after which we injected bone cement around the prosthesis percu-
taneously under CT- and fluoroscopy guidance. The first chapter describes the social 
and medical impact of revision hip arthroplasty in patients 80 years and older, and 
thereby the reason we searched for an alternative treatment. The next three chapters 
describe preclinical studies, in chapter 3 and 4 cell studies are described that show that 
interface cells can be killed by the gene therapy. Chapter 5 shows the importance of a 
pre-treatment arthrogram. In chapters six to eight the clinical protocol is outlined, and 
results are shown. Finally, chapter nine describes a short case series of patients who 
had percutaneous cement injections without previous interface removal.
Revision surgery in octogenarians
In Chapter 2 we retrospectively reviewed all patients 80 years and older undergoing 
revision total hip arthroplasty in two hospitals in the Netherlands between 1994 and 
2007. Primary objective was social outcome after hospital admittance for revision hip 
surgery. Secondary objectives were occurrence of complications during hospital stay, 
patient survival, and use of walking aids before and after revision surgery. After hos-
pital admittance for revision surgery eventually 75% of patients could return to their 
previous social situation, in 12% the social situation worsened, and in 4% the situation 
improved. For the patients living independently before the revision surgery, we used a 
logistic regression analysis to predict which patients could return home, and which pa-
tients had to go to a nursing facility for a longer period of time. The regression analysis 
revealed that the sole predictor for returning home was the presence of a spouse. This 
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feature was also mentioned in the study by Strehle et al.,114 who found that 95% of 
patients living with a spouse could return to home, compared to 70% of patients not 
living with a spouse. Although revision surgery of the hip prosthesis was intended to 
improve the ADL (Activities in Daily Living) of the patients, our study shows that the 
social situation worsened more than improved. There can be several reasons for this. 
One explanation can be that although function of the hip is improved by revision sur-
gery, the patient’s condition is deteriorated by the hospital stay. Although there was no 
correlation between hospital stay and the number of complications occurred, the dura-
tion of hospital stay was long (mean of 34 days), and the amount of complications was 
high, with a mean of 1.3 complications per patient, and a statistically significant corre-
lation between ASA - category (American Society of Anesthesiologists)121 and number 
and seriousness of complications. 26% of the patients had a delirium, implicating that 
the revision surgery had a high impact on physical and mental status. Beside deterio-
ration of the physical and mental status of the patient during hospital stay, another 
explanation for worsening in social situation is that the situation at home was already 
unacceptable, and the hospital admittance was the trigger to change it. Another fea-
ture that involves elderly patients is that the risk for peri-prosthetic fractures is higher 
than in younger patients.92 This is explained by the fact that elderly patients usually 
have a poorer bone stock. Although we only studied octogenarians, we found that 
13% of patients in ASA-3 had a periprosthetic fracture, compared to 5.4% of patients 
in ASA-2 (p = 0.10). In conclusion, chapter 2 shows that revision hip surgery has a 
high impact on the physical, mental and social status of elderly patients. Indications 
for revision surgery should be extensively considered, and consequently there remains 
a group of elderly patients with serious comorbidity and/or a low bone stock, who are 
not eligible for revision surgery. For these patients the alternative treatment described 
in this thesis is developed.
Preclinical studies
For the removal of the interface tissue between prosthesis and bone a gene-directed 
enzyme prodrug therapy (the vector CTL102 in combination with the prodrug CB1954) 
is used. The primary effect of CTL102 infection of a cell is the delivery of the Ntr gene 
expression cassette. After cell entry and unpackaging from the viral capsid, the CTL102 
genome exists as an extra chromosomal DNA element from which the machinery of 
the infected cell transcribes Ntr mRNA. This in turn will be translated into active nitro-
reductase, which will accumulate in the cytosol. Intracellular Ntr activity is responsible 
for the activation of prodrug CB1954 to a toxic bifunctional alkylating agent inside the 
cell.68 Cells able to bioactivate CB1954 are cytotoxically affected by crosslink formation 
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at very high frequency. As a consequence, cells activating CB1954 are destroyed.18,34 
The intended outcome is that infected cells expressing Ntr, which take up CB1954, will 
be killed by the activated prodrug. Synovial tissue has the histological and histochemi-
cal characteristics of interface tissue43 and in a previous study in our lab by Goossens 
et al.46 it was demonstrated that genes can be transferred to synovial tissue in vivo in 
rhesus monkeys, by direct injection into the joint, and that the synoviocytes can be 
killed with injection of a specific prodrug. 
 In Chapter 3 the efficient killing of interface cells by gene-directed enzyme prodrug 
therapy is shown. To test the susceptibility of interface cells to HAdV-5 vectors, pri-
mary cultures of interface cells were exposed to the HAdV-5 vector Ad.CMV.LacZ. The 
transduction efficiency increased with vector concentration and at 400 pfu/ cell 88% 
of cells expressed the reporter gene. Separately, the vector CTL102 and the prodrug 
CB1954 were not toxic to the interface cells at low to intermediate doses. However, 
CTL102-transduction of interface cells resulted in a 60-fold sensitisation to the prodrug 
CB1954. Before intra-articular injection of a therapeutic ingredient the position of the 
needle in the joint space is usually confirmed by injection of a small amount of con-
trast medium into the cavity, while making fluoroscopic images. For the use in a clini-
cal study, a possible effect of contrast medium on the efficiency of transduction and 
killing of interface cells should be tested. Results in chapter 3 show that the contrast 
medium has no effect on the viability of interface cells but, in the presence of iodide-
containing contrast medium, transduction of the cells by an adenoviral vector is almost 
negligible. The mechanism for this remains unclear, however we showed that the effect 
is not caused by a change in the cells themselves as transient exposure does not lead 
to inactivation of the vector. Furthermore, the effect is independent on the receptor, 
and is not caused by the iodide itself. In conclusion, chapter 3 shows that interface 
cells can be killed by the Ntr/CB1954 enzyme prodrug approach. However, the currently 
employed contrast medium cannot be used to verify the position of the needle during 
intra-articular injection of the vector and prodrug, given the effect on the transduction 
of cells.
 Chapter 4 describes two methods we tested to optimise transgene expression. 
When the gene expression can be made more predictable and efficient, the vector dose 
can be decreased. This has several advantages, including less evocation of an immune 
response and a smaller demand for the production of clinical grade adenovirus.66 One 
of the methods to increase gene expression is to facilitate interaction of the promoter 
with the DNA sequences. Normally, the chromatin of DNA is wrapped around a com-
plex of histone proteins. Sodium butyrate (NaB) causes hyperacetylation of histones, 
which alters the chromatin structure and increases gene expression. Furhtermore, NaB 
probably upregulates transcription factors which also increases reporter-gene expres-
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sion.11,17,27,42 We showed that NaB at a concentration of 6mM increases reporter gene 
expression in vitro with a factor 7 to 16 compared to a control condition without NaB. 
NaB has two main disadvantages that could withhold use in a clinical study. The first 
disadvantage is that NaB is rapidly metabolised in vivo (half-life of 6.1 min), making 
it difficult to maintain at an effective therapeutic level. To overcome this problem es-
terified butyrate derivatives with longer half-lives have been developed.88,96,97 Pobably, 
when a high concentration of NaB can be achieved locally (when injected in a closed 
compartment, like a joint), NaB can be advantageous to increase transgene expression 
in vivo. The second disadvantage is that the effect of NaB will not only be on the trans-
gene intended, but also on other genes that are being transcribed. Additional studies 
are needed to examine the long-term effects of NaB before it can be used in a clinical 
gene therapy study.
 In an attempt to increase local effect on transgene expression while keeping 
systemic effects at a minimum, a vector was developed with a ubiquitous chroma-
tin opening element (UCOE) inserted in the vector DNA. The mode of action of this 
UCOE is that the promoter is packed in a DNA sequence containing methylation-free 
CpG-islands, making the promoter resistant to heterochromatin-mediated silencing of 
these genes.74,126 This will prevent that transgene expression decreases over time. In 
our study we found no difference in expression between the vector with and without 
UCOE. A possible explanation can be that the promoter is not silenced in the first days 
after infection, rendering no effect of an anti-silencer insert. In a clinical study where 
transgene expression is needed for a longer period of time, insertion of a UCOE in the 
vector DNA could probably be a good option.
 In all studies a good exposure of the target tissue is essential, and for clinical stud-
ies in which the active ingredient is injected intra-articularly, the active ingredient must 
remain in the joint for a sufficiently long period. Beside size of the therapeutic par-
ticle46,90, the integrity of the surrounding joint capsule (containment) is important in 
retaining the active particles within the joint space. Containment of the joint space 
can be visualised by arthrography in which the joint space is filled with radio-opaque 
contrast medium and this procedure is visualised with fluoroscopy. Efficacy of intra-ar-
ticular treatment is also dependent on the joint volume. In large joint spaces the active 
ingredient will be more diluted than in small joint spaces or a higher dose will be re-
quired with the potential for increased toxicity. In a clinical study where intra-articular 
injection is used as the method of delivery of the therapeutic ingredient, it is important 
to perform an arthrogram in the inclusion period. This ensures that patients who have 
a non-contained joint can be excluded from the study. Furthermore, the volume of 
the joint space is known and this is important for the preparation of the therapeutic 
solution. Chapter 5 shows a retrospective study of 221 hip arthrograms performed 
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for diagnosis of prosthesis loosening. In 74% of the arthrograms the joint space was 
contained, and these patients would have been suitable for intra-articular therapy. The 
mean volume of the contained joints was 31 mL. This chapter shows that, as 26% of 
the patients have a non-contained joint and the volume differs considerably among pa-
tietns, it is important to perform an arthrogram before intra-articular therapy to know 
which patients should be excluded from treatment and what volume can be injected.  
Clinical studies
After completion of the pre-clinical studies a study protocol for a phase -1 clinical trial 
was developed. In this study 12 patients were included. Treatment involved intra-artic-
ular injection of the human adenoviral-5 vector CTL102 and, 2 days later, intra-articular 
injection of the prodrug CB1954. 7 Days later the loosened hip prosthesis was refixed 
by percutaneous peri-prosthetic bone cement injection. The study protocol was ap-
proved by the Central Committee on Research Involving Human Subjects (CCMO, The 
Hague, The Netherlands); The Ministry of Housing, Spatial Planning, and the Environ-
ment (VROM, The Hague, The Netherlands), and the local ethics committee and was 
conducted according to the principles of the Declaration of Helsinki (as amended in 
Tokyo, Venice, Hong Kong, Somerset West, and Edingburgh), and in accordance with 
the Guidelines for Good Clinical Practice (CPMP/ICH/135/95-July 17, 1996). Chapter 6 
describes the clinical protocol in detail. 
 As the clinical study is a phase-1 trial, safety is the primary objective. Recommen-
dations for grading of acute and subacute toxic side effects (World Health Organisa-
tion, 1979) were used to report adverse events. Adverse events were recorded up to 
6 weeks after vector injection. Chapter 7 describes all adverse events that occurred 
during the first 6 weeks after gene therapy. No dose limiting toxicity occurred. Vector 
administration could be continued until the proposed highest dose of 1 x 1011 par-
ticles. Nine of 12 patients experienced nausea and vomiting starting 6 h after prodrug 
injection, with one patient needing parenteral fluid administration because of dehy-
dration. These side effects are likely to be caused by the prodrug (and not the vector), 
as their occurrence decreased after lowering the prodrug dose and did not increase 
with the 30-fold increase in HAdV-5 vector. Besides nausea and vomiting eight patients 
had a rise in aspartate aminotransferase (AST), with a maximum 4 days after prodrug 
injection, and four of these patients also had a rise in alanine aminotransferase (ALT). 
These hepatic side effects were asymptomatic and completely reversible. However, as 
2 of the patients had grade 2 rises in AST and ALT, and one patient needed parenteral 
feeding due to dehydration, prodrug dose was lowered to 16 mg/m2 after 4 patients 
were treated. Pathophysiology of the gastrointestinal adverse events of the prodrug is 
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unknown; two possible explanations are considered. First, the most likely explanation 
is indirect gastrointestinal epithelial toxicity. Another explanation might be conversion 
of CB1954 to the activated form by Ntr from E.coli present in colonic flora. CB1954 
metabolism is predominantly hepatic.23 This underscores that the rise in transaminase 
levels can be explained by liver cell damage by CB1954 metabolites during drug clear-
ance. In conclusion, no dose-limiting toxicity occurred with Ntr-CB1954 gene therapy. 
However, prodrug dose was lowered to 16 mg/m2 due to inconvenient gastrointestinal 
and hepatic side effects.
 Secondary objectives in the study were (1) to establish that this procedure does not 
cause shedding of the virus into the environment (2) histological investigation of biop-
sies of interface tissue (3) to investigate the possibility to stabilise the loosened pros-
thesis by means of bone cement and (4) to investigate clinical results, i.e., pain relief 
and improvement in ADL. Secondary objectives are discussed in Chapter 8. Shedding 
of the virus in blood plasma, urine, and stool samples, and in nose and throat swabs, 
was measured by quantitative polymerase chain reaction (PCR) analysis. Two patients 
in the highest vector dose group (1 x 1011 particles) showed virus load in the blood 
plasma after 24 h. Therefore, these patients were kept in isolation and new samples 
were taken the next day, which showed negative. In previous studies with CTL102 
as a vector no shedding was shown after 24 h.91 An explanation for the presence of 
vector in our study can be that the vector is injected in the joint, which is a more or 
less closed space from which particles will slowly release. Although adenoviral vector 
DNA could not be detected outside the joint after 48 h, puncture of joint fluid showed 
positive for adenoviral DNA even after 11 months in one of the patients. In seven pa-
tients needle biopsies provided a sufficient amount of tissue for histological analysis. 
These samples mostly showed tissue necrosis without apoptosis. This is in concordance 
with the study by Lipinksi et al.,76 who concluded that in CTL102-CB1954 suicide gene 
therapy, cells appeared to die by pathways that suggest necrosis more than classical 
apoptosis. Percutaneous cement injection was used to stabilise the prosthesis after 
killing of the interface tissue. Chapter 8 shows that part of the radiolucent zone can 
be filled with cement, but not all. The question remains whether stabilisation of the 
prosthesis with cement injection will lead to increase of bone stock over time, due to 
reduction of stress shielding of the bone, and consequent bone loading after fixation 
of the prosthesis. Finally, clinical outcome was assessed by Harris Hip Score and by 
Visual Analogue Scales (VASs) for pain, walking distance, and activities of daily living. 
All these features of clinical outcome improved after cement injection, especially in the 
two highest dose groups. Whether this difference in dose groups is caused by a higher 
vector dose or by an increasing learning curve for the percutaneous cement injection 
cannot be differentiated. However, this is inevitable when implementing a new tech-
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nique. In clonclusion, gene therapy to remove interface tissue, followed by percutane-
ous cement injection to stabilise the prosthesis is a safe and feasible approach. Clinical 
function improves according to the patient’s opinion and radiographs show partial 
filling of the radiolucent zone with cement. However, it remains to be seen whether 
stabilisation of the prosthesis leads to increase in bone stock over the longer term. 
 A drawback of gene therapy to remove interface tissue is that patients need to be 
admitted to the hospital for at least one week. Furthermore, most of the patients suf-
fered from systemic side effects by the prodrug. To investigate whether percutaneous 
periprosthetic cement injection was possible without previous removal of interface 
tissue, we performed a small case series on 7 patients. This case series and the results 
are discussed in Chapter 10. Seven elderly patients not eligible for regular revision hip 
arthroplasty due to serious comorbidity or poor bone stock were entered in the case 
series. These patients received CT- and fluoroscopy guided periprosthetic cement injec-
tion, like the patients in the gene therapy trial, but without the gene therapy. A mean 
volume of 16 ml of bone cement could be injected around the stem, and 5.5 ml around 
the cup of the prosthesis. All patients reported clinical improvement. Due to the low 
numbers of patients in both studies no conclusions can be drawn on the best method 
to refix the prosthesis. Furthermore, no predictions can be made for results at the lon-
ger term follow up. Although the percutaneous cement injection is a relatively small 
procedure, we recommend only to use it in patients who are ineligible for revision sur-
gery, as regular revision surgery has proven to be effective although complications may 
occur. Furthermore, long term results of the percutaneous injections are yet unknown. 
On the other hand, after percutaneous cement injection, the option for revision sur-
gery is still open. A drawback of percutaneous cement injection is that it can only be 
performed when the position of the prosthesis is good and the patient’s complaints 
are not caused by excessive polyethylene wear or recurrent dislocations. Especially in 
patients with high risks, it is very important to verify that the pain is caused by loos-
ening of the prosthesis, e.g., by marcainisation, and not by other causes (e.g. lower 
back pathology), before considering revision surgery. In conclusion, chapter 10 shows 
that percutaneous cement injection around an aseptically loosened prosthesis without 
previously removing the interface tissue is possible, but since the interface tissue is not 
removed, it will probably be limited to rare indications. Furthermore, based on the cur-
rent data no conclusions can be made on the preference to remove the interface tissue 
before injecting cement. However, it seems logical that removal of the interface tissue 
will give a better stabilisation compared to a situation where the interface tissue is left 
in place. 
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Jaarlijks worden wereldwijd ongeveer 1 miljoen totale heupprothesen geplaatst, 
meestal bij patiënten met reumatoïde artritis (5%) of artrose (95%). Een belangrijke 
complicatie bij totale heupprothesen is mechanische loslating van de prothese, wat 
kan leiden tot pijn en problemen met lopen en een groter risico op luxaties en patho-
logische fracturen.54 Binnen 10 jaar na plaatsing van de totale heupprothese heeft 
7-13% van de patiënten een revisie nodig, omdat er loslating van de prothese is op-
getreden.79 Het aantal revisie operaties van een heupprothese gaat waarschijnlijk de 
komende jaren flink toenemen, omdat we geneigd zijn protheses op steeds jongere 
leeftijd te plaatsen en omdat de patiënten steeds ouder worden. Revisie chirurgie van 
de heup geeft veel complicaties bij oudere patiënten6,92,99,114 en is geassocieerd met 
minder verbetering in sociale uitkomst, vergeleken met primaire totale heup artroplas-
tiek bij patiënten van alle leeftijden.103 Veel studies hebben zich geconcentreerd op de 
relatief goede technische resultaten van revisie heupartroplastiek bij patiënten van alle 
leeftijden. De impact op de kwaliteit van het leven van de patiënt, vooral bij oudere 
patiënten, wordt echter onderbelicht. 
 Dit proefschrift is opgezet om een alternatieve behandeling voor heup prothese 
loslating te ontwikkelen en te analyseren. We gebruikten een gene-directed enzyme 
prodrug therapie (GDEPT) om interface weefsel te doden en te verwijderen, waarna 
we botcement rond de prothese spoten onder doorlichting en CT-geleid. Het eerste 
hoofdstuk beschrijft de sociale en medische impact van een revisie heup artroplastiek 
bij patiënten van 80 jaar en ouder, en daarmee de reden waarom we deze alternatieve 
behandeling ontwikkelden. De volgende drie hoofdstukken beschrijven pre-klinische 
studies; in hoofdstuk 3 en 4 worden celstudies beschreven die laten zien dat interface 
cellen gedood kunnen worden door gentherapie. Hoofdstuk 5 laat zien hoe belangrijk 
het is om voor de start van de behandeling een artrogram te verrichten. In de hoofd-
stukken 6 t/m 8 wordt het klinische protocol samengevat en worden de resultaten van 
de klinische studie getoond. Uiteindelijk wordt in hoofdstuk 9 een korte case-serie 
beschreven van patiënten die percutane cement injectie hebben ondergaan zonder dat 
van tevoren het interface weefsel is verwijderd.
Revisie chirurgie bij 80-plussers
In Hoofdstuk 2 hebben we alle patiënten van 80 jaar en ouder die een revisie totale 
heupprothese operatie ondergingen tussen 1994 en 2007 in 2 ziekenhuizen in Neder-
land, retrospectief nagekeken. De primaire onderzoeksvraag was de sociale uitkomst 
na de ziekenhuisopname voor revisie heup artroplastiek. Secundaire onderzoeksvragen 
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waren het optreden van complicaties tijdens het verblijf in het ziekenhuis, overleving 
van de patiënten en het gebruik van loop hulpmiddelen voor en na de operatie. Na de 
ziekenhuisopname voor de revisie-operatie kon uiteindelijk 75% van de patiënten terug 
naar hun eerdere sociale situatie, in 12% van de gevallen verslechterde de situatie en 
in 4% verbeterde de situatie. Om te kunnen voorspellen welke patiënten terug zouden 
kunnen naar hun eigen huis en welke patiënten voor langere tijd in een verpleeghuis 
zouden moeten verblijven, hebben we een logistische regressie analyse gedaan voor 
de patiënten die voor de opname zelfstandig in een huis of appartement woonden. De 
regressie analyse liet zien dat de enige voorspeller voor het terugkeren naar het eigen 
huis de aanwezigheid van een partner was. Dit gegeven was ook al beschreven in de 
studie van Strehle et al.114 die zagen dat 95% van de patiënten die met een partner 
zelfstandig woonden naar huis terug konden na revisie totale heup artroplastiek, ver-
geleken met 70% van de patiënten die zonder partner zelfstandig woonden. Hoewel 
een van de doelen van revisie chirurgie van de heupprothese was om de activiteiten 
van het dagelijks leven (ADL) van de patiënt te verbeteren, laat onze studie zien dat 
de sociale situatie vaker verslechterde dan verbeterde. Hiervoor kunnen verschillende 
verklaringen zijn. Eén verklaring kan zijn dat hoewel de functie van de heup verbetert 
door de revisie chirurgie, de conditie van de patiënt achteruit gaat door de ziekenhuis-
opname. Hoewel we geen correlatie konden vinden tussen duur van de ziekenhuisop-
name en het aantal complicaties dat optrad, was de opname duur lang (gemiddeld 
34 dagen) en het aantal complicaties hoog, met een gemiddelde van 1,3 complicaties 
per patiënt, en een statistisch significante correlatie tussen ASA-categorie (American 
Society of Anesthesiologists)121 en het aantal en de ernst van de complicaties. 26% 
van de patiënten had een delier, wat aangeeft dat de revisie chirurgie een grote impact 
had op de fysieke en mentale status van de patiënt. Naast achteruitgang in fysieke en 
mentale status van de patiënt tijdens de ziekenhuisopname, zou een andere verklaring 
voor de verslechtering in sociale situatie kunnen zijn dat de situatie thuis eigenlijk al 
onacceptabel was en dat de ziekenhuisopname een aanleiding was om die situatie te 
veranderen. Een ander belangrijk probleem bij oudere patiënten is dat het risico voor 
periprosthetische fracturen hoger is dan bij jongere patienten.92 Dit wordt verklaard 
door het feit dat oudere patiënten meestal een slechtere bone stock hebben. Hoewel 
we alleen 80-plussers hebben onderzocht, vonden we dat 13% van de ASA-3 patiën-
ten een periprosthetische fractuur had, vergeleken met 5,4% van de ASA-2 patiënten 
(p = 0,10). Concluderend laat hoofdstuk 2 zien dat revisie chirurgie een hoge impact 
heeft op fysieke, mentale en sociale status van oudere patiënten. Indicaties voor revi-
sie chirurgie moeten daarom uitgebreid gewogen worden in het licht van potentiële 
voordelen, maar zeker ook nadelen voor de patiënt. Er zal hierdoor altijd een groep 
patiënten overblijven met ernstige comorbiditeit of een slechte botkwantiteit, die niet 
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in aanmerking komt voor revisie chirurgie. Voor deze patiënten is de alternatieve be-
handeling ontwikkeld die in dit proefschrift beschreven wordt. 
Preklinische studies
Voor het verwijderen van het interface weefsel tussen de prothese en het bot wordt 
een gene-directed enzyme prodrug therapie (de vector CTL102 in combinatie met de 
prodrug CB1954) gebruikt. Het primaire effect van de CTL102 infectie van de cellen is 
de bezorging van de Ntr gen expressie cassette. Na binnenkomst in de cel en uitpak-
ken uit het virale kapsel, bestaat het CTL102 genoom als extrachromosomaal DNA 
element waarvan mRNA transcriptie optreedt door de transcriptie-machinerie van de 
geïnfecteerde cel. Dit wordt vervolgens weer getransleerd in actief nitroreductase, wat 
zich ophoopt in het cytosol. De intracellulaire Ntr activiteit is verantwoordelijk voor de 
activatie van de prodrug naar een toxische bifunctioneel alkylerend middel binnen in 
de cel.68 In cellen die in staat zijn tot bioactivatie van CB1954 ontstaat vorming van 
een grote hoeveelheid crosslinks, wat toxisch is voor de cel. Cellen die CB1954 activeren 
worden daarom vernietigd.18,34 De beoogde uitkomst is dat geïnfecteerde cellen die 
Ntr tot expressie brengen en CB1954 opnemen, gedood worden door activatie van de 
prodrug. Synoviaal weefsel heeft dezelfde histochemische en histologische kenmerken 
als interface weefsel43 en in een eerdere studie in ons lab door Goossens et al.46 is al 
aangetoond dat genen getransfereerd kunnen worden naar synoviaal weefsel in vivo 
in rhesus apen door directe injectie in het gewricht, en dat de synoviocyten gedood 
kunnen worden door injectie van een specifieke prodrug. 
 In Hoofdstuk 3 wordt het efficiënt doden van de interface cellen door gene-direc-
ted enzyme prodrug therapie getoond. Om de gevoeligheid van interface cellen voor 
HAdV-5 vectoren te testen werden primaire kweken van interface cellen blootgesteld 
aan de HAdV-5 vector Ad.CMV.LacZ. De effectiviteit van transductie nam toe met de 
vector concentratie en bij 400 pfu/cel bracht 88% van de cellen het reporter-gen tot 
expressie. Los van elkaar waren de vector CTL102 en de prodrug CB1954 niet toxisch 
voor interface cellen in lage tot gemiddelde concentraties. Echter, CTL102-transductie 
van interface cellen zorgde voor een 60-voudige sensitisatie voor de prodrug CB1954. 
Voor intra-artriculaire injectie van een therapeutisch middel wordt de positie van de 
naald in de gewrichtsholte meestal gecontroleerd door injectie van een kleine hoeveel-
heid contrastmiddel, terwijl doorlichtingsbeelden worden gemaakt. Voordat het in een 
klinische studie gebruikt kan worden, moet een mogelijk effect van het contrastmiddel 
op de effectiviteit van transductie en doden van de interface cellen getest worden. De 
resultaten in hoofdstuk 3 laten zien dat het contrastmiddel geen effect heeft op de 
vitaliteit van de interface cellen, maar in de aanwezigheid van jodide-bevattend con-
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trastmiddel is de transductie van de cellen door een adenovirale vector bijna verwaar-
loosbaar. Het mechanisme hiervan is onduidelijk, maar we hebben wel aangetoond 
dat het effect niet veroorzaakt wordt door een verandering in de cellen zelf, omdat 
tijdelijke blootstelling van de cellen aan het contrastmiddel niet leidde tot een inacti-
vatie van de vector. Daarnaast is het effect onafhankelijk van de receptor en wordt het 
niet veroorzaakt door het jodide zelf. Concluderend laat hoofdstuk 3 zien dat interface 
cellen gedood kunnen worden door de Ntr/CB1954 enzym prodrug benadering. Echter, 
het op dit moment gebruikte contrastmiddel kan niet gebruikt worden om de positie 
van de naald tijdens intra-articulaire injectie te controleren, gezien het effect daarvan 
op de transductie van de cellen. 
 Hoofdstuk 4 beschrijft 2 methoden die we hebben getest om transgen-expressie 
te optimaliseren. Als we de genexpressie voorspelbaarder en efficiënter kunnen maken, 
kan de vectordosis verlaagd worden. Dit heeft verschillende voordelen, onder andere 
dat de immuunrespons die optreedt minder groot zal zijn en dat er minder vector voor 
klinische toepassingen geproduceerd hoeft te worden.66 Eén van de methoden om de 
genexpressie te vergroten is door de interactie van de promoter met de DNA-sequen-
ties te vereenvoudigen. Normaal is het chromatine van DNA gevouwen om een com-
plex van histon eiwitten. Natrium butyraat (NaB) veroorzaakt hyperacetylatie van de 
histonen, waardoor de chromatine structuur verandert en de genexpressie toeneemt. 
Daarnaast zorgt NaB voor up-regulatie van transcriptiefactoren, waardoor de reporter-
gen expressie nog meer toeneemt.11,17,27,42 We hebben aangetoond dat NaB in een 
concentratie van 6 mM de reporter-gen expressie in vitro vergroot met een factor 7-16 
vergeleken met een controle groep zonder NaB. NaB heeft 2 nadelen die gebruik in een 
klinische studie kunnen tegenhouden. Het eerste nadeel is dat NaB snel gemetaboli-
seerd wordt in vivo (half-waarde tijd 6,1 min), waardoor het moeilijk wordt om een 
effectief therapeutisch niveau te behouden. Om dit probleem op te lossen is een ge-
esterde afgeleide van butyraat ontwikkeld die een langere half-waarde tijd heeft.88,96,97 
Als een hoge concentratie van NaB lokaal kan worden verkregen (bijvoorbeeld als het 
in een afgesloten ruimte wordt ingespoten, zoals in een gewricht) kan de toevoeging 
van NaB waarschijnlijk voordelig zijn om de transgen-expressie in vivo te laten toene-
men. Het tweede nadeel is dat het effect van NaB waarschijnlijk niet alleen zal optreden 
bij het beoogde transgen, maar dat ook de expressie van andere genen zal toenemen. 
Aanvullende studies zijn nodig om de lange termijn effecten van NaB te onderzoeken 
voordat het gebruikt kan worden in een klinische gentherapie studie. 
 In een poging het lokale effect van transgen-expressie te vergroten terwijl de sys-
temische effecten tot een minimum worden beperkt, is een vector ontwikkeld met een 
ubiquitous chromatin opening element (UCOE) ingevoegd in het DNA van de vector. 
Het werkingsmechanisme van deze UCOE is dat de promoter wordt ingepakt in een 
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DNA-sequentie die methylering-vrije CpG-eilanden bevat, waardoor de promoter re-
sistent is tegen heterochromatine-gemedieerde silencing van de genen.74,126 Dit zal 
voorkomen dat de transgen-expressie afneemt in de tijd. In onze studie vonden we 
geen verschil in expressie tussen de vector met en zonder UCOE. Een mogelijke verkla-
ring kan zijn dat de promoter niet wordt gesilenced in de eerste dagen na de infectie, 
waardoor er geen effect is van een anti-silencer invoeging. In een klinische studie waar 
transgen-expressie voor een langere tijd nodig is zou insertie van een UCOE in het vec-
tor DNA wel een goede optie kunnen zijn.
 In alle studies is een goede blootstelling van het beoogde weefsel essentieel en 
voor klinische studies waarbij het actieve middel in het gewricht wordt gespoten is 
het belangrijk dat het middel lang genoeg in het gewricht blijft. Naast grootte van 
de therapeutische deeltjes,46,90 is de integriteit van het omgevende gewrichtskapsel 
(containment) belangrijk in het behouden van de actieve deeltjes in het gewricht. Con-
tainment van de gewrichtsholte kan gevisualiseerd worden door artrografie, waarbij 
de gewrichtsholte wordt gevuld met radio-opaak contrastmiddel onder doorlichting. 
Effectiviteit van de intra-articulaire behandeling is ook afhankelijk van het gewrichtsvo-
lume. In grote gewrichten zal het actieve middel meer verdund worden dan in kleine 
gewrichten of een hogere dosis zal nodig zijn met een grotere kans op toxiciteit. In 
een klinische studie waar intra-articulaire injectie wordt gebruikt als methode om het 
therapeutische middel op de juiste plaats te brengen is het belangrijk om van tevoren 
een artrogram te doen in de inclusie-periode. Dit garandeert dat patiënten met een 
non-contained gewricht ge-excludeerd kunnen. Verder is dan het volume van het ge-
wricht bekend en dit kan belangrijk zijn voor de bereiding van de studie medicatie. In 
Hoofdstuk 5 wordt een retrospectieve studie getoond van 221 heup-artrogrammen 
die verricht zijn voor de diagnose van prothese loslating. In 74% van de artrogrammen 
was het gewricht afgesloten, en deze patiënten zouden in aanmerking kunnen komen 
voor intra-articulaire therapie. Het gemiddelde volume dat in de gewricht was ingespo-
ten was 31 ml. Dit hoofdstuk laat zien dat, omdat toch 26% van de patiënten een niet-
afgesloten gewricht hebben en het volume tussen de patiënten behoorlijk varieert, het 
verrichten van een artrogram belangrijk is alvorens intra-articulaire therapie te starten. 
Klinische studies
Nadat de pre-klinische studies waren afgerond werd een studie protocol voor een kli-
nische fase 1 studie ontworpen. In deze studie werden 12 patiënten geïncludeerd. De 
behandeling bestond uit intra-articulaire injectie van de humane adenovirale-5 vector 
CTL102 en 2 dagen later intra-articulaire injectie van de prodrug CB1954. 7 Dagen later 
werd de losse heupprothese weer vastgezet door middel van percutane peri-prostheti-
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sche bot-cement injectie. Het studieprotocol werd goedgekeurd door de Centrale Com-
missie voor Mensgebonden Onderzoek (CCMO), het Ministerie van Volkshuisvesting, 
Ruimtelijke Ordening en Milieu (VROM) en de locale medisch ethische commissie; en 
werd uitgevoerd volgens de principes van de Verklaring van Helsinki (zoals aangepast 
in Tokyo, Venetië, Hong Kong, Somerset West en Edinburgh) en volgens de Richtlijnen 
voor Good Clinical Practice (CPMP/ICH/135/95-July 17.1996). Hoofdstuk 6 beschrijft 
het klinische protocol in detail.
 Omdat de klinische studie een fase 1 onderzoek is, is veiligheid de primaire on-
derzoeksvraag. Aanbevelingen voor het graderen van acute en subacute toxische bij-
werkingen (World Health Organisation, 1979) werden gebruikt om bijwerkingen te 
rapporteren. De bijwerkingen werden bijgehouden tot 6 weken na vector injectie. 
Hoofdstuk 7 beschrijft alle bijwerkingen die optraden in de eerste 6 weken na de 
gentherapie. Er is geen dose-limiting toxicity opgetreden. De vector toediening kon 
gecontinueerd worden tot de voorgestelde hoogste dosis van 1 x 1011 deeltjes. Negen 
van de 12 patiënten hadden last van misselijkheid en braken, beginnend 6 uur na 
de prodrug injectie, waarbij één patiënt parenterale voeding nodig had in verband 
met dehydratie. Deze bijwerkingen worden waarschijnlijk veroorzaakt door de pro-
drug (en niet door de vector), omdat het voorkomen van de bijwerkingen verminderde 
nadat de prodrug dosis verlaagd was en niet toenam na een 30-voudige toename in 
HAdV-5 vector dosis. Naast misselijkheid en braken hadden 8 patiënten een stijging 
in aspartaat aminotransferase (ASAT), met een piek 4 dagen na prodrug injectie en 4 
van deze patiënten hadden ook een stijging in alanine aminotransferase (ALAT). Deze 
hepatische bijwerkingen waren asymptomatisch en volledig reversibel. Echter, omdat 
2 patiënten een graad 2 stijging in ASAT en ALAT hadden en omdat één van de pa-
tiënten parenterale voeding nodig had in verband met dehydratie, werd de prodrug 
dosis na 4 patiënten verlaagd naar 16 mg/ m2. De pathofysiologie van de gastrointes-
tinale bijwerkingen van de prodrug is onbekend; twee mogelijke verklaringen worden 
overwogen. Ten eerste is de meest waarschijnlijke verklaring een indirecte toxiciteit op 
het gastrointestinale epitheel. Een andere verklaring kan zijn dat het CB1954 omgezet 
wordt naar de geactiveerde vorm door nitroreductase van E. coli die aanwezig is in de 
darmflora. Het CB1954 metabolisme is voornamelijk hepatisch.23 Dit benadrukt dat 
de stijging in transaminases verklaard kan worden door levercel schade door CB1954 
metabolieten tijdens klaring van het middel. Concluderend trad er geen dose-limiting 
toxicity op tijdens de Ntr-CB1954 gentherapie. De prodrug dosis werd echter verlaagd 
naar 16 mg/m2 in verband met nadelige gastrointestinale en hepatische bijwerkingen. 
Secundaire onderzoeksvragen in de studie waren (1) beoordelen of de procedure niet 
zorgt voor vrijkomen van het virus in het milieu (2) histologisch onderzoek van biop-
ten van interface weefsel (3) de mogelijkheden onderzoeken om de losse prothese 
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weer vast te zetten door middel van botcement en (4) de klinische uitkomsten van 
het onderzoek bekijken, zoals vermindering van pijn en verbetering in ADL. De secun-
daire onderzoeksvragen worden besproken in Hoofdstuk 8. Vrijkomen van het virus in 
bloedplasma, urine, feces en neus- en keeluitstrijken werd gemeten met kwantitatieve 
polymerase ketting reactie (PCR) analyse. Twee patiënten in de hoogste vector dosis 
groep (1 x 1011 deeltjes) hadden nog een aantoonbare virus hoeveelheid in hun bloed-
plasma na 24 uur. Daarom werden deze patiënten in isolatie gehouden en werden de 
dag erna opnieuw monsters afgenomen, die negatief bleken. In eerdere studies met 
CTL102 werd geen vrijkomen van virus meer gemeten na 24 uur.91 Een verklaring voor 
aanwezigheid van vector na 24 uur in onze studie kan zijn dat de vector is geinjecteerd 
in een gewricht, wat een min of meer afgesloten ruimte is waaruit de vector maar 
langzaam zal vrijkomen. Hoewel de vector na 48 uur niet meer buiten het gewricht kon 
worden waargenomen, liet punctie van gewrichtsvloeistof uit de heup zien dat zelfs na 
11 maanden bij één patiënt nog adenoviraal DNA aanwezig was. Bij 7 patiënten kon bij 
biopten van het interface weefsel voldoende weefsel worden verkregen voor histolo-
gische analyse. Deze monsters lieten met name necrose zien zonder apoptose. Dit is in 
overeenstemming met de studie van Lipinski et al.76, die concludeerde dat in CTL102-
CB1954 gentherapie, de cellen meer blijken te sterven door necrose dan door de klas-
sieke apoptose. Percutane cement injectie werd gebruikt om de prothese te stabiliseren 
na het doden van het interface weefsel. Hoofdstuk 8 laat zien dat een gedeelte van de 
radiolucente zone gevuld kan worden met cement maar niet alles. De vraag blijft of 
stabilisatie van de prothese door cement injectie leidt tot toename van bot kwantiteit 
over de tijd door afname van stress shielding van het bot en toename van belasting 
na fixatie van de prothese. Uiteindelijk werd de klinische uitkomst bekeken door de 
Harris Hip Score en door Visual Analogue Scales (VASsen) voor pijn, loopafstand en 
activiteiten van het dagelijks leven (ADL). Al deze onderdelen van de klinische uitkomst 
verbeterden na de cement injectie, vooral in de twee hoogste vector dosis groepen. Of 
dit verschil veroorzaakt wordt door de hogere vector dosis of door een toenemende 
leercurve voor de percutane cementinjectie kan niet worden beoordeeld. Dit is echter 
onvermijdbaar als een nieuwe techniek wordt geïmplementeerd. Concluderend kan 
gezegd worden dat gentherapie om interface weefsel te verwijderen, gevolgd door 
percutane cement injectie om de prothese te stabiliseren, een veilige en haalbare bena-
dering is. De klinische functie verbetert volgens de mening van de patiënt en röntgen-
foto’s laten zien dat de radiolucente zone gedeeltelijk gevuld kan worden met cement. 
Het blijft echter de vraag of stabilisatie van de prothese op de langere termijn leidt tot 
vergroting van de bone stock.
 Een nadeel van de gentherapie om het interface weefsel te verwijderen is dat de pa-
tiënten minimaal een week in het ziekenhuis moeten worden opgenomen. Daarnaast 
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hadden de meeste patiënten last van systemische bijwerkingen van de prodrug. Om 
te onderzoeken of percutane periprosthetische cementinjectie mogelijk was zonder 
vooraf het interface weefsel te verwijderen, hebben we een kleine patiëntenserie van 
7 patiënten verricht. Deze patiëntenserie en de resultaten hiervan worden bediscussi-
eerd in Hoofdstuk 10. Zeven patiënten die niet in aanmerking kwamen voor normale 
revisie-chirurgie omdat ze ernstige comorbiditeit hadden of een slechte bot kwantiteit, 
deden mee in de serie. De patiënten ondergingen CT-geleide periprosthetische cement 
injectie onder doorlichting, zoals de patiënten in de gentherapie-studie, maar zonder 
de gentherapie. Gemiddeld kon 16 ml cement rond de steel geïnjecteerd worden en 
5,5 ml rond de cup. Alle patiënten meldden een klinische verbetering. Door het geringe 
aantal patiënten in beide studies kunnen geen conclusies getrokken worden over wat 
de beste methode is om de prothese te fixeren. Daarnaast kunnen geen voorspellingen 
gedaan worden voor de langere termijn. Ondanks dat de percutane cementinjectie een 
relatief kleine procedure is, adviseren we het alleen te gebruiken bij patiënten die niet 
in aanmerking komen voor revisie chirurgie, omdat reguliere revisie chirurgie bewezen 
effectief is en de langere termijn effecten van percutane cementinjectie nog onbekend 
zijn. Aan de andere kant blijft de optie voor revisie chirurgie na percutane cementinjec-
tie gewoon open. Een nadeel van de percutane cementinjectie is dat het alleen uitge-
voerd kan worden als de prothese in een goede stand staat en als de klachten van de 
patiënt niet veroorzaakt worden door polyethyleen slijtage of recidiverende luxaties. In 
ieder geval, en zeker bij patiënten met hoge risico’s, is het belangrijk te verifiëren of de 
pijn veroorzaakt wordt door loslating van de prothese, bv door marcainisatie, en niet 
door een andere oorzaak, voordat revisie chirurgie overwogen wordt. Concluderend 
laat hoofdstuk 10 zien dat percutane cementinjectie rond een aseptisch losgelaten 
prothese mogelijk is zonder dat eerst het interface weefsel verwijderd is. Met de hui-
dige data kunnen geen conclusies getrokken worden over de voorkeur om het interface 
weefsel te verwijderen voor de cementinjectie. Het lijkt echter logisch dat verwijdering 
van het interface weefsel een betere stabilisatie geeft vergeleken met de situatie waar-
bij het interface weefsel nog in situ is. 
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